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- Abstract - 
 
It is established that patients with knee osteoarthritis (OA) exhibit marked muscle 
weakness, one of the most frequent and earliest reported symptoms associated with 
knee OA. Weakness primarily affects the quadriceps muscle with little evidence of 
hamstring involvement. Traditionally, muscle weakness has been considered a 
secondary effect in knee OA, resulting from disuse of the affected joint due to the 
presence of pain and/or inflammation, and therefore has received little attention 
with regards to its involvement in the initiation or progression of OA. However, there 
is clinical evidence which suggests that quadriceps weakness may precede the onset 
of radiographic evidence of OA and subsequent pain, and therefore may be directly 
involved in its pathogenesis. Furthermore, targeted exercise regimes aimed at 
improving quadriceps function indicate therapeutic benefits with regards to both the 
initiation and progression of knee OA. Quadriceps muscle dysfunction in knee OA is 
currently poorly understood and represents an unmet clinical need. 
 
Consequently, the main aims of this work were to characterise quadriceps muscle 
dysfunction in the rodent meniscectomy-induced (MNX) and spontaneous guinea pig 
model of OA at the molecular level determining changes in muscle fibre type, 
metabolic potential, and muscle atrophy signalling. Furthermore, the effects of 
clenbuterol-induced quadriceps hypertrophy, prior to the induction of OA, on disease 
severity were considered in the rat MNX model. Thus far, the cDNA sequences 
encoding each member of the myosin heavy chain (MHC) gene family have yet to be 
determined in the guinea pig. Therefore, a further aim of this work was to generate 
novel cDNA sequence pertaining to the skeletal muscle-associated isoforms of MHC 
in the guinea pig, and to develop specific oligonucleotide primers to determine the 
abundance of each specific mRNA.  
 
The development of MNX-induced and spontaneous OA was associated with changes 
in MHC I expression indicative of an increase in slow, type I muscle fibres. The 
assessment of muscle atrophy-associated genes revealed that neither model was 
  
associated with overt quadriceps muscle atrophy, or increased muscle atrophy 
signalling. Combined, these data suggest that OA associated quadriceps dysfunction 
may result predominantly from altered contractile properties, as evidenced by 
altered MHC expression, rather than from reduced quadriceps mass per se. The 
administration of clenbuterol for 14 days induced marked increases in quadriceps 
mass relative to bodyweight. However, clenbuterol induced hypertrophy was unable 
to favourably modulate OA severity in the MNX-induced model in this experimental 
setting.  
 
In conclusion this work has shown that OA is associated with altered quadriceps 
muscle properties, suggestive of a switch towards a slow-twitch muscle fibre type, in 
two independent animal models. Such data have important implications for the 
development of targeted pharmaceuticals and in the prescription of rehabilitation 
regimes aimed at improving OA severity or reducing disease progression. Moreover, 
the relationship of increased MHC I expression to joint stability and muscle function 
warrants further investigation in the OA setting.  
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CHAPTER 1  ? GENERAL INTRODUCTION 
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1.1  ? Osteoarthritis 
 
1.1.1  ? Background and definition 
Osteoarthritis (OA), the most common joint disorder worldwide, is an active disease 
process involving cartilage destruction, subchondral bone thickening, and new bone 
formation (Peat, McCarney et al. 2001). OA comprises a heterogeneous group of 
disorders that affect all joint tissues, although articular cartilage and the adjacent 
subchondral bone show the most marked changes (Herrero-Beaumont, Roman-Blas 
et al. 2009). OA may be defined by the symptoms which it elicits, by radiographic 
evidence of structural pathology, or by a combination of the two. With reference to 
OA of the knee, the primary symptoms include quadriceps muscle weakness, joint 
stiffness, crepitus (grinding on joint motion) and pain.  
 
1.1.2  ? Prevalence 
In the western world, OA is one of the primary causes of pain, functional loss and 
disability within the adult population. By 65 years of age, the majority of people have 
radiographic evidence of OA. On reaching 75 years of age, 80% of the population 
present with positive radiology. OA affects the knee, hip, hand and spine, and less 
commonly, the wrists and ankles (Arden and Nevitt 2006). Knee OA represents one 
of the most prevalent forms of osteoarthritis, with population-based studies 
estimating severe radiographic disease amongst 1% of 25-34 year olds, and 30% in 
those aged 75 and above (Arden and Nevitt 2006). 
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1.1.3  ? Diagnostic criteria and current therapy 
In the clinical setting, OA is routinely graded using standard radiographic films. The 
radiographic features associated with OA include joint space narrowing (JSN), bone 
contour abnormalities, subchondral sclerosis, osteophytosis and cyst formation 
(Arden and Nevitt 2006) and are graded using a system first described by Kellgren 
and Lawrence in 1957 (Kellgren and Lawrence 1957) (TABLE 1.1). This system assigns 
one of five grades to osteoarthritic lesions at various sites in comparison to a 
radiographic atlas.  
 
 
TABLE 1.1  W Kellgren and Lawrence radiographic scoring system 
Grade OA Description 
Grade 0 None No features of OA 
Grade 1 Doubtful Minute osteophyte, doubtful significance 
Grade 2 Minimal Definite osteophyte, unimpaired joint space 
Grade 3 Moderate Moderate diminution of joint space 
Grade 4 Severe Joint space greatly impaired / sclerosis of subchondral bone 
 
 
The most widely utilised criteria for reaching a positive OA diagnosis were developed 
by the American College of Rheumatology (Altman, Alarcon et al. 1991). The criteria 
combine clinical features with the radiographic grading system of Kellgren and 
Lawrence, identifying only patients with knee-pain for most days of the prior month 
(TABLE 1.2). Knee OA is confirmed if knee pain is experienced for most days of the 
prior month in addition to; osteophytes, synovial fluid changes, morning stiffness and 
crepitus, or morning stiffness and creptius alone in patients over the age of 40 years.  
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TABLE 1.2  W American College of Rheumatology scoring criteria 
Grade Clinical and Radiographic feature OA if present 
1 Knee pain for most days of the prior month 1, 2 or 1, 3, 5, 6 or 1, 4, 5, 6 
2 Osteophytes at joint margins (radiograph)  
3 Synovial fluid typical of OA (laboratory)  
4 Age > 40 years  
5 Morning stiffness > 30 minutes  
6 Crepitus on active joint motion  
 
 
Although routine histological diagnosis is rarely performed for the diagnosis of 
human OA, the microscopic features of OA include loss of chondrocytes and 
proteoglycan from the cartilage surface, cartilaginous ulceration and erosion, 
subchondral degeneration and osteophytosis (Bendele 2001). Histological diagnosis 
is useful for the assessment of OA in laboratory animals and other smaller species 
and has been described in detail by Bendele, 2001 (Bendele 2001), and specific 
animal scoring criteria developed by Huebner and Kraus, 2006 (Huebner 2006).  
 
Recommendations for the treatment of OA underwent a NICE review in 2008, to 
include a more holistic approach to disease management. Following diagnosis, 
patient education and counselling are recommended in combination with monthly 
consultation by telephone. Aerobic exercise and local muscle strengthening are 
indicated in addition to weight loss in over-weight patients. Pain management 
recommendations suggest the administration of paracetamol and topical non-
steroidal anti-inflammatory drugs (NSAIDS) in the first instance. Oral NSAIDS 
(including COX-II inhibitors) are only indicated if other analgesics are insufficient, and 
should be prescribed with caution due to potential gastrointestinal and 
cardiovascular side-effects. Surgery is only indicated in those patients were the 
severity of disease is having a substantial impact on their quality of life (NICE 2008).  
To date, no disease modifying drugs are available for the treatment of OA, which 
represents a great and unmet clinical need.  
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1.1.4  ? Risk factors 
Data from epidemiological studies have been used to elucidate several risk factors 
associated with the development and progression of OA. Such studies have provided 
an insight into those who are likely to develop the disease, which joint will be 
affected and moreover provided clues to its complex pathogenesis. A model for the 
pathogenesis of OA was developed by Dieppe in 1995 (Dieppe 1995) which separates 
risk factors into those systemic factors increasing the overall risk of disease, and 
mechanical risk factors which tend to be the primary determinant of which joint will 
likely be affected. 
 
1.1.4.1  ? Systemic risk factors 
Systemic risk factors are thought to increase the overall susceptibility to 
degenerative joint changes and to decrease the effectiveness of the reparative 
response resulting in a predisposition to OA. The most compelling evidence links the 
incidence of OA with advancing age (Oliveria, Felson et al. 1995; Kirkwood 1997; 
Murphy and Lamb 2008). The age-related increase in OA prevalence is noted at all 
commonly affected sites, but is particularly notable in knee and hand OA (Arden and 
Nevitt 2006). This association is true of both radiographic and symptomatic disease in 
patients over the age of 65 years (Felson, Naimark et al. 1987).   
 
Throughout reproductive life, both males and females share a comparable 
susceptibility to OA (Arden and Nevitt 2006). However, postmenopausal women 
experience an increased predisposition suggesting that differences in sex hormones 
may modulate the disease. Despite this, to date there is no definitive evidence linking 
oestrogen levels, or reproductive history with the incidence of OA (Samanta, Jones et 
al. 1993). Current hormone replacement therapy (HRT) is protective of osteophytosis 
and may protect against joint space narrowing however, this effect is lost when HRT 
has been discontinued for more than 12 months (Spector, Nandra et al. 1997). 
Moreover, post menopausal women taking oestrogen replacement therapy in 
various forms have been found to have larger tibial cartilage volumes than those who 
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have never taken HRT as assessed by magnetic resonance imaging, again 
strengthening the link with reduced OA severity (Wluka, Davis et al. 2001).  
 
Obesity is amongst the most established and strongest risk factors for knee OA 
(Grotle, Hagen et al. 2008). Numerous longitudinal studies have identified a strong 
relationship between a body mass index (BMI) of >30 and the incidence of knee OA 
(Spector, Hart et al. 1994; Hochberg, Lethbridgecejku et al. 1995). However, 
increasing evidence notes a relationship between obesity and the incidence of hand 
OA (Carman, Sowers et al. 1994), suggesting that this involvement is not simply 
biomechanical and is therefore systemic in this capacity (Grotle, Hagen et al. 2008). 
Further studies have correlated both elevated serum cholesterol (Sturmer, Sun et al. 
1998) and triglyceride (Cheras, Whitaker et al. 1997) concentration with OA, with 
serum cholesterol concentration reported as an independent risk factor for OA 
(Sturmer, Sun et al. 1998) in one large human clinical study. 
 
Other systemic risk factors include high bone density (Hart, Cronin et al. 2002), 
genetics (Spector and MacGregor 2004) and nutritional status (McAlindon, Jacques et 
al. 1996). Please refer to Arden, 2006 for a comprehensive review of the systemic risk 
factors involved in the development of OA.  
 
1.1.4.2  ? Mechanical risk factors 
Whereas systemic risk factors modulate the overall risk of developing OA, mechanical 
factors are more closely linked with determining which anatomical sites will be 
affected. Joint injury is widely accepted as a risk factor for knee OA (Davis, Ettinger et 
al. 1989; Felson 1990; Wilder, Hall et al. 2002). In addition to the direct effects of 
injury on the joint, disruption of joint biomechanics is suggested to further 
accentuate pathological damage, and contribute towards an increased risk of OA in 
later years (Arden and Nevitt 2006). The risk of knee OA is also elevated in patients 
who have gait abnormalities resulting in increased knee loading (Marks, Kumar et al. 
1994), patients with anterior cruciate ligament insufficiencies (Longino, Frank et al. 
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2005) and most commonly, patients who have undergone partial meniscectomy 
surgery (Mills, Wang et al. 2008).  
 
More recent studies have begun to describe a role of quadriceps muscle weakness in 
the pathogenesis of knee OA. Quadriceps involvement in the incidence and 
progression of knee OA will be reviewed in detail in CHAPTER 1.3.8. 
 
 
1.1.5  ? Summary 
Osteoarthritis of the knee is a common disorder affecting cartilage, bone and skeletal 
muscle and causes significant morbidity. Current therapies for osteoarthritis offer 
only limited symptomatic relief. To date, no pharmaceuticals exist which are able to 
modulate the underlying disease process and therefore OA represents a great and 
unmet clinical need (Flannery 2010).  
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1.2  ? Structure and Function of the Knee Joint 
 
The knee joint is essentially composed of four main bones; the femur, tibia, fibula 
and patella. The knee joint comprises two different articulations between the femur 
and tibia, and between the femur and the patella forming the femorotibial and 
patellofemoral joints respectively.  Each joint is held in the correct plane by a series 
of ligaments and muscles with associated tendons.  
 
The knee is complemented with a selection of ligaments including the anterior and 
posterior cruciates, and the medial and lateral collateral ligaments. These serve to 
strengthen the knee structure as well as place restraints on the range of movements 
through which it can travel. Due to its location within the human skeleton, and the 
fact humans are bipeds, the knee joint is constantly exposed to varying forces which 
it must cushion and absorb to prevent the formation of pathological stresses. To 
cushion joint load, the articular surfaces are covered in cartilage, and the knee is 
equipped with the medial and lateral menisci which sit between the two articular 
surfaces of the femur and tibia. For a comprehensive review of the structure and 
biomechanics of the knee joint, see Bendjaballah, 1995 (Bendjaballah, Shirazi-Adl et 
al. 1995) (FIGURE 1.1). 
 
Many muscles have insertions around the knee joint. Although some of these do not 
necessarily take part in gross knee movement, they play a crucial role in dynamic 
knee stability. The quadriceps muscle group sits above the patella and comprises the 
rectus femoris, vastus lateralis, intermedius and medialis. The quadriceps muscle 
group interacts with the patella via the patella ligament to extend the knee and 
maintain dynamic knee stability (FIGURE 1.2). 
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FIGURE 1.1  W Anatomical features of the human knee joint. (A) anterior extended, (B) 
posterior extended, (C) anterior at moderate flexion.   
 
 
 
FIGURE 1.2  W Musculature of the human lower limb. The quadriceps muscle group 
comprising the vastus medialis, intermedius, lateralis and rectus femoris is 
highlighted.   
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1.3  ? Skeletal Muscle 
 
Skeletal muscle is one of the most highly organised structures in the biological world, 
and is primarily involved in the execution of voluntary movement (McNally, Lapidos 
et al. 2006). Skeletal muscle is composed of a number of muscle fibre types that 
differ with respect to their contractile, metabolic and molecular properties (Pette 
and Staron 2001). The characteristics of a skeletal muscle are a function of the 
contractile and metabolic properties of the muscle fibres from which it is composed. 
 
1.3.1  ? Structure 
Skeletal muscle is composed of many individual muscle fibres (Dubowitz 2007). Each 
fibre is covered in endomycium and beneath this, resides the cell membrane or 
sarcolemma. Structurally, each muscle fibre is composed of many protein bundles 
called myofibrils, which in turn comprise alternate dark and light staining filaments 
(Dubowitz 2007). The sarcomere is composed of the thin (mostly actin) filaments, the 
thick (mostly myosin) filaments, and the giant filamentous molecule titin.  The thin 
filaments are anchored in the Z-line, where they are cross-linked by ɲ-actinin. The 
thick filament is located centrally in the sarcomere and constitutes the sarcomeric A-
band. The myosin heads, or cross-bridges, on the thick filament interact with actin 
during activation. Titin spans the half-sarcomeric distance from the Z-line to the M-
line, thus forming a third sarcomeric filament. In the I-band region, titin is extensible 
and functions as a molecular spring that develops tension upon stretch. In the A-
band titin is inextensible due to its strong interaction with the thick filament. The 
distance from one Z-line to the next is defined as one sarcomere, the smallest 
integral contractile unit (McNally, Lapidos et al. 2006) (FIGURE 1.3). 
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FIGURE 1.3  W Simplified model of two muscle sarcomeres in parallel. Bottom: 
electromicrograph showing the ultra-structural organisation of sarcomeres in 
parallel. Image reprinted from (Ottenheijm, Heunks et al. 2008) 
 
1.3.2  ? Skeletal muscle contraction 
Muscle contraction consists of a cyclical interaction between myosin and actin driven 
by the concomitant hydrolysis of adenosine triphosphate (ATP) (Rayment, Holden et 
al. 1993). Myosin and actin, the components which respectively form the thick and 
thin filaments were amongst the first proteins to be purified with reference to 
muscle function (Block 1996). The hexametric protein myosin comprises two heavy 
chains (220 KDa) and four light chains (20-25 KDa), and forms the thick filaments. The 
terminus of myosin forms a globular head region required for the hydrolysis of ATP 
and binding of actin. The four light myosin chains are located between the globular 
head and the carboxy-terminal rod region (McNally, Lapidos et al. 2006). Thin muscle 
filaments are comprised of several proteins; however actin (43 KDa) is by far the 
most abundant constituent. Thick and thin regions of physical overlap form in which 
globular myosin heads project from the thick filaments to interact with thin actin 
filaments. ATP hydrolysis mediates a conformational change in the globular myosin 
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heavy chain head region, resulting in an interaction between the globular head and 
actin further along the filament and inducing a shortening of the muscle fibre.  
 
Multiple isoforms of myosin heavy chain (MHC) exist, which comprise a family of 
molecular motors able to modulate the speed of skeletal muscle contraction (Rinaldi, 
Haddad et al. 2008). The contractile speed of a particular muscle fibre may therefore 
be determined, in part, by the isoform of MHC protein which it expresses.  The 
sarcomeric MHC family consists of at least eight known isoforms, each encoded by a 
distinct gene located in two multigenic regions on two separate chromosomes (Weiss 
and Leinwand 1996). Six genes are encoded by a 300  W 600Kb segment on human 
and mouse chromosomes 17 and 11 respectively, in a cluster arrangement in the 
order MyH3/MyH2, MyH1/MyH 4, MyH 8/ MyH13  ? ? ?  W  ? ? ? ?The MyH2, MyH1 and 
MyH4 genes encode the protein isoforms commonly termed MHC IIA, IIX and IIB. Of 
the eight sarcomeric isoform genes of MHC, four are known to be expressed in adult 
ƐŬĞůĞƚĂů ŵƵƐĐůĞ P ŽŶĞ  “ƐůŽǁ-ƚǁŝƚĐŚ ?  ?dǇƉĞ / ? ŵƵƐĐůĞ ĂƐƐŽĐŝĂƚĞĚ D, ŝƐoform is 
ĞŶĐŽĚĞĚďǇƚŚĞDǇ, ?ɴŐĞŶĞĂŶĚƚŚƌĞĞ  “ĨĂƐƚ-ƚǁŝƚĐŚ ?  ?dǇƉĞƐ // ? //yĂŶĚ // ?ŵƵƐĐůĞ
associated isoforms, associated with increasing contractile speed. A combination of  
ƚŚĞ ůĂƚƚĞƌ  “ĨĂƐƚ-ƚǁŝƚĐŚ ? ŝƐŽĨŽƌŵƐ ĂĐĐŽƵŶƚ ĨŽƌ ŽǀĞƌ  ? ?A? ŽĨ D, ŝŶ ĂĚƵůƚ ƐŬĞůĞƚĂů
muscle (Allen, Sartorius et al. 2001). 
 
1.3.3  ? Skeletal muscle metabolism 
Muscle contraction is driven by the hydrolysis of adenosine triphosphate (ATP) 
(Rayment, Holden et al. 1993) which may be derived from the metabolism of fatty 
ĂĐŝĚƐ ?ɴ-ŽǆŝĚĂƚŝŽŶ ?ŽƌĐĂƌďŽŚǇĚƌĂƚĞƐ ?ŐůǇĐŽůǇƐŝƐ ? ?dŚĞɴ-oxidation of fatty acids takes 
place in the mitochondria of muscle fibres. Endothelial lipoprotein lipase (LPL) is 
involved in the transport of fatty acids from the circulatory system into the 
myocellular compartment (Fluck 2006). Hormone sensitive lipase (HSL) liberates free 
fatty acids from the intramyocellular lipid (IMCL) pool which are transported into the 
ŵŝƚŽĐŚŽŶĚƌŝŽŶ ĨŽƌ ɴ-oxidation by carnitine palmitoyltransferase 1 (CPT-1). The 
ƉƌŽĚƵĐƚŝŽŶŽĨdWǀŝĂƚŚĞɴ-oxidation of fatty acids is an oxygen-dependent process. 
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Carbohydrates reach the myofibre from the circulatory system and may be stored as 
glycogen, converted to ƚƌŝŐůǇĐĞƌŝĚĞƐ ? ŽƌŵĞƚĂďŽůŝƐĞĚǀŝĂŐůǇĐŽůǇƐŝƐ ? /Ŷ ĐŽŶƚƌĂƐƚ ƚŽɴ-
oxidation, the metabolism of carbohydrates via glycolysis is an oxygen independent 
process; however metabolism under these conditions leads to the production of 
lactate (Fluck 2006).    
 
1.3.4  ? Skeletal muscle fibre type classification - a historical overview 
The characteristics of skeletal muscles are a function of the contractile and metabolic 
properties of the muscle fibres from which they are composed. Historically, the most 
basic form of skeletal muscle classification was based upon visual muscle 
pigmentation. Using this system, skeletal muscles were ĐĂƚĞŐŽƌŝƐĞĚ ĂƐ  “ƌĞĚ ? Žƌ
 “ǁŚŝƚĞ ?(Dubowitz and Pearse 1960). For example, the soleus muscle was designated 
red, due to its appearance in contrast to the extensor digitorum longus (EDL) which 
was designated white. Physiological measurements of contractile speed (Brooke and 
Kaiser 1970) revealed that red fibres contracted slowly, whilst white fibres 
contracted more rapidly, enabling the delineation of type I (slow-twitch) and type II 
(fast-twitch) as the major skeletal muscle fibre types.  
 
Early work using metabolic staining methods to measure oxidative and glycolytic 
activity noted that whereas type I fibres tended to be more oxidative, type II muscle 
fibres presented with varying degrees of glycolytic activity (Dubowitz and Pearse 
1960). This resulted in the classification of slow oxidative fibres, and fast glycolytic 
fibres. Refined histochemical techniques later discriminated muscle fibres based 
upon their myosin ATPase activities and further subdivided type II fibres into IIA and 
IIB (Engel 1963; Guth and Samaha 1969; Brooke and Kaiser 1970). Further advances 
were also made with regards to the metabolic discrimination of fibre type and 
resulted in the classification slow-twitch oxidative (SO), fast-twitch oxidative (FO) and 
fast-twitch glycolytic (FG) (Peter 1972) fibres which were termed type I, IIA and IIB 
respectively.  
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More recent studies concentrated on the expression of muscle contractile elements, 
and reported that skeletal muscle fibres predominantly express a single isoform of 
myosin heavy chain (MHC) and that muscles could be classified by the predominant 
isoform of MHC expressed by their fibres (Gorza 1990). Moreover, Gorza and 
colleagues (Gorza 1990) reported a novel population of type II muscle fibres 
(subsequently named IIX), the contractile speed of which appeared to be 
intermediate between type IIA and type IIB. Because the muscle ATPase has been 
shown to reside within the heavy chain portion of myosin (Weiss and Leinwand 
1996), it is unsurprising that histochemical differences in muscle fibre ATPase activity 
correlated well with the expression of specific isoforms of MHC. Within the last 
decade, advancing fibre typing methodologies have elucidated the existence of 
hybrid myoĨŝďƌĞƐ ?tŚĞƌĞĂƐ “ƉƵƌĞ ?ŵǇŽĨŝďƌĞƐĞǆƉƌĞƐƐƐŝŶŐůĞŝƐŽĨŽƌŵƐŽĨĂĚƵůƚŵǇŽƐŝŶ
(I, IIA, IIX and IIB); hybrid fibres express multiple, discrete isoforms of the MHC within 
a single fibre (Pette and Staron 2001). Hybrid fibres contain pairs of the major MHC 
isoforms and are classified according to their predominant isoform. 
 
Based on these proposed systems, skeletal muscle fibres may be categorised into 
four different types; type I, IIA, IIX and IIB. Type I (slow oxidative) fibres are found in 
postural muscles were rapid movement is not essential. These fibres are particularly 
fatigue resistant and are therefore suited to prolonged periods of low-intensity 
contractile activity. Type IIA (fast oxidative, glycolytic) fibres display characteristics 
similar to both slow and fast fibres. They are relatively fatigue resistant, however 
have a faster contractile speed and are able to utilise both triglyceride and glycogen. 
Type IIX fibres are the fastest fibre found within human muscle (Harridge 2007) and 
have a rapid contractile speed and utilise glycogen for respiration. As such, they are 
particularly susceptible to fatigue and are only useful for short duration activities. 
Type IIB (fast glycolytic) fibres are found in many laboratory species. They have very 
rapid contractile speeds and utilise glycogen for respiration similarly to IIX fibres. 
Type IIB fibres are highly susceptible to fatigue and can sustain tetanus for less than 
one minute. TABLE 1.3 contains a summary of the characteristics of current muscle 
fibre type nomenclature. Important inter-species differences include the absence of 
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IIB fibre expression in the locomotor muscles of the human (Harridge 2007), and 
evidence to suggest that rat type IIA muscle fibres are higher in oxidative activity 
than rat type I muscle fibres (Spangenburg and Booth 2003). 
 
 
TABLE 1.3  W Characteristics of current muscle fibre type nomenclature.   
 
Fibre Type I IIA IIX IIB 
MHC Isoform MHC I MHC IIA MHC IIX MHC IIB 
Colour Red   White 
Contractile Speed Slow Moderate Fast Very Fast 
Fatigability Low Moderate High Highest 
Metabolism Oxidative Oxidative / Glycolytic Glycolytic Glycolytic 
Mitochondrial Content High High Medium Low 
 
 
1.3.5  ? Regulation of skeletal muscle fibre type 
Skeletal muscle fibre type is determined by the differential expression of numerous 
genes which regulate contractile and metabolic processes. Muscle fibres are dynamic 
structures and are capable of modulating their phenotype in response to various 
conditions (Pette and Staron 2001). Phenotypic modulations affect all functional 
aspects of the muscle fibre including the expression of myofibrillar proteins, 
metabolic enzymes, glucose and fatty acid transporters and capillary density (Pette 
and Staron 2001). This section will consider the fibre type changes associated with 
innervation, exercise, mechanical load and hormone concentrations.   
 
1.3.5.1  ? Innervation 
The importance of innervation in the specification of skeletal muscle fibre type has 
been reported in several studies (Pette and Staron 2001). Skeletal muscle is 
innervated by numerous motor neurones, each of which serves a small number of 
muscle fibres (McNally, Lapidos et al. 2006). Slow and fast muscle fibres are 
innervated by motor neurones which deliver slow and fast impulse patterns 
respectively (McNally, Lapidos et al. 2006). The importance of neuronal input in the 
specification of skeletal muscle fibre type has been derived from cross-innervation 
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studies which have reported reciprocal changes from fast to slow type muscle fibres 
when they are innervated with neurones of different impulse patterns (Eccles, Eccles 
et al. 1958; Buller, Eccles et al. 1960). Moreover, the importance of neuronal input in 
the maintenance of skeletal muscle fibre type has been demonstrated through 
studies which have shown that denervation leads to the loss of slow fibres in slow 
muscles and fast fibres in faster muscles respectively (d'Albis, Goubel et al. 1994; 
Huey and Bodine 1998). Although more recent studies suggest that the expression of 
neurotrophic factors may be implicated in the specification and maintenance of 
muscle fibre type (Boncompagni, Kern et al. 2007), studies replicating the effects of 
cross-innervation with electrical stimulation confirm that neuronal activity is central 
to this process (Pette, Smith et al. 1973).   
 
1.3.5.2  ? Exercise 
Endurance training is associated with a conversion of muscle fibre type from type IIB 
(in rodents) towards type IIA (Wang, Zhang et al. 2004), an increase in oxidative 
metabolic enzymes and increased capillary density (Henriksson 1992). Similarly, 
strength training has also been associated with changes in muscle fibre type from IIB 
towards IIA (Staron, Malicky et al. 1990; Adams, Hather et al. 1993) however whether 
or not oxidative enzymes are also increased is less clear (Bishop, Jenkins et al. 1999). 
 
1.3.5.3  ? Loading and unloading 
Both the induction of stretch-overload and mechanical loading result in the transition 
of muscle fibres from a fast to a slow phenotype (Pette and Staron 2001). 
Overloaded muscles have been reported to have increased type I muscle fibre 
abundance (Tsika, Wiedenman et al. 1996) and an associated elevation in MHC I 
mRNA and protein expression (Pette and Staron 2001). Conversely, muscle unloading 
is associated with the transition from slow to fast muscle fibre types. Unloaded rat 
soleus muscles have been reported to have reduced MHC I, increased MHC IIA 
expression and de novo synthesis of MHC IIB (Stevens, Gohlsch et al. 1999), a MHC 
isoform not normally found in the slow soleus muscle. Although muscle fibre 
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transitions are also evident in unloaded fast muscles, they tend to be less obvious 
and constitute more subtle fast to faster fibre-type switches (Adams, Haddad et al. 
2000).  
 
1.3.5.4  ? Hormones 
Of all hormones, thyroid hormone appears to have the greatest effect on skeletal 
muscle fibre type. Thyroid hormone is required for the decrease in neonatal MHC 
expression, and concomitant increase in type IIX (human) / IIB (rodents) muscle 
fibres occurring during development (Adams, Haddad et al. 2000). Hypothyroid rats 
show no impairment to type I muscle fibres however retain embryonic and neonatal 
MHC isoform expression in lieu of type II muscle fibre types (Adams, Haddad et al. 
2000). Postnatally, a reduction of thyroid hormone is associated with fast to slow 
muscle fibre type transitions, whilst an increase in thyroid hormone concentration 
results in transitions from slow to fast (Adams, Haddad et al. 2000). 
 
1.3.5.5  ? Possible molecular control mechanisms 
Changes in muscle fibre type require the coordinated expression of numerous 
functional gene groups including those encoding the contractile proteins, 
mitochondrial number, and fatty acid and glucose transport. As such it is appreciated 
that one single control mechanism is unlikely to be responsible for the diversity of 
fibre type (Spangenburg and Booth 2003). FIGURE 1.4 contains a simplified overview 
of multiple possible fibre type gene regulatory pathways.  
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FIGURE 1.4: A simplified overview of multiple fibre type gene regulatory pathways. 
CAMK - calcium/calmodulin-ĚĞƉĞŶĚĞŶƚ ƉƌŽƚĞŝŶ ŬŝŶĂƐĞ // ? W' ?ɲ- peroxisome 
proliferator-activated receptor gamma coactivator-1 alpha, NFAT - Nuclear factor of 
activated T-cells, MEF-2  W myocyte enhancer factor-2, SURE  W slow upstream element 
of troponin 1 promoter, MyoD  W myogenic differentiation 1, AT rich  W AT rich region 
of fast MHC promoter, CArG  W fast MHC promoter element with NF1 and SRF binding 
capacity. Diagram adapted from (Spangenburg and Booth 2003). 
 
1.3.6  ? Regulation of skeletal muscle mass 
In addition to fibre type plasticity, skeletal muscle is also subject to changes in mass, 
the maintenance of which is a fine balance between protein synthesis and protein 
degradation (Lang, Frost et al. 2007; Russell 2009). Skeletal muscle mass is increased 
when there is a net gain in protein synthesis. Increased skeletal muscle mass may 
result from hyperplasia, hypertrophy, or a combination of the two processes 
(Rehfeldt, Fiedler et al. 2000). Conversely, skeletal muscle mass is reduced when 
protein degradation occurs more rapidly than protein synthesis (Russell 2009), 
resulting in a decrease in the mass of existing muscle fibres (Chang 2007). 
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Postnatal growth is primarily a result of the enlargement and elongation of existing 
skeletal muscle fibres. The differentiation of skeletal muscle is therefore a 
prerequisite to the induction of skeletal muscle hypertrophy (Chang 2007). Skeletal 
muscle is derived from the specification of mesodermal pleuripotent stem cells to a 
myogenic lineage via the expression of myoblast determination factor (MyoD) and 
myf-5 (Johnston 2006). Myogenic precursor cells (myoblasts) undergo proliferation, 
associated with an increase in proliferating cell nuclear antigen (PCNA), to form 
myoblast pools (Rehfeldt, Fiedler et al. 2000). During differentiation, myoblasts are 
forced to exit the cell cycle and terminate proliferation. Cell cycle exit is associated 
with an increase in p21 expression (Johnston 2006) and is under the control of 
myogenin, MRF-4 and MEF-2 expression (Johnston 2006). On differentiation, 
myoblasts begin to express muscle-specific proteins and fuse to form multinucleated 
myotubes (Rehfeldt, Fiedler et al. 2000). During muscle development, muscle fibres 
develop from distinct myoblast populations (Miller, Everitt et al. 1993). Primary 
myofibres form first, and provide a framework for the subsequent formation of 
secondary myofibres (Miller, Everitt et al. 1993). A further pool of myoblasts, termed 
satellite cells, do not form muscle fibres but remain in close proximity to the 
myofibres where they retain their ability to proliferate and provide a source of new 
muscle tissue during postnatal growth (Amthor, Otto et al. 2009). In the adult, 
satellite cells are normally mitotically quiescence, and must therefore be activated in 
order to proliferate (Ono, Boldrin et al. 2010).  
 
1.3.6.1  ? Hypertrophy and Akt signalling 
The IGF/PI3K/AKT axis is possibly one of the most well described pathways involved 
in the regulation of skeletal muscle mass (Glass 2005; Russell 2009). Insulin-like 
growth factor I (IGF-1) is sufficient for the induction of marked skeletal muscle 
hypertrophy (Rommel, Bodine et al. 2001).  IGF-I stimulates the phosphatidylinositol-
3-kinase (PI3K) pathway, resulting in the activation of downstream targets required 
for protein translation (Rommel, Bodine et al. 2001). Protein synthesis is controlled 
at the level of translational initiation by the inhibition of eukaryotic initiation factor 
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4e (eIF4E) by PHAS-1 (4EBP1) binding (Connolly, Braunstein et al. 2006) and the 
inhibition of eukaryotic initiation factor 2b (eIF2B) by glycogen synthase 3ɴ (GSK3ɴ) 
(Pap and Cooper 2002). The initial step in this pathway involves the phosphorylation, 
and inactivation of tuberous sclerosis complex 1 and 2 (Tsc1/2) known to inhibit 
mammalian target of rapamycin (mTOR) by PI3K activated Akt (Glass 2005). Activated 
mTOR hyperphosphorylates and inactivates PHAS-1 (4EBP1) thereby liberating eIF4E 
and enhancing protein synthesis (Connolly, Braunstein et al. 2006). Activated Akt is 
ĂďůĞƚŽĚŝƌĞĐƚůǇŝŶĚƵĐĞƚŚĞŝŶŚŝďŝƚŝŽŶŽĨ'^< ?ɴďǇƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ?and the activation 
of eukaryotic initiation factor 2b (eIF2B) (Glass 2005). Both exercise (McKoy, Ashley 
et al. 1999) and mechanical loading (Bamman, Shipp et al. 2001) are associated with 
hypertrophy and increased localised muscle expression of IGF-I. Over-expression 
studies in mice have also noted marked muscle hypertrophy in response to localised 
IGF-1 production (Musaro, McCullagh et al. 2001).  
 
1.3.6.2  ? Satellite cell proliferation 
Skeletal muscle satellite cells are normally mitotically quiescent (Ono, Boldrin et al. 
2010), although retain the ability to generate new muscle fibres or to provide new 
myonuclei (Rehfeldt, Fiedler et al. 2000; Amthor, Otto et al. 2009) following 
activation. ɴ-ĐĂƚĞŶŝŶ ?ĚŽǁŶƐƚƌĞĂŵŽĨ'^< ?ɴ ?ŚĂƐďĞĞŶŝŵƉůŝĐĂƚĞĚŝŶƚŚĞŵĂŝŶƚĞŶĂŶĐĞ
of the satellite cell population by promoting self-renewal (Perez-Ruiz, Ono et al. 
2008). After muscle damage, satellite cells are activated and proliferate for muscle 
repair and regeneration (Kadi, Charifi et al. 2005). Satellite cell number is reported to 
increase following exercise, (Kadi, Schjerling et al. 2004) and steadily decrease in 
response to prolonged periods of detraining (Kadi, Schjerling et al. 2004). They are 
therefore considered imperative for the maintenance of skeletal muscle (Kurosaka 
and Naito 2009). The activation of satellite cells can be attributed to exercise, 
exercise-induced release of growth factors such as IGF-I, or the exercise-induced 
release of inflammatory substances (Kadi, Charifi et al. 2005). IGF-I has been shown 
to increase the proliferation of satellite cells via activation of the Raf-MEK-Erk 
pathway (Kadi, Schjerling et al. 2004).  
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1.3.6.3  ? STARS signalling 
In order for skeletal muscle to adapt to mechanical stresses, there is the requirement 
for a system capable of sensing such changes, and transducing these signals into an 
appropriate response. It has been proposed that the STARS (striated activator of Rho 
signalling) pathway provides such a system and links the transduction of external 
stress to the maintenance of skeletal muscle function via growth and remodelling 
(Russell 2009). The expression of STARS specific mRNA, and its downstream target 
serum response factor (SRF) have been found to increase during functional muscle 
overload (Mahadeva, Brooks et al. 2002). Moreover, STARS has been shown to be 
regulated by both MEF-2 and MyoD. Both of these transcription factors are activated 
by Akt (Xu and Wu 2000) and it has therefore been suggested that STARS and Akt 
may converge to form a complex pathway which regulates muscle growth and 
regeneration (Russell 2009). 
 
1.3.6.4  ? Atrophy and Akt signalling 
Given that AKT signalling is associated with the induction of skeletal muscle 
hypertrophy, numerous studies have investigated the role of this signalling pathway 
in skeletal muscle atrophy (Russell 2009). Mechanical muscle unloading, 
dennervation,  as well as numerous human muscle atrophy conditions are associated 
with reduced IGF-I production  (Grounds 2002) and reduced AKT activation (Russell 
2009). Moreover, molecular studies have reported reduced downstream activation 
of p70S6K, increased binding of 4EBP1 to eIF4E (Bodine, Stitt et al. 2001) and 
therefore reduced protein translation.   
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1.3.6.5  ? Atrogene signalling  
Although skeletal muscle atrophy may involve the calcium-dependent calpain 
system, the lysosomal protease system and the proteasome system (Jackman and 
Kandarian 2004), the majority of skeletal muscle proteolysis in many disease states 
may be attributed to an activation of the ubiquitin proteasome pathway (Jagoe and 
Goldberg 2001) as evidenced by numerous studies in humans and animal models of 
disease (Lecker, Jagoe et al. 2004). Degradation via the ubiquitin-proteasome 
pathway is a multistep process requiring ATP hydrolysis. The first stage involves the 
transfer of activated ubiquitin to the E2 ubiquitin-conjugating protein by E1 
ubiquitin-activating enzyme. E2 ubiquitin-conjugating protein then transfers the 
ubiquitin to an E3 ubiquitin-ligase protein, which forms a complex with the protein 
destined for degradation. Following the addition of multiple ubiquitin molecules, the 
targeted protein is recognised by the 19S cap proteins of the 26S proteasome. The 
protein is then fed into the 20S core of the proteasome where it is degraded by 
active proteolytic enzymes (Orlowski and Dees 2003). Although several hundred 
different E3 ligases have been identified (Glass 2005), skeletal muscle atrophy has 
been consistently associated with significant increases in muscle ring-finger I 
(MuRF1) and muscle atrophy F-box (MAFBx) expression, which are often termed the 
 “ĂƚƌŽŐĞŶĞƐ ?. Both MuRF1 and MAFBx have been shown to have E3 ligase activity 
(Bodine, Latres et al. 2001). MuRF1/MAFBx expression is induced by dennervation 
(Lecker, Jagoe et al. 2004), chronic lipopolysaccharide-induced infection  (Dehoux, 
van Beneden et al. 2003), as well as in 13 independent animal models of muscle 
atrophy (reviewed by Glass, 2005) confirming their pivotal role in skeletal muscle 
proteolysis. dŚĞ ĞǆƉƌĞƐƐŝŽŶŽĨ ƚŚĞ  ? ůŝŐĂƐĞƐ ŝƐ ĐŽŶƚƌŽůůĞĚǀŝĂE&ʃɴƐŝŐŶĂůůŝŶŐ ŝŶ ƚŚĞ
case of MuRF1, or the p38 MAPK cascade in the case of MAFBx. Tumour necrosis 
factor-ůŝŬĞǁĞĂŬŝŶĚƵĐĞƌŽĨĂƉŽƉƚŽƐŝƐ ?dǁĞĂŬ ?ĂĐƚŝǀĂƚĞƐE&ʃɴďǇƉŚŽƐƉŚŽƌǇůĂƚŝŽŶĂŶĚ
ĚĞŐƌĂĚĂƚŝŽŶ ŽĨ /ʃɴɲ (Dogra, Changotra et al. 2006) which in turn induces the 
expression  of MuRF1 (Cai, Frantz et al. 2004) ?^ŝŵŝůĂƌůǇ ?E&ʃɴŵĂǇďĞĂĐƚŝǀĂƚĞĚďǇ
ƚƵŵŽƵƌ ŶĞĐƌŽƐŝƐ ĨĂĐƚŽƌ ĂůƉŚĂ  ?dE&ɲ ? ? ĂůƐŽ ĨŽƵŶĚ ƚŽ ďĞ ĞůĞǀĂƚĞĚ ŝŶ ƐĞǀĞƌĂů ĂƚƌŽƉŚǇ
conditions (Hafer-Macko, Yu et al. 2005). E&ʃɴ ŚĂƐ ďĞĞŶ ĨŽƵŶĚ ƚŽ ďĞ ĞůĞǀĂƚĞĚ ŝŶ
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skeletal muscle atrophy due to disuse and sepsis (Glass 2005), and blockade of the 
E&ʃɴƉĂƚŚǁĂǇcan attenuate skeletal muscle atrophy (Li and Reid 2000). p38 MAPK 
activates MAFBx expression (Chen, Jin et al. 2007), the action of which is antagonised 
by dual specificity phosphatase 1 (Dusp1) via inhibition of p38 (Franklin and Kraft 
1997) ? dE&ɲ ŚĂƐ ďĞĞŶ ƐŚŽǁŶ ƚŽ ŝŶĚƵĐĞ D&ǆ ĞǆƉƌĞƐƐŝŽŶ ? ĂŶĞĨĨĞĐƚ ƚŚĂƚ ŝƐ
ameliorated by p38 inhibition (Li, Chen et al. 2005). Myosin heavy chain has been 
reported to be a specific target for proteosome degradation (Acharyya, Ladner et al. 
2004). 
 
 
 
FIGURE 1.5: Summary of some of the signalling pathways involved in skeletal muscle 
proliferation, glycogen synthesis, protein synthesis, skeletal remodelling events and 
protein degradation. Raf  W proto-oncogene c-raf , MEK  W mitogen-activated protein, 
ERK  W extracellular-signal-ƌĞŐƵůĂƚĞĚ ŬŝŶĂƐĞ ? '^< ?ɴ  W ŐůǇĐŽŐĞŶ ƐǇŶƚŚĂƐĞ  ?ɴ ? '^  W 
glycogen synthase, eIF2B  W eukaryotic translation initiation factor 2b, mTOR  W 
mammalian target of rapamycin, p70S6K  W ribosomal protein S6 kinase, 4EBP1 
(PHAS-1)  W eIF4E binding protein 1, STARS  W striated activator of Rho signalling, SRF  W 
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serum response factor, FOXO  W forkhead box O, MAFBx  W muscle atrophy F-box, 
MuRF1  W muscle ring finger protein 1, IKK  W IK B kinase, NFKB  W nuclear factor kappa-
light-chain-enhancer of activated B cells ?dE&ɲ Wtumour ŶĞĐƌŽƐŝƐĨĂĐƚŽƌĂůƉŚĂ ?/> ?ɴ W 
ŝŶƚĞƌůĞƵŬŝŶ ?ɴ ? 
 
 
1.3.6.6  ? Summary 
The regulation of skeletal muscle may encompass both changes in muscle fibre type 
(contractile and metabolic), and changes in skeletal muscle mass. The regulation of 
skeletal muscle fibre type stems from several molecular pathways which result in the 
differential regulation of numerous gene groups which encode contractile, metabolic 
and transport-associated proteins. The regulation of skeletal muscle mass involves 
the complex interplay of protein synthesis and protein degradation. Increases in 
skeletal muscle mass are associated with both hypertrophic and hyperplastic 
responses which are mediated by numerous interconnecting molecular pathways. 
Decreases in skeletal muscle mass are associated with both increased protein 
degradation and decreased protein synthetic drive. The next section will consider 
changes in skeletal muscle fibre and mass in several pathological conditions. 
 
1.3.7  ? The effects of pathology on skeletal muscle fibre type and mass  
Many human pathologies impact upon skeletal muscle function, both with respect to 
muscle fibre type, and the regulation of skeletal muscle mass. This section will give a 
brief overview of the effects of sarcopenia, cachexia, disuse and chronic obstructive 
pulmonary disease on parameters of muscle function. The effects of knee 
osteoarthritis will be considered separately in the next section. 
 
Sarcopenia was originally described by Evans (Evans and Campbell 1993) and defined 
as an  age-related decrease in lean body mass. Sarcopenia results in reduced 
strength, metabolic rate and aerobic capacity (Evans 2010). Sarcopenia is a 
multifactorial condition resulting from disuse, endocrine changes, inflammation and 
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insulin resistance (Lecker, Jagoe et al. 2004). The reduction of muscle bulk in 
sarcopenia has been attributed to the coordinate loss (Lexell, Taylor et al. 1988) and 
atrophy (Sato, Akatsuka et al. 1984) of muscle fibres. Although there is some 
contention with regards which fibre types are preferentially affected (Evans 2010), 
the general consensus indicates that type II muscle fibres are more susceptible to 
age-related atrophy than type I fibres (Bua, McKiernan et al. 2002).  
 
Cachexia is the accelerated loss of skeletal muscle protein in the absence of reduced 
energy intake (Evans 2010) and may or may not include loss of adipose tissue 
(Lecker, Jagoe et al. 2004). Cachexia results in marked skeletal protein loss and 
contributes to nearly one-third of cancer related deaths (Acharyya, Ladner et al. 
2004). As with many atrophy conditions, cachexia is thought to result from a 
coordinate increase in proteolysis and decrease in protein synthesis. Cachexia is 
moreover associated with inflammation and insulin resistance. Similarly to 
sarcopenia, cachexia results in the preferential atrophy of type II muscles fibres 
(Baracos, Devivo et al. 1995; Acharyya, Ladner et al. 2004), with type I fibres less 
affected.  Despite many similarities with sarcopenia, cachexia is a distinct disease, 
and requires more careful management (Evans, Morley et al. 2008) given the high 
level of mortality associated with this condition.   
 
Disuse atrophy has been well-described in patients following extended bed rest 
(Ohira, Yoshinaga et al. 1999) and in numerous animal models of un-loading (Giger, 
Bodell et al. 2009). More commonly, disuse atrophy is noted in patients undergoing 
orthopaedic surgery requiring joint casting (Reardon, Davis et al. 2001). Both human 
and animal studies have demonstrated a rapid decrease in protein synthesis and 
concomitant increase in proteolysis via the ubiquitin-proteasome pathway (Reardon, 
Davis et al. 2001). Unlike the majority of atrophy conditions that comprise type II 
fibre atrophy (Ohira, Yoshinaga et al. 1999; Giger, Bodell et al. 2009), disuse atrophy 
preferentially affects type I muscle fibres, with little evidence of type II fibre 
involvement. Type I fibres tend to accrue in slow, postural muscles such as the soleus 
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(Caiozzo, Haddad et al. 1996). Similar effects of slow type I muscles are also noted in 
rodents maintained in microgravity environments, with the exception that some 
studies report the de novo synthesis of MHC IIX fibres in space-flown rodents 
(Caiozzo, Haddad et al. 1996; Adams, Haddad et al. 2000), an observation that is not 
generally reported in disuse atrophy. 
 
Chronic obstructive pulmonary disease is a generalised term used for chronic 
bronchitis, emphysema or both of these conditions. COPD results in breathlessness, 
increased incidence of chest infections and marked muscle weakness (Gosker, 
Engelen et al. 2002). Interestingly, COPD is associated with atrophy of the vastus 
lateralis, a component part of the quadriceps muscle group. The degree of atrophy is 
considered an independent predictor of mortality (Hansen, Gualano et al. 2006). 
There is no consensus with regards to which muscle fibres are preferentially affected. 
Whilst some studies report the preferential atrophy of MHC IIX fibres (and MHC 
IIA/IIX hybrid fibres) (Gosker, Engelen et al. 2002), others report type I / IIA fibre 
predominant atrophy (Jobin, Maltais et al. 1998; Whittom, Jobin et al. 1998). 
 
1.3.8  ? The effects of osteoarthritis on parameters of muscle function 
It is established that patients with knee osteoarthritis (OA) exhibit marked muscle 
weakness (Slemenda, Heilman et al. 1998; Brandt, Heilman et al. 1999; Hurley 1999; 
Brandt, Heilman et al. 2000; Becker, Berth et al. 2004; Eyigor 2004; Ikeda, Tsumura et 
al. 2005; Mikesky, Mazzuca et al. 2006; Mohammadi, Taghizadeh et al. 2008; 
Nishimura, Hasegawa et al. 2010), which is one of the most frequent and earliest 
reported symptoms associated with knee OA (Longino, Frank et al. 2005). Weakness 
primarily affects the quadriceps muscle with little or no evidence of hamstring 
involvement (Brandt, Heilman et al. 1999), resulting in a reduced quadriceps to 
hamstring mass (Q/H) ratio (Hayes, Song et al. 2002). 
 
Historically, muscle weakness has been considered a secondary effect in knee OA, 
resulting from disuse of the affected joint due to the presence of pain and/or 
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inflammation, and therefore has received little attention with regards to its 
involvement in the initiation or progression of OA. However, there is clinical evidence 
which suggests that quadriceps weakness may precede the onset of radiographic 
evidence of OA and subsequent pain (Hurley 1999), and therefore may be directly 
involved in its pathogenesis (Ikeda, Tsumura et al. 2005). Firstly, quadriceps 
weakness has been reported in patients with radiographic signs of knee OA in the 
absence of pain, suggesting that muscle weakness is unlikely to be due to disuse of a 
painful joint (Slemenda, Brandt et al. 1997). Secondly, quadriceps weakness was 
noted in a number of patient groups who are susceptible to developing knee OA, for 
example patients who have gait abnormalities resulting in increased knee loading 
(Marks, Kumar et al. 1994), patients with anterior cruciate ligament (ACL) 
insufficiencies (Longino, Frank et al. 2005) and most commonly patients who have 
undergone partial meniscectomy surgery as a treatment of medial meniscal tears 
(Mills, Wang et al. 2008). Initially, patients who have undergone meniscectomy have 
marked muscle weakness of the ipsilateral limb in the absence of manifest OA 
(Becker, Berth et al. 2004; Ericsson, Roos et al. 2006). However, at long-term follow-
up, meniscectomised patients have an elevated incidence of OA (odds ratio = 10), 
compared to age and sex matched subjects with no history of meniscal injury 
(Lohmander, Englund et al. 2007). In these patient groups, quadriceps dysfunction 
was noted prior to any radiographic evidence of OA, again suggesting that the 
quadriceps dysfunction reported in knee OA was unlikely to be solely due to disuse 
atrophy. 
 
Whether a strong quadriceps muscle can also be a protective factor in the initiation 
of OA is perhaps more debatable.  A study examining the incidence of OA at a 5-year 
follow up in subjects with no radiographic evidence of OA at baseline, found that 
those subjects who developed OA had weaker quadriceps strength at baseline 
(Thorstensson, Petersson et al. 2004). Conversely, a recent longitudinal study 
conducted by Segal and colleagues 2009 found that although quadriceps strength 
was reduced with increasing Kellgren-Lawrence (KL) grade for tibiofemoral OA at 
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baseline, neither strength nor normal Q/H ratio was protective against the 
development of incident radiographic OA. However, of interest, increased quadriceps 
strength was protective against the development of incident symptomatic whole 
knee OA, albeit this was restricted to female participants once corrected for knee 
pain at baseline (Segal, Torner et al. 2009).   
 
There is also contradictory evidence with regards quadriceps strength and disease 
progression in individuals with established knee OA. The assessment of patients with 
established knee OA showed that a strong quadriceps muscle was protective for 
cartilage loss at the lateral compartment of the patellofemoral joint (Amin, Baker et 
al. 2009)  and joint space narrowing (Segal, Glass et al. 2010) over a 30 month period. 
Moreover an association between restricted quadriceps range-of-motion and 
increased progression (Nishimura, Hasegawa et al. 2010) has been reported. 
However, other studies have found this protective effect to be limited to females 
only (Slemenda, Heilman et al. 1998) and one study found a detrimental effect in 
malaligned and lax knees (Sharma, Dunlop et al. 2003). 
  
Morphological studies suggest that the muscle dysfunction associated with knee OA 
is due, in part, to atrophy of quadriceps muscle fibres. A recent study noted that all 
patients assessed with knee OA presented with atrophy of type II fast-twitch muscle 
fibres, whilst less than one third of the patients presented with atrophy of type I 
slow-twitch muscle fibres (Fink, Egl et al. 2007) as assessed by histochemical staining. 
This suggests that quadriceps dysfunction in knee OA is most commonly associated 
with atrophy of fast-twitch type II muscle fibres, an observation supported by 
previous histochemical studies (Nakamura and Suzuki 1992), and reported in many 
other muscle atrophy associated conditions. 
 
1.3.9 - Interventions for the amelioration of atrophy associated conditions 
Atrophy is often a consequence of aging, cachexia, disuse, chronic obstructive 
pulmonary disease and osteoarthritis. Moreover, the effectiveness of glucocorticoid 
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treatments, such as dexamethasone, is limited due to muscle wasting which is a 
commonly reported side effect (Glass 2003). Currently, there are no safe and 
effective medicines available for the treatment of skeletal muscle atrophy (Glass 
2003). Due to the clinical implications of skeletal muscle atrophy, amelioration of this 
debilitating condition has been considered in numerous studies.  
 
1.3.9.1  ? Exercise 
The effects of various exercise paradigms have been shown to increase protein 
synthesis (Boirie 2009) and attenuate both age-related (Song, Kwak et al. 2006) and 
glucocorticoid-induced (Falduto, Czerwinski et al. 1990) muscle fibre atrophy. It is 
possible that exercise mediates the inhibition of atrophy via contractile input 
(Falduto, Czerwinski et al. 1990), via increased local IGF-I production (Chang 2007) 
and downstream increases in protein translation, or a combination of the two 
processes.  
 
With reference to osteoarthritis, a number of studies have shown that exercises 
aimed at improving quadriceps function have beneficial symptomatic effects in knee 
OA patients (O'Reilly, Muir et al. 1999; Baker, Nelson et al. 2001; Thomas, Muir et al. 
2002; Eyigor 2004; Keefe, Blumenthal et al. 2004; Rosemffet, Schneeberger et al. 
2004; Diracoglu, Aydin et al. 2005; Mikesky, Mazzuca et al. 2006; Jan, Lin et al. 2008; 
Bezalel, Carmeli et al. 2010). For example, the impact of both high and low resistance 
training on subjects with knee OA was recently investigated, where it was reported 
that improved quadriceps function was associated with a reduction in knee pain and 
increased physical ability (Jan, Lin et al. 2008). Similarly, strength training and 
balance exercises were also shown to significantly reduce knee pain and improve 
physical ability (Diracoglu, Aydin et al. 2005). To date, only one randomised-
controlled trial, evaluating the effects of strength training programs on the onset and 
progression of knee OA, has been conducted (Mikesky, Mazzuca et al. 2006). Patients 
with established knee OA undergoing 3 sessions of strength training (ST) per week 
had reduced joint space narrowing (JSN) at 30 month follow-up compared with those 
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patients undertaking range of motion (ROM) exercises for the same duration. 
However, patients undertaking ST who were radiographically normal at baseline 
exhibited a slightly elevated incidence of JSN than those undertaking ROM exercises. 
 
1.3.9.2  ? Molecular 
Numerous studies have attempted to ameliorate atrophy by modulating components 
of molecular pathways known to be involved in the process (see FIGURE 1.5). At the 
molecular level, the inhibition of E3-ligases MuRF1 and MAFBx (Bodine, Latres et al. 
2001), the constitutive activation of AKT (Bodine, Stitt et al. 2001) and the direct 
administration of IGF-I  (Stitt, Drujan et al. 2004) have been shown to decrease 
(MuRF1/MAFBx) or even ablate (AKT/IGF-I) skeletal muscle atrophy. Such studies 
have provided new molecular drug targets against which novel pharmaceuticals may 
be directed in the hope of ameliorating muscle atrophy in a variety of clinical 
conditions (Glass 2005).   
 
1.3.9.3  ? Pharmacological 
Testosterone is an important male steroid hormone, the effects of which increase 
muscle mass and reduce adipose tissue (Chang 2007). Anabolic steroids have been 
reported to increase skeletal muscle protein synthesis (Kadi, Eriksson et al. 1999; 
Sheffield-Moore 2000; Bhasin, Calof et al. 2006), decrease skeletal muscle proteolysis 
(Kutscher, Lund et al. 2002; Bhasin, Calof et al. 2006) and induce the activation of 
satellite cells (Kadi 2000; Bhasin, Calof et al. 2006). Testosterone administration has 
been associated with the hypertrophy of both type I and type II muscle fibres (Sinha-
Hikim, Artaza et al. 2002; Bhasin, Calof et al. 2006), but has not been associated with 
relative changes in muscle fibre type composition (Sinha-Hikim, Roth et al. 2003). 
Testosterone administration has been reported to reverse atrophy induced by 
sarcopenia (Kovacheva, Sinha Hikim et al.), glucocorticoid administration (Bhasin, 
Calof et al. 2006) and human immune deficiency virus (HIV) infection (Bhasin, Calof 
et al. 2006). Conversely, testosterone administration has not been found to elicit any 
effects on atrophy induced by dennervation (Beehler, Sleph et al. 2006). Limited 
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information is available with respect to the potential signalling pathways via which 
testosterone elicits such hypertrophic effects, however the primary mechanism is 
thought to be via localised production of IGF-I  (Chang 2007) and the subsequent 
activation AKT signalling (Stitt, Drujan et al. 2004). 
 
dŚĞĂĚŵŝŶŝƐƚƌĂƚŝŽŶŽĨɴ ?-adrenergic agonists, such as clenbuterol, has been reported 
to induce skeletal muscle hypertrophy and decrease atrophy. Moreover, clenbuterol 
administration has been associated with slow to fast muscle fibre-type shifts, thereby 
demonstrating a potential to maintain the very fibre types lost to atrophy in 
numerous conditions (Baracos, Devivo et al. 1995; Whittom, Jobin et al. 1998; Bua, 
McKiernan et al. 2002; Gosker, Engelen et al. 2002; Acharyya, Ladner et al. 2004; 
Evans 2010). By virtue of their hypertrophic effects on skeletal muscle, the 
ĂĚŵŝŶŝƐƚƌĂƚŝŽŶŽĨɴ ?-agonists has been examined in a number of atrophy associated 
conditions with a view to positively modulating disease outcomes.  
 
dŚĞŚǇƉĞƌƚƌŽƉŚŝĐĂĐƚŝŽŶŽĨɴ ?-agonist administration is thought to result from both 
increases in protein synthetic rate and decreased proteolysis. The binding of ɴ ?-
agonists ƚŽ ɴ ?-ARs leads to the activation of adenyl cyclase, an enzyme which 
catalyses the conversion of ATP to cAMP. cAMP binds to protein kinase A (PKA) and 
in doing so releases a catalytic subunit. The catalytic subunit phosphorylates a 
number of intracellular proteins including the cAMP response element binding 
protein (CREB). CREB is able to bind to the cAMP response element of various genes 
are thereby induce their transcription. ɴ ?-agonists have also been shown to activate 
the PI3K/Akt pathway leading to the activation of downstream signalling and 
subsequent increase in protein synthesis (Ryall and Lynch 2008). Kline and colleagues  
(Kline, Panaro et al. 2007) demonstrated that whilst clenbuterol-induced fast-fibre 
hypertrophy could be ablated by the use of rapamycin inhibitors (therefore 
blockading factors signalling downstream of mTOR), slow-fibre hypertrophy was 
unaffected suggesting the hypertrophy slow and fast fibres may be differentially 
regulated (Kline, Panaro et al. 2007). Moreover, ɴ ?-agonist administration has been 
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shown to have marked effects on skeletal muscle proteolytic systems. Although the 
precise mechanism of proteolytic inhibition remains unclear (Ryall and Lynch 2008), 
ɴ ?-agonists have been shown to reduce calcium dependent (calpain) mediated 
proteolysis by decreasing µ-calpain expression (Forsberg, Ilian et al. 1989), and 
increase expression of the endogenous inhibitor of calpain, calpastatin (PARR, 
BARDSLEY et al. 1992) ?ɴ ?-agonist administration has been further demonstrated to 
have potent effects on the ubiquitin-proteasome pathway. It has been proposed that 
ƚŚĞ ĚĞĐƌĞĂƐĞĚ ƉƌŽƚĞŽůǇƐŝƐ ǀŝĂ ƚŚŝƐ ƉĂƚŚǁĂǇ ŝƐ ŵĞĚŝĂƚĞĚ ďǇ ŶƵŵĞƌŽƵƐ ɴ ?-agonist 
induced changes including decreased ubiquitin availability (Costelli, GarcÃ­a-
MartÃ­nez et al. 1995), decreased ubiquitination of target proteins (Busquets, 
Figueras et al. 2004), decreased E3 ligase expression (Kline, Panaro et al. 2007) and 
reduced proteasome activity (Busquets, Figueras et al. 2004). 
 
ɴ ?-agonists have been implicated in the shift from slow to faster-twitch muscle fibre 
type (Ricart-Firinga, Stevens et al. 2000; Stevens, Firinga et al. 2000). Whether the 
increase in faster-fibre types is associated with an increase in glycolytic metabolic 
potential is perhaps less clear. Whilst Pellegrino and colleagues noted an increase in 
glycolytic metabolism (phosphofructokinase, PFK and lactate dehydrogenase, LDH) 
following clenbuterol administration in mice (Pellegrino, D'Antona et al. 2004), 
Mounier and colleagues, 2007 failed to replicate this finding in the rat (Mounier, 
Cavalié et al. 2007). Clenbuterol has been shown to have a greater hypertrophic 
effect on slow-twitch muscle when compared with faster-twitch muscles (Ricart-
Firinga, Stevens et al. 2000; Stevens, Firinga et al. 2000; Herrera, Zimmerman et al. 
2001), further suggesting a fibre type specific response. 
 
ƵĞƚŽƚŚĞŝƌŚǇƉĞƌƚƌŽƉŚŝĐĂŶĚĨŝďƌĞŵŽĚƵůĂƚŝŶŐĞĨĨĞĐƚƐ ?ɴ ?-agonist use has recently 
been considered for the treatment of human pathologies which include a component 
of muscle weakness or atrophy including sarcopenia, cancer cachexia, disuse, 
microgravity and chronic obstructive pulmonary disorder. To date, ɴ ?-agonist 
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administration has not been considered with respect to ameliorating osteoarthritis 
associated skeletal muscle atrophy.  
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1.4  ? Summary and Global Hypothesis 
 
Osteoarthritis of the knee is associated with skeletal muscle dysfunction of the 
quadriceps muscle. Fibre typing studies have reported variable changes to the fibre-
type composition of the quadriceps muscle group in response to osteoarthritis. 
Whilst the majority of evidence suggests that type II fibres are preferentially affected 
(Nakamura and Suzuki 1992), others report that up to one third of patients present 
with type I fibre atrophy (Fink, Egl et al. 2007). Furthermore, population-based 
studies have shown that a larger quadriceps mass may be protective of both the 
initiation of OA and disease progression in established disease. Central to this thesis 
is the hypothesis that muscle fibre type is altered in response to developing and 
progressing osteoarthritis of the knee.  
 
The following specific hypotheses are addressed as follows; 
 
Chapter 3  W Hypotheses 
The development of meniscectomy-induced osteoarthritis will be associated with 
changes to the fibre-type composition of the quadriceps muscle group, potentially 
manifesting as a reduced type II fibre complement. Clenbuterol administration for 14 
days will result in marked hypertrophy of the quadriceps muscle group, with an 
associated increase in the proportion of type II fast twitch muscle fibres. The 
induction of quadriceps hypertrophy and the potential modulation towards a faster-
twitch muscle phenotype prior to the induction of OA will have a protective effect on 
the knee joint, assessed histologically 21 days post induction. 
 
Chapter 4  W Hypotheses 
The structure of the sarcomeric MHC family in the laboratory guinea pig will be 
clustered in a head-to-tail fashion, consistent with that of other species which have 
been previously described (chapter 1.3.3). Furthermore, enough sequence variability 
will exist between the various isoforms of MHC, at the mRNA level, as to allow the 
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design and validation of isoform-specific oligonucleotide primers for expression 
studies by quantitative PCR.  
 
Chapter 5  W Hypotheses 
Bilateral knee OA will present in the Dunkin Hartley guinea pig from around 3 months 
of age. Consistent with other literature, it is expected that the severity of OA will 
increase with advancing age and increasing body mass. Functional changes to the 
quadriceps muscle will occur coincident with the development of knee OA, and 
animals may present with changes to contractile (MHC) or metabolic muscle 
parameters.  
 
Chapter 6  W Hypotheses 
Rat-derived myotubes (L6.G8.C5) will express a range of MHC isoforms, indicative of 
the presence of multiple fibre types, and thus model the in vivo situation. 
Osteoarthritis has been associated with both elevated serum dE&ɲ concentration 
and type II muscle fibre atrophy. Therefore it is hypothesised that the administration 
ŽĨƌĞĐŽŵďŝŶĂŶƚƌĂƚdE&ɲƚŽƌĂƚ-derived myotubes will result in changes to their MHC 
composition, indicative of fibre type shifts. More specifically, it is hypothesised that 
dE&ɲ will induce a reduction in the abundance of fast-type II fibre specific mRNAs 
(MHC IIX, MHC IIB). 
 
The hypotheses are investigated within this thesis in four separate results chapters. 
Chapter 3 reports the effects of ɴ ?-adrenergic agonist administration on the severity 
of osteoarthritis in a rodent meniscectomy induced model. Chapter 4 comprises 
molecular tool development for the assessment of muscle MHC profile in the 
laboratory guinea pig, whilst Chapter 5 characterises muscle dysfunction in a 
spontaneous model of OA. Chapter 6 considers whether osteoarthritis-associated 
cytokines are able to induce skeletal muscle fibre-type changes in an isolated in vitro 
system.  
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CHAPTER 2  ? ROUTINE MATERIALS AND METHODS 
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2.1  ? Nucleic Acid Extractions and Procedures 
 
2.1.1  ? Extraction of total ribonucleic acids (RNA) 
Prior to extraction, all plastic and glassware was autoclaved to ensure sterility. All 
solutions were prepared in RNase and DNase-free water (Molecular Biology grade 
water, Sigma). Total RNA was extracted from snap-frozen samples using TRIzol ? 
reagent (Invitrogen). Briefly, 1ml of TRIzol was added to a sterile 1.5ml tube 
containing 100mg of crushed sample. Samples were homogenised using a 10mm 
diameter Polytron ? probe for 2 cycles of 12 seconds; at all times the samples were 
kept on ice. Following centrifugation at 16,000g (Accuspin Micro, Fisher) for 10 
minutes at 2oC, the supernatant was transferred to a clean 1.5ml tube. The 
supernatant was incubated at room temperature for 5 minutes before the addition 
of 200µl chloroform per 1ml TRIzol. The tube was mixed vigorously by hand for 30 
seconds and incubated at room temperature for 3 minutes. After centrifugation at 
16,000g for 15 minutes at 2oC, the upper aqueous phase was removed to a clean 
1.5ml tube, avoiding the interphase. 500µl isopropanol and 250µl 0.8M sodium 
citrate / 1.2M sodium chloride was added per 1ml TRIzol. Samples were precipitated 
for 1 hour at -20oC.  
 
Following precipitation, samples were centrifuged at 16,000g for 10 minutes at 2oC 
and the supernatant removed and discarded. The resulting RNA pellet was washed in 
75% ethanol with DEPC treated water, and following centrifugation at 9,000g for 5 
minutes at 2oC, the supernatant discarded. The resultant RNA pellet was dissolved in 
40µl of molecular biology grade water (Sigma) and stored at -80oC until analysis.  
 
2.1.2  ? Removal of contaminating genomic deoxyribonucleic acid (DNA) 
Prior to reverse transcription, all extracted total ribonucleic acids were treated with 
ZY ?EĂƐĞ ? ?WƌŽŵĞŐĂ ?ƚŽƌĞŵŽǀĞĐŽŶƚĂŵŝŶĂƚŝŶŐŐĞŶŽŵŝĐE ?dŽƚĂůZEA (40µl as 
previously resuspended) was incubated with 1U DNase in 5µl of buffer comprising 
400mM Tris-HCl pH8.0, 100mM MgSO4 and 10mM CaCl2 for 30 minutes at 37
oC. 
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Following incubation, 150µl water and 200µl phenol/chloroform/isoamylalcohol 
(25:24:1) were added, vortexed briefly and the sample centrifuged at 16,000g for 5 
minutes. The upper phase containing RNA was removed to a fresh tube containing 
15µl 3M sodium acetate and 375µl ethanol and precipitated at -80oC for 2 hours. 
Samples were centrifuged at 16,000g for 15 minutes and the supernatant discarded, 
washed in 75% (v/v) ethanol and then re-centrifuged at 16,000g for 5 minutes and 
resuspended in 40µl molecular biology grade water. 
 
2.1.3  ? RNA quality assessment and quantification 
The concentration of RNA in molecular biology grade water was determined 
spectrophotometrically using the Nanodrop system (Thermo Scientific) blanked 
against a water standard. Measurements were taken at 260nm for nucleic acids, and 
280nm for proteins. The ratio of these two measurements was calculated and a ratio 
of 1.8  W 2.0 (nucleic acid to protein) deemed acceptable.  
 
RNA integrity was determined by 1.2% (w/v) agarose gel electrophoresis (METHOD 
2.1.4). 5µl of RNA was combined with 1µl of loading buffer (Promega) and 
electrophoresed for 30  W 40 minutes at 70V - samples were stained and visualised in 
accordance with (METHOD 2.1.4). RNA samples with well-defined 18S and 28S 
ribosomal bands were deemed acceptable. Any samples with diffuse bands, 
indicative of RNA degradation were re-extracted from another 100mg tissue prior to 
first strand cDNA synthesis. 
 
2.1.4  ? Agarose gel electrophoresis 
PCR amplicons and extracted RNAs were routinely resolved by horizontal non-
denaturing agarose gel electrophoresis. The % concentration of agarose gel utilised 
was dependent on the size of the fragments to be resolved. 1.2% (w/v) agarose gels 
were used to resolve RNA extractions and larger PCR amplicons (> 1Kb). For PCR 
amplicons of 350 bp  W 1 Kb, 1.5% (w/v) agarose gels were used, whilst smaller 
fragments (< 350 bp) were resolved on 1.8  W 2.0% (w/v) gels.  
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Agarose (Melford, UK) was prepared in TAE buffer (APPENDIX A), heated to boiling 
point in a standard microwave oven, and stirred to ensure that all agarose powder 
was dissolved. The solution was cooled to around 50oC (hand hot) and poured into a 
gel former (Bio-Rad) with the corresponding gel comb (15-well). Gels were allowed to 
solidify initially at room temperature, before being set for 30 minutes at 4oC. 
 
Samples (generally 5µl) were combined with 1µl loading buffer (Promega) and loaded 
onto 1.2% (w/v) RNase and DNase-free agarose gel (Melford) prepared in TAE buffer 
(APPENDIX A). Samples were electrophoresed at 70V for 30  W 45 minutes, stained for 
30 minutes in ethidium bromide (0.5µg/ml) and visualised under a UV light source. 
Images were captured (GelDoc 2000, Bio-Rad) and densitometry performed using 
software configured for ethidium bromide staining methodologies (Quantity-one, 
Bio-Rad). DNA markers (DNA ladder, Promega) were included in all runs to delineate 
the length (bp) of unknown resolved products.  
 
2.1.5  ? Generation of first-strand complimentary DNA (cDNA) 
First strand complimentary DNA (cDNA) was obtained from total RNA by means of 
the reverse transcriptase reaction (Promega) using random primers. Reverse 
transcriptase, derived from Moloney Leukaemia Virus (MMLV) in this instance, 
transcribes RNA to DNA in a 5  W  ? ? ĚŝƌĞĐƚŝŽŶ ĨƌŽŵ Ă ƐŝŶŐůĞ ŽůŝŐŽŶƵĐůĞŽƚŝĚĞ ƉƌŝŵĞƌ 
using free nucleotides resulting in complementary DNA (cDNA) formation. 500ng 
total RNA (50ng/µl) was added to 0.5µg random hexamers (Promega) (unless 
otherwise stated) and 9µl of DNase/RNase free-water in thin-walled tubes (Alpha 
Laboratories). Samples were heated for exactly 5 minutes at 70oC and then 
immediately placed on ice. 10 µl of master mix containing 5µl MMLV Reverse 
Transcriptase Buffer, 1.25µl 10mM dNTPs, 25U RNase inhibitor, 200U MMLV Reverse 
Transcriptase and 2.25µl molecular biology grade water was added to the RNA and 
left to incubate at room temperature for 10 minutes. Samples were heated to 42oC 
for 1 hour to complete the elongation phase. The resulting cDNA was diluted 1 in 4 
(v/v) with water, and stored at -20oC prior to further analysis. 
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2.1.6  ? Oligonucleotide primer design 
Primers were designed from database sequences (details of which are included in the 
respective results chapter) in the case of rat studies, or conserved regions as 
determined from multi-species sequence alignment in the case of guinea pig 
expression studies. Sequence data was input into Primer3 in FASTA format, and 
primers designed using the default criteria (Primer size: 18  W 27bp, Melting 
Temperature: 55  W 62oC, Amplicon size: 50  W 150bp) and sourced from MWG 
(Eurofins). All primers were high-purity salt free (HPSF) and synthesised at a 
concentration of 0.01µM. All oligonucleotide primer pairs were assessed by endpoint 
PCR, to ensure a single amplicon of the expected size was produced.  
 
For quantitative PCR use, the efficiency of amplification by each primer set was 
assessed in a reaction using a series of known dilutions of pooled cDNA. The cDNA 
pool was produced, in general, by combining an equal aliquot of all samples from a 
particular study. To ensure the cDNA pool was as representative of the data set of 
possible, each sample was quantified independently by the primer pair in question, 
and any sample with a concentration > 2 standard deviations from the mean 
excluded from the pool. This step was introduced to reduce skewness of the data, 
and to identify samples which may be contaminated with potential PCR inhibitors 
and thus prevent them from affecting the total cDNA pool. The remaining samples, 
falling within 2 standard deviations of the mean were combined, diluted and 
amplified using the primer pair.  
 
The efficiency of a PCR reaction is calculated by 10(-1/slope), where the slope is 
determined by plotting log10 cDNA concentration against the crossing point (Cp). An 
efficiency of 2.0 represents the theoretical PCR reaction, with a doubling of amplicon 
abundance following each cycle. Efficiency was determined for all primer pairs, 
ensuring that the efficiency of amplification fell within the range 1.8  W 2.0 (90  W 
100%).  
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2.1.7  ? Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is the amplification of a target sequence that is 
specific to a gene of interest. PCR can be used to obtain semi-quantitative (End-
Point) or quantitative gene expression data dependent on the methodology used. 
Irrespective of technique, the basic principle of PCR is the same. 
 
For the assessment of gene expression, total RNA was extracted, treated to remove 
contaminating genomic DNA and reverse transcribed as per (METHODS 2.1.1  ? 
2.1.5). For each PCR cycle, the cDNA strands were denatured at 94oC, and the 
temperature reduced to the specific melting temperature of the oligonucleotide 
primer pair (55  W 65oC) to allow annealing. The temperature was raised to 72oC for 30 
seconds, allowing the primers to extend and form the desired amplicon. PCR was 
allowed to proceed for a maximum of 35 cycles.  
 
The cycle number at which the PCR is quantified is critical to how reflective the 
product abundance is of the amount of starting material. The initial phases of the 
PCR are characterised by exponential amplification, with each cycle resulting in a 
doubling in specific product. At this stage, quantification of the specific product 
abundance is reflective of the amount of starting material. As the amount of specific 
product increases, reaction constituents (primers, polymerase, and free nucleotides) 
become limited, and the relationship between the amount of specific product and 
amount of starting material declines. Therefore, quantification must be carried out in 
the exponential amplification phase (FIGURE 2.1).  
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FIGURE 2.1  W Schematic of PCR Amplification Curve. The highlighted box shows the 
exponential phase of a theoretic PCR reaction from which expression data can be 
obtained. Following the exponential phase, the PCR reaction begins to plateau due to 
decreasing reaction constituent availability.  
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2.1.7.1  ? End point PCR 
End-point PCR reactions were utilised for confirming the presence or absence of a 
particular mRNA, and for confirming the size of the resulting amplicon were absolute 
quantification of mRNA abundance was not required.  
 
End-point PCR reactions were performed on 5µl cDNA in AmpliTaq Gold PCR Buffer 
(ABI) with a final concentration of 1.5mM MgCl2, 0.2mM dNTP mix (Promega), 0.3µM 
forward and reverse oligonucleotide primers (Eurofins) and 1.25U AmpliTaq (ABI) in a 
total reaction volume of 50µl in 200µl thin-walled tubes (Alpha Laboratories). 
Reactions were run on the DNA Engine (PTC200, MJ Research); cycling parameters 
were 94oC for 10 minutes; 35 cycles of 94oC for 30s, 55 - 60oC* for 30s, 72oC for 30s 
followed by a final extension at 72oC for 10 minutes. PCR products were resolved by 
1.2% (w/v) agarose gel electrophoresis as per (METHOD 2.1.4). 
 
*The initial annealing temperature for all reactions was determined by calculating 
the melting temperature of each primer ((4 x C + G) + (2 x A +T)) and subtracting 2oC 
from the primer with the lowest melting temperature. 
 
2.1.7.2  ? Quantitative PCR 
Quantitative PCR methodologies permit the rapid and relative quantification of 
specific DNA or RNA sequences from tissue samples, and thus provide a powerful 
means by which to assess gene expression. In contrast to end-point PCR where the 
amount of specific product is assessed at the end of a number of cycles (possibly 
outside of the exponential phase), quantitative PCR allows the assessment of specific 
product following each individual cycle. Quantitative PCR reactions were performed 
using the SYBR green system optimised for the LightCycler 480 (Roche). SYBR green 
technology utilises a sensitive dye that fluoresces only when bound with double 
stranded DNA (dsDNA). The fluorescence emitted from SYBR green is relative to the 
abundance of the target sequence, thereby enabling the quantification of PCR 
products in real-time. Quantitative PCR reactions were performed in triplicate on 5µl 
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cDNA in SYBR 1 Master mix (Roche), with a final concentration of  0.25µM forward 
and reverse primers in a total volume of 15µl. Cycling parameters were 95oC for 5 
minutes prior to; 35 cycles of 10 seconds 95oC, 10 seconds 55oC and 30 seconds at 
72oC. Single signal acquisition was set to read at 72oC for 1 second. All reactions were 
run on a 384-well white (Roche) microplate on a LightCycler LC480 (Roche) 
configured for SYBR green fluorescence determination as specified by the 
manufacturers. Quantitative data was generated by running all samples alongside a 
series of known serial dilutions of pooled cDNA. As SYBR green intercalates with any 
dsDNA, melt curve analysis was performed at the end of each completed analysis run 
to ensure only the specific product was amplified as indicated by a single melt peak, 
and therefore ensuring the SYBR green signal was derived only from the intended 
amplicon (FIGURE 2.2). 
 
 
 
 
FIGURE 2.2  W Melting peak determined from the rate of change of the melt curve 
showing the presence of a single product size.  
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2.1.7.3  ? Data normalisation 
Quantitative PCR data was normalised by the use of internal reference genes or by 
the determination of cDNA concentration following reverse transcription. Detailed 
methodology of the chosen normalisation method is included within each chapter. 
 
 
2.2  ? Cloning of Polymerase Chain Reaction Amplicons 
 
2.2.1  ? PCR amplicon cleanup 
Where indicated, PCR amplicons were purified from contaminating excess primers, 
ŶƵĐůĞŽƚŝĚĞƐ ĂŶĚ ƐĂůƚƐ ƵƐŝŶŐ 'ĞŶůƵƚĞ ? ĐŽůƵŵŶ-based technology (Sigma) prior to 
cloning. Briefly, fresh PCR amplicons were bound to the silica spin column, washed in 
0.5ml of proprietary wash solution, and eluted in 50µl of molecular biology grade 
water. Products were either used immediately, or stored for up to 7 days at -20oC. 
 
2.2.2  ? pGEMT Easy Vector cloning of PCR amplicons 
Purified amplicons (as above) were cloned using the pGEM T-Easy vector system 
(Promega). 5µl Rapid Ligation Buffer, 1µl pGEM T-Easy vector, Xng PCR product and 
3U of T4 Ligase were mixed well and incubated at 21oC for 1 hour. The PCR amplicons 
were ligated at a molar ratio of 1:1 and 3:1 insert : vector to enhance the likely 
number of transformants. The amount of PCR product (X) to add was calculated as 
follows; 
 
Insert (ng) = [Vector(ng) x Insert (Kb) / Vector (Kb)] x Insert/Vector molar ratio 
 
Following ligation, the mixture (vector + insert) was transformed into competent 
E.coli JM109 (Promega). Briefly, 2µl of ligation reaction was added to a chilled, sterile 
1.5ml tube and gently mixed with 50µl of thawed competent JM109 cells (107 
cfu/µg). The mixture was flicked gently to mix, and then left on ice for 20 minutes. 
The cells were heat shocked at exactly 42oC for 50 seconds upon which the ligated 
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vector + insert were taken into the cells via the fenestrated cell wall. The cells were 
returned to ice for 2 minutes and a 950ul aliquot of LB media (APPENDIX A) added. 
The cultures were incubated at 37oC aerobically with shaking for 1.5 hours. Following 
transformation, 100µl of the culture was plated onto 150mm diameter plates 
(Sarstedt) containing LB agar (APPENDIX A) supplemented with ampicillin (100µg/ml) 
under aseptic conditions, inverted, and incubated aerobically overnight at 37oC.  
Discrete colonies were harvested into 3ml of LB media containing 100µg/ml 
ampicillin, grown overnight at 37oC with shaking at 170rpm (Lab Therm, Kuhner) 
purified and then identified by restriction endonuclease digest (METHOD 2.2.5).  
 
2.2.3  ? TOPO TA Vector cloning 
Fresh PCR amplicons, without any additional preparation, were cloned using the 
dKWK d ? ǀĞĐƚŽƌ ƐǇƐƚĞŵ  ?/ŶǀŝƚƌŽŐĞŶ ? ? dǁŽ ƌĞĂĐƚŝŽŶ ĐŽŶ ĞŶƚƌĂƚŝŽŶƐ ŝŶĐůƵĚŝŶŐ  ? ? ?A?ů
and 4µl of un-purified PCR amplicon per 6µl reaction were conducted to enhance the 
likely number of transformants. The PCR amplicon was incubated at 21oC for 30 
minutes in a sterile 1.5ml tube containing 1µl salt solution (1.2M NaCl, 0.06M MgCl2), 
1µl TOPO TA vector (10ng plasmid DNA, 50% v/v glycerol, 50mM Tris-HCl pH 7.4, 
1mM EDTA, 1mM DTT, 0.1% v/v Triton X-100, 100µg/ml BSA) and RNase/DNase-free 
water to a total volume of 6µl. The reactions were placed on ice for 30 seconds, and 
then 2µl transferred to a thawed aliquot of TOPO 10 competent cells. Cells were 
incubated on ice for 30 minutes before being heat shocked at 42oC for 30 seconds in 
a thermostatically control water bath. Cells were immediately placed on ice for 1 
minute following heat shock to prevent irreversible damage. The cells were then 
incubated in 250µl of S.O.C media (APPENDIX A) for 60 minutes at 37oC under 
aerobic conditions with shaking at 170 RPM (Lab Therm, Kuhner).  Finally, 50µl of the 
resultant culture was plated- out onto on pre-warmed LB plates (150mm) containing 
50µg/ml ampicillin and incubated overnight under the same conditions.  
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2.2.4  ? Plasmid miniPrep 
Plasmid mini-preparations were carried out using the GenElute plasmid miniprep kit 
(Sigma) which included all the required materials and reagents and was carried out 
ĂĐĐŽƌĚŝŶŐƚŽƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ ?ƌŝĞĨůǇ ? ? ? ?ŵůŽĨŽǀĞƌŶŝŐŚƚĐƵůƚƵƌĞǁĂƐ
pelleted by centrifugation and resuspended in 200µl of proprietary re-suspension 
solution. The resulting solution was subjected to alkaline lysis and, following 
neutralization, the liberated plasmid DNA bound to a proprietary binding column.  
The bound plasmid DNA was washed using an ethanol containing wash solution, and 
eluted in 100µl of molecular biology grade water. All plasmid DNA was stored at -
20oC prior to use. 
 
2.2.5  ? Restriction endonuclease digest 
All restriction endonuclease digest reactions were carried out in accordance with the 
manufacturĞƌ ?Ɛ ƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐ  ?EĞǁ ŶŐůĂŶĚ ŝŽ>ĂďƐ ? E ? ?EcoR1 digest was 
used to liberate cloned products from the multiple cloning site of pGEM-TEasy or 
TOPO TA plasmids. 5µl of purified plasmid DNA (250  W 500ng) was added to a 
reaction mixture containing 2µl proprietary buffer (NEB), 2µg bovine serum albumen 
(BSA), 10U EcoR1 and 12.3µl water. Reactions were incubated at 37oC for 60 
minutes. 
 
Bgl1 digest was used to linearise the TOPO TA vector sequence for the production of 
linear clones with which to test the specificity of oligonucleotide primers. 10µl of 
purified plasmid DNA (500  W 1000ng) was added to a reaction mixture containing 5µl 
proprietary buffer (NEB), 2U Bgl1 and 34µl water. Reactions were incubated at 37oC 
for 60 minutes. All reaction products were resolved on 1.2% (w/v) agarose gel 
(Melford), stained for 30 minutes in ethidium bromide (0.5µg/ml) and visualised 
under a UV light source (METHOD 2.1.4). 
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2.2.5  ? DNA sequencing 
Plasmid DNA was purified by plasmid mini-preparation (METHOD 2.2.4), its 
concentration determined spectrophotometrically (Nanodrop), diluted to 75ng/µl 
and submitted to MWG (Germany) for bi-directional sequencing using T7 and SP6 
oligonucleotide primers targeting the vector sequence. This technique allowed 
sequencing across the cloning boundary, ensuring the full insert sequence was 
determined from insert sizes below 500-600bp. 
 
 
2.3  ? Protein Methodology 
 
2.3.1  ? General protein extraction 
Samples of skeletal muscle (1g) were crushed to a powder under liquid nitrogen and 
homogenised using a 10mm diameter Polytron ?ƉƌŽďĞĨŽƌ ?ĐǇĐůĞƐŽĨ ? ?ƐĞĐŽŶĚƐĂƚ
speed setting 25 in 5ml of ice-cold protein extraction buffer (APPENDIX A). Prior to 
use, the protease inhibitors 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
(AEBSF), leupeptin and pepstatin were added to the extraction buffer at a 
concentration of 200µg/ml, 1 µg/ml and 1µg/ml respectively. 1ml of the resulting 
homogenate was removed to a separate 1.5ml tube containing 1ml of 2 X SDS PAGE 
loading buffer (APPENDIX A) and stored at -20oC prior to analysis. The remaining 
homogenate was centrifuged at 16 000g for 10 minutes at 4oC and the supernatant 
removed to a separate 1.5ml containing 1ml 2 X SDS PAGE loading buffer as previous. 
An independent 50µl aliquot of each fraction was added to 950µl 0.1M NaOH for 
protein concentration determination. 
 
2.3.3  ? Protein concentration determination 
Protein concentration was determined according to the method of Bradford, 1976 
(Bradford 1976) using sample aliquots diluted in 0.1M NaOH as above. BSA standards 
ranging from 0 - 60µg/ml were prepared from a stock solution of BSA (100µg/ml) and 
stored at -20oC prior to use. 10µl of sample or BSA standard was added to a 96-well 
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microtitre plate (Sarstedt) in duplicate. 200µl of Bradford reagent (Bio-Rad) prepared 
according to the manufactures instructions was added to each well, mixed by 
pipetting and incubated at room temperature for 5 minutes. Absorbance was read at 
520nm (Bio-Rad 680 XR), a calibration curve of A520 against the amount of protein in 
the BSA standards produced and the protein concentration of the unknown samples 
estimated. 
 
2.3.4  ? Sodium dodecyl sulphate polyacrylamide gel electrpohoresis (SDS PAGE) 
SDS PAGE was carried out in accordance with the original method of Laemmli, 1970 
(Laemmli 1970). Quadriceps muscle extracts prepared according to (METHOD 2.3.1) 
were diluted to 5µg/µl total protein in 1 x SDS PAGE loading buffer (APPENDIX A). 
Samples were boiled for 3 minutes to ensure complete denature of proteins and 
centrifuged at 16,000g at room temperature for 3 minutes to sediment any 
connective tissue.  
 
Samples were applied to discontinuous 12% (w/v) polyacrylamide gels, of 1.5mm 
thickness cast using the Mini-Protean III system (Bio-Rad). The separating gel 
comprised 4ml 30% (w/v) acrylamide/0.8% (w/v) bis-acrylamide solution, 1.88ml 2M 
Tris-HCl pH 8.8, 0.1ml 10% (w/v) SDS and 3.93ml water. Polymerisation was induced 
by the addition of 80µl 10% (w/v) ammonium persulphate and 8µl E ?E ?E ? ?E ?-
tetramethylethylenediamine (TEMED). The separating gel was poured into a gel 
former, and overlaid with a layer of water saturated butanol to ensure a level 
interface and prevent drying. Once set, the separating gel was washed in distilled 
water, and any excess water removed using filter paper (3M). The stack comprised 
0.85ml 30% (w/v) acrylamide/0.8% (w/v) bis-acrylamide solution, 0.63ml 1M Tris-HCl 
pH 6.8, 50µl 10% (w/v) SDS and 3.40ml water. Polymerisation was induced by the 
addition of 80µl 10% (w/v) ammonium persulphate and 8µl TEMED as above and the 
stack poured directly on top of the separating gel. A gel-comb of corresponding 
thickness (1.5mm) with the desired number wells was placed in the stack and the 
whole gel set for 30 minutes at 40C. 
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For the detection of 4EBP1 protein (15  W 20 KDa), samples were diluted to 5µg/µl 
total protein, and 15µl loaded resulting in a total load of 75µg. Pre-stained protein 
markers (7  W 175KDa, BioRad) were included on each gel to delineate the size of any 
resultant proteins. Gels were run in SDS PAGE running buffer (APPENDIX A) at 200 V 
(constant voltage) for 40 minutes or until the samples had run around ¾ the length of 
the gel.  
 
2.3.5  ? Western blotting 
Following electrophoresis, acrylamide gels were soaked in transfer buffer comprised 
of 0.4M glycine, 25mM Tris and 5% (v/v) propan-2-ol for 10 minutes at room 
temperature. One piece of 45µm pore size nitrocellulose and two pieces of filter 
paper (3M) per gel were cut to the size of the gel and soaked in the buffer alongside 
the gels. The nitrocellulose was placed on top of the pre-soaked gel and housed 
between two pieces of filter paper in a western blotting cassette (BioRad). The 
assembly was secured in a transfer tank (Mini-Protean III, BioRad) filled with transfer 
buffer, ensuring the gel-side of the assembly was orientated towards the cathode 
(and thus ensuring that proteins were transferred from the gel to the nitrocellulose 
membrane as the current passed through the apparatus). Gels were transferred at 
0.2A for 2 hours (Power-Pac 300, Bio-Rad), with cool-water passed through the 
apparatus to prevent heating. A magnetic stir-bar was placed into the tank and the 
whole apparatus placed on a magnetic stirrer at moderate speed to prevent the 
precipitation of glycine from the transfer buffer. Precipitated glycine is known to 
adhere to the nitrocellulose membrane, increasing background signal following 
immunodetection (FIGURE 2.3).  
 
Following transfer, the nitrocellulose was removed from the assembly and stored in 
TBS-T buffer (APPENDIX A) at 4oC. 
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FIGURE 2.3  W Schematic showing Western blotting assembly. The arrangement of the 
sponges, filter paper, acrylamide gel and nitrocellulose membrane are shown in 
relation to the cathode and anode of the transfer apparatus.   
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2.3.6  ? Ponceau staining 
Prior to immunodetection, the nitrocellulose membrane was stained to ensure 
transfer of proteins (METHOD 2.3.5). The membrane was incubated in Ponceau S 
stain (APPENDIX A) with gentle agitation for 5 minutes. The membrane was de-
stained in distilled water and viewed over a white light source. Successful transfer 
was confirmed by the presence of well-defined protein bands, of uniformed 
appearance across the length of the membrane. Membranes were completely de-
stained prior to immunodetection in TBS-T buffer for 5 minutes with gentle agitation.  
 
2.3.7  ? Immunodetection 
Electroblotted nitrocellulose membranes were immersed in 5% (w/v) non-fat milk 
powder in TBS-T buffer for 30 minutes at room temperature to prevent non-specific 
binding of antibodies to the surface of the membrane. For the detection of 
phosphorylated and total 4EBP1 protein, anti-4EBP1 and anti-phosphorylated 4EBP1 
(thr37/46) (Cell Signalling Technology) rabbit anti-rat primary antibodies were 
sourced and each diluted 1:1000 in 5% (w/v) non-fat milk powder. 
 
First, anti-phosphorylated 4EBP1 (thr37/46) was applied to the membrane for 1 hour 
at room temperature, shaking constantly throughout the incubation. The membrane 
was washed with 1% (w/v) non-fat milk powder for 30 minutes, changing the solution 
every 5 minutes. Following washing, the membrane was incubated in horseradish 
peroxidise conjugated anti-rabbit antibody diluted 1:5000 in TBS-T buffer for 1 hour. 
Following 30 minutes of washing as previous, immunodetection was carried out 
using enhanced chemiluminescence (ECL, GE Healthcare) according to the 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ ? dŚĞ ŵĞŵďƌĂŶĞ ǁĂƐ ĞǆƉŽƐĞĚƚŽ ƉŚŽƚŽŐƌĂƉŚŝĐ Ĩŝůŵ
(Hyperfilm, GE Healthcare) in a dark room for 1  W 3 minutes, developed in developing 
reagent (Kodak) for 2 minutes, rinsed in water and fixed (Kodak) for 2 minutes. Films 
were captured (Bio-Rad, FluorS) and analysed by densitometry (Quantity-One, 
V4.4.1, Bio-Rad) ĂĐĐŽƌĚŝŶŐƚŽƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ. 
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Following immunodetection with anti-phosphorylated 4EBP1 (thr37/46), the 
membrane was stripped of bound primary antibody by incubation in Restore solution 
(Pierce) with gentle agitation for 10 minutes at room temperature. To ensure all 
primary antibody-antigen complexes were removed, the membrane was washed in 
TBS-T buffer for 5 minutes, and then subjected to secondary antibody incubation, 
ECL treatment and exposure to photographic film as above. The lack of a signal 
following membrane exposure to photographic film for 5 minutes was considered 
indicative that all bound primary antibody had been successfully removed. 
 
Total 4EBP1 protein was determined by repeating the procedure as above, treating 
the stripped membrane using the anti-4EBP1 antibody. 
 
2.3.8  ? Isocitrate dehydrogenase / lactate dehydrogenase enzyme activity 
Isocitrate dehydrogenase (ICDH) and Lactate dehydrogenase (LDH) enzyme activities 
were respectively measured as an index of oxidative (aerobic) metabolism and 
glycolytic (anaerobic) metabolism. Both enzyme activities were measured in 
accordance with the original method of Brandstetter, 1998 (Brandstetter, Picard et 
al. 1998).  
 
Whole quadriceps homogenates were prepared by combining frozen quadriceps 
tissue crushed under liquid nitrogen, with 40 volumes of homogenisation buffer 
comprising (250mM Sucrose, 2mM EDTA, 10mM Tris-HCl pH 8.0) and homogenising 
on high speed for 30 seconds on ice using a Polytron probe. Homogenates were 
cleared of any connective tissue by centrifugation at 9,000g for 15 minutes at 4oC, 
and the resulting supernatants kept on ice.  
For the determination of ICDH activity, 375.4mM isocitrate trisodium was prepared 
in ICDH reaction buffer comprising (38.9mM disodium phosphate, 0.5mM 
manganese chloride, 0.05% (v/v) Triton X100 ĂŶĚ  ? ? ? ?ŵD ɴ-Nicotinamide adenine 
dinucleotide phosphate  ?ɴ-NADP), pH 7.3). 7.5µl of supernatant (as above) was 
added to a transparent 96-well microtitre plate (Sarstedt) containing 270µl reaction 
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buffer per well. The plate was incubated at 28oC for 15 minutes, and the absorbance 
at 340nm determined 6 times at intervals of 20 seconds.  
 
For the determination of LDH activity, 2mM sodium pyruvate was prepared in a LDH 
reaction buffer comprising (50mM triethanolamine (TEA) and 5mM EDTA, pH 7.5). 
Quadriceps supernatants were diluted 1 in 10 in homogenisation buffer and 1µl  
added to a 96-well microtitre plate containing 290µl reaction buffer and 10µl 
0.026mM NADH per well. The plate was incubated at 28oC for 2.5 minutes, and the 
absorbance at 340nm determined 6 times at intervals of 20 seconds.  
 
The rates of both enzymes were determined by measuring the absorbance change at 
340nm (680XR plate reader, Bio-Rad) and expressed as mOD/min normalised to the 
total extractible protein of each sample (determined using the method of Bradford). 
 
With reference to alternative histochemical techniques, it is suggested that the 
assessment of succinate dehydrogenase (SDH) and glycerophosphate could be 
performed on frozen skeletal muscle sections for the determination of oxidative and 
glycolytic metabolic potential respectively.   
 
 
2.4  ? Histopathology 
 
2.4.1  ? Fixation, processing and embedding 
Knee joints were obtained for histopathological analysis by making a full thickness 
cut 2cm above and below the patella. Specimens were fixed in 10% neutral buffered 
formalin at 90oC flexion for > 72 hours. To aid cutting, specimens of bone, removed 
of any extraneous tissue, were decalcified in 10% formic acid for 5 days  W changing 
the solution every other day. Samples were dehydrated in ascending concentrations 
of ethanol, cleared in xylene and infiltrated with paraffin wax using a vacuum 
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assisted auto-processor (Leica TP 120 Carousel) following the following program (all 
concentrations are % v/v prepared in distilled water); 
 
 70% Ethanol  W 1hr 
 70% Ethanol  W 1hr 
 95% Ethanol  W 1hr 
 95% Ethanol  W 1hr 
 95% Ethanol  W 1hr 
 100% Ethanol  W 1hr 
 100% Ethanol  W 1hr 
 100% Ethanol  W 1hr 
 100% Xylene  W 1hr 
 100% Xylene  W 1hr 
 Paraffin wax (61oC)  W 1hr 
 Paraffin wax (61oC)  W 1hr 
 
Following wax infiltration, samples were orientated into wax moulds with the 
anterior surface facing downwards. Samples were embedded in paraffin wax and 
allowed to harden on a cooled surface (4oC). 4µm step-coronal sections were taken 
using a rotary microtome (RM 2245, Leica) at 300µm intervals resulting in 
approximately 10-sections per joint. Sections were adhered to charged slides 
(Superfrost) and dried at 50oC overnight (FIGURE 2.4).  
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FIGURE 2.4  W Orientation of knee joints for microtomy. Dotted lines indicate angle of 
tissue sections, grey arrow indicates the direction of cutting. 
 
Details of the comprehensive scoring criteria used to assess histological joint changes 
are included within CHAPTER 3.2.5 and CHAPTER 5.2.3 for the assessment of rat and 
guinea pig pathology respectively.  
 
2.4.2  ? Toluidine blue staining 
Sections were de-waxed in xylene (10 minutes), rehydrated in descending 
concentrations of ethanol for 10 minutes at each concentration (100%, 90%, 70% 
v/v), and washed in running tap-water. Sections were incubated in 0.2% toluidine 
blue (w/v), 2% aluminium sulphate (w/v) in distilled water for 25 minutes at room 
temperature.  Following staining, sections were dehydrated in ascending 
concentrations of ethanol (70%, 90%, and 100% v/v), cleared in xylene (10 minutes) 
and mounted using Di-n-butyl-phthalate-polystyrene-xylene (DPX, Thermo Scientific).  
 
 
2.5  ? Statistical Analysis 
Details of the specific statistical tests used to assess statistical significance are 
included in each separate results chapter.  
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CHAPTER 3 - d,&&d^K&Ȳ ?RENERGIC AGONIST 
ADMINISTRATION ON THE SEVERITY OF OSTEOARTHRITIS IN A 
MENISCECTOMY-INDUCED RODENT MODEL 
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3.1  ? Introduction and Rationale 
 
Improving skeletal muscle strength and functional performance through intensive 
exercise regimes is often inappropriate or contraindicated for certain OA patients 
who are elderly, overweight, co-ŵŽƌďŝĚ ĂŶĚ ŵĂǇ ďĞ ĨƌĂŝů ? ɴ ?-adrenergic agonists, 
such as clenbuterol, have potent anabolic effects on skeletal muscle, inducing 
increases in lean mass and contractile speed (Lynch, Schertzer et al. 2008) similar to 
those observed through targeted strength training protocols (as reviewed in chapter 
1.3.4.3). ůĞŶďƵƚĞƌŽů ŝŶĚƵĐĞƐ ŵƵƐĐůĞ ŚǇƉĞƌƚƌŽƉŚǇ ǀŝĂ ƚŚĞ ƐƚŝŵƵůĂƚŝŽŶ ŽĨ ɴ2-
adrenoceptors and the subsequent activation of downstream signalling pathways 
(Lynch and Ryall 2008). In addition to marked increases in skeletal muscle mass in a 
number of animal models of muscle wasting (Maltin, Hay et al. 1989; Carbó, López-
Soriano et al. 1997; Stevens, Firinga et al. 2000; Herrera, Zimmerman et al. 2001), 
clenbuterol has been shown to induce slow to fast muscle fibre-type transitions in 
certain muscle groups (Ricart-Firinga, Stevens et al. 2000; Stevens, Firinga et al. 
2000).  
 
Developing a pharmacological agent that is able to mimic intensive exercise regimes 
by improving muscle function in knee OA patients could provide a plausible route 
through which to modify the course of OA during both the initiation, and progression 
of this disorder (Hurley 1999; Pap, Machner et al. 2004; Mikesky, Mazzuca et al. 
2006). The purpose of this study was to investigate whether clenbuterol induced 
hypertrophy of the quadriceps muscle, prior to disease induction, was able to modify 
the severity of joint disease, assessing joint pathology and behavioural pain in a 
meniscectomy-induced rodent model of OA.  
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3.1.1  ? Hypotheses and aims  
The development of meniscectomy-induced osteoarthritis will be associated with 
changes to the fibre-type composition of the quadriceps muscle group, potentially 
manifesting as a reduced type II fibre complement. Clenbuterol administration for 14 
days will result in marked hypertrophy of the quadriceps muscle group, with an 
associated increase in the proportion of type II fast twitch muscle fibres. The 
induction of quadriceps hypertrophy and the potential modulation towards a faster-
twitch muscle phenotype prior to the induction of OA will have a protective effect on 
the knee joint, assessed histologically 21 days post induction. 
 
The following specific aims will be addressed utilising a rodent model of OA; 
 
 Elucidate the effects of clenbuterol on quadriceps mass and function 
 Investigate the effects of induced knee OA on quadriceps mass and function 
 Determine whether a hypertrophic quadriceps can modulate OA severity 
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3.2 - Experimental Protocol 
 
3.2.1  ? Animals, housing and experimental outline 
A total of 35 male Lewis rats (bodyweight = 280.4 + 1.7g) were group housed with 
free access to standard laboratory chow and water. Animals were subcutaneously 
ĂĚŵŝŶŝƐƚĞƌĞĚ ǁŝƚŚ ƚŚĞ ƉŽƚĞŶƚ ɴ2-adrenergic agonist clenbuterol HCl at a dosage of 
1.5mg/kg/day bodyweight (n=15), or saline vehicle (n=20) for a total of 14 days. 
Animals were weighed daily, and the dosage of clenbuterol calculated based upon 
the most recent animal weight and administered immediately. Following pre-
treatment (saline or clenbuterol), 5 animals from each group were sacrificed to 
assess the immediate effects of clenbuterol on muscle parameters. The remaining 
animals underwent either meniscectomy surgery (MNX) (clenbuterol pre-treated 
n=10; saline pre-treated n=10) or a sham control surgical procedure (saline pre-
treated n=5).  
 
Animal procedures were carried out by AstraZeneca pharmaceuticals, Alderley Edge, 
Macclesfield in accordance with the Home Office Animals (Scientific Procedures) Act 
1986.  
 
3.2.2  ? Preparation of clenbuterol for subcutaneous administration 
Clenbuterol hydrochloride (C12H18Cl2N2O.HCl MW 277.2) was sourced from Alexis 
pharmaceuticals, UK. A 1.5mg/ml (w/v) solution was prepared in sterile physiological 
(0.9%) saline and 2ml aliquots stored at -20oC. A fresh aliquot of compound was 
thawed for each day of dosing to minimise any degradation over the course of the 
study. 
 
3.2.3  ? Induction of OA via meniscectomy surgery 
All surgery was carried out under 3.5% Isofluorane inhalational anaesthetics by an 
experienced surgeon (Mrs Ruth Webster, AstraZeneca, Macclesfield). The left leg of 
the rat was shaved and cleaned with pevidine antiseptic solution (National Vet 
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Supplies) prior to surgery in a separate designated preparation area.  A small incision 
with iris scissors (Tungsten carbide iris scissors, Interfocus; 14558-11) was made 
longitudinally down the medial side of the knee and a cauteriser (Interfocus; 18000-
00) used to work through both the connective tissue and muscle layers until the 
medial collateral ligament, anchoring the medial meniscus to the tibial plateau, was 
identified. Blood vessels along the line of the medial collateral ligament and the 
surrounding area were cauterised to maintain haemostasis. The ligament was 
grasped with fine tooth forceps (Bonn 1x2 teeth forceps, Interfocus; 11084-07) at the 
tibial end and cut with fine micro surgical scissors (Bonn extra fine iris scissors, 
Interfocus Ltd; 14084-08) until fully transected. The ligament was then transected 
again at the femoral end to remove the portion overlying the meniscus.  This allowed 
direct access to the medial meniscus, and removed the possibility of the collateral 
ligament re-forming.  The meniscus was freed from the fine connective tissue, 
allowing it to be held with fine forceps (Moria MC40 Straight Forceps, Interfocus; 
11370-40) while a full thickness, medial transection was made. The knee was closed 
in two separate layers: the connective bilayer was sutured with 8-0 braided, 
absorbent suture material with a round bodied needle, using single interrupted 
stitches (Ethicon W9577) and the skin was closed with 5-0 braided, absorbent suture 
material with a spatula needle (Ethicon W9553), using a subcuticular running stitch, 
the terminal end of which is buried through the wound, towards the iliac crest.  
When necessary, a single support stitch was included as a precautionary measure 
using 8-0 suture material with a spatula needle (Ethicon W9560). The area was then 
cleaned with sterile physiological saline.  
 
Following surgery, each animal was allowed to recover in a heated cage for up to 6 
hours before being returned to their home cage. Wet diet (prepared by adding water 
to standard laboratory chow) was also provided for up to 12 hours post surgery. 
Cefalexin antibiotics were administered orally one hour prior to surgery and at 12, 24 
and 36 hours post surgery (0.03ml/100g Ceporex oral drops; Schering-Plough Animal 
Health; granules dissolved in 6ml drinking water). Carprofen analgesics were 
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administered subcutaneously on induction of anaesthesia and 24 hours post surgery 
(0.01ml/100g Rimadyl; Pfizer). 
 
Sham animals underwent the same surgical procedure with the omission of 
transection of the medial meniscus.  All other treatment of these rats was identical to 
the other surgical group, including administration of antibacterial prophylaxis and 
post-operative analgesia. 
 
3.2.4  ? Incapacitance assessment 
Weight bearing, as a surrogate of behavioural joint pain, was measured using an 
incapacitance meter (Linton Instrumentation, UK) on study days -2, 7, 14, 21, 28 and 
35 as described previously (Ivanavicius, Ball et al. 2007). The operator was blinded to 
both the pre-treatment regime and any previous measurements. The difference in 
weight borne by the two hind limbs was measured by placing the rat in a Perspex 
tube so that each hind paw was resting on a separate transducer pad. The 
distribution of bodyweight on each paw over 3 seconds was recorded and the 
average of 3 separate measurements taken. Weight readings for the left and right 
limbs were taken and the difference between these calculated and plotted. Prior to 
inclusion in the study, rats were trained for one week to acclimatise them to the new 
apparatus. 
  
3.2.5  ? Termination and histopathology 
Animals were terminated 21 days post surgery with a rising concentration of C02 and 
death confirmed by cervical dislocation. Knee joints were obtained for 
histopathological analysis by making a full thickness cut 2cm above and below the 
patella. The joints were formalin fixed and decalcified in 10% formic acid prior to 
processing by routine vacuum assisted wax infiltration (CHAPTER 2.4). Toluidine blue 
stained step-coronal sections were evaluated for proteoglycan loss, cartilage erosion 
and subchondral cartilage deposits. Sections were subjectively graded for the most 
severe changes in cartilage morphology assessing proteoglycan loss, erosion, 
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proliferation and fibrillation on any single section and given a score of between 0 and 
4 as follows;  
 
0 - Pathology not present 
1 - Minimal change, small foci 
2 - Mild change, up to 20% affected 
3 - Moderate change, up to 50% affected 
4 - Severe change, greater than 50% affected.  
 
The maximum score for the tibial and femoral condyles was 12 respectively, giving a 
total obtainable knee score of 24. Proteoglycan loss was generally associated with a 
loss of chondrocytes and some chondrocyte clustering. Proliferation at the joint 
margin only referred to proliferation at the edge of the articular cartilage plateau and 
not proliferation down the lateral border resulting from the operative procedure.  
ƌŽƐŝŽŶ ǁĂƐ ƌĞŐĂƌĚĞĚ ĂƐ ƚŚĞ ĨƌĂŶŬ ůŽƐƐ ŽĨ ĐĂƌƚŝůĂŐĞ ŵĂƚƌŝǆ ŶŽƚ ũƵƐƚ  ‘ƐŚƌŝŶŬĂŐĞ ? Žƌ
 ‘ƚŚŝŶŶŝŶŐ ? ?ůůŚŝƐƚŽůŽŐǇǁĂƐ ƌĞƉŽƌƚĞĚďǇĂŶĞǆƉĞƌŝĞŶĐ ĚďŽĂƌĚ-certified pathologist 
(Dr Russell Westwood, AstraZeneca, Macclesfield) and second screened in house 
following appropriate training (AstraZeneca, Charnwood).    
 
3.2.6  ? Electrophoretic separation of MHC 
Quadriceps muscle fibres were classified based upon their expression of myosin 
heavy chain protein. Quadriceps muscle samples (100mg) were crushed to a powder 
under liquid nitrogen and homogenised in 5ml of extraction buffer comprising 0.5M 
NaCl, 20mM pyrophosphate, 50mM Tris-HCl, 1mM EDTA, and 1mM DTT in distilled 
water, pH 8.0. Following centrifugation at 1000g for 10 minutes, 500µl aliquots of the 
resulting supernatant were added to an equal volume of 87% v/v glycerol (Fluka). 
Preparations were vortexed to ensure thorough mixing and stored at -200C until 
required. Following total protein determination (METHOD 2.3.3) 50ng protein was 
mixed with loading buffer 4% v/v 87% glycerol, 25mM 1M Tris-HCl pH 6.8, 8% w/v 
SDS and 20mg pyronin Y, with 10% v/v beta-mercaptoethanol added prior to use. The 
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myosin preparations were separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) as described by Mizunoya, 2008 (Mizunoya, Wakamatsu 
et al. 2008). Separating gels consisted of 35% v/v glycerol, 8% w/v acrylamide bis-
acrylamide 49:1 (Sigma), 0.2M Tris-HCl (pH 8.8), 0.1M glycine, 0.4% w/v SDS, 0.1% 
ǁ ?ǀĂŵŵŽŶŝƵŵƉĞƌƐƵůƉŚĂƚĞ ?ĂŶĚ  ? ? ? ?A?ǀ ?ǀ E ?E ?E ? ?E ?-tetramethylethylenediamine 
(TEMED). The stacking gel consisted of 30% v/v glycerol, 4% w/v acrylamide bis-
acrylamide 49:1, 70mM Tris-HCl (pH 6.7), 4mM EDTA, 0.4% w/v SDS, 0.1% w/v 
ammonium persulphate, and 0.05% v/v TEMED. Gels were prepared the day prior to 
running and stored at 40C. The lower running buffer consisted of 0.05M Tris HCl, 
75mM glycine, and 0.05% w/v SDS. The upper running buffer was 6 x the 
concentration of the lower running buffer and beta-mercaptoethanol was added 
before use at a final concentration of 0.12% v/v. Electrophoretic separation was 
performed in two stages; sample entry into the stacking gel was run at 10mA for 40 
minutes, whilst the remainder of the electrophoresis was carried out at 140V 
(constant voltage) for 21.3 hours. Throughout the electrophoresis, the apparatus was 
kept in a cold room at 40C.  
 
Following electrophoresis, the different MHC isoforms were detected by silver 
staining (Talmadge and Roy 1993) using a silver staining kit (Plus One, GE Health 
Care) according to the manufactures instructions. Silver stained gels were imaged 
(Bio-Rad, FluorS) and densitometry performed (Quantity One, V4.0). The expression 
of each isoform of MHC was expressed as a percentage of the total MHC signal, 
allowing for subtle variations in sample load to be normalised. 
 
Although traditional histochemical staining of frozen muscle sections provides data 
at the individual fibre level, the detection of MHC protein isoforms in quadriceps 
muscle homogenates allows the global assessment of MHC, and is therefore 
indicative of the contractile properties of the muscle as a whole. 
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3.2.7  ? Low density microfluidic card array 
In order to elucidate molecular changes in the transcriptome of the quadriceps 
skeletal muscle, a custom low-density array was designed comprising 48 targets of 
interest using the ABI Assay on Demand system, Applied Biosystems. The microfluidic 
card system utilises a one-step reverse-transcriptase (RT) polymerase chain reaction 
(PCR) based detection system arrayed onto a 384-well plate to determine relative 
mRNA expression changes.  
 
Total RNA was prepared from 100mg of frozen quadriceps muscle using the TRIzolTM 
extraction method (METHOD 2.1.1). For each sample, a mastermix containing 53.1ul 
probes master (Qiagen, UK), 4U reverse transcriptase (Qiagen, UK), 47.8ul 
RNase/DNase-free water (Sigma, UK) and 212.5ng of total RNA was prepared on ice. 
The mixture was vortexed thoroughly, 100ul added to each sample well on the 
microfluidic card and centrifuged at 2000g, room temperature for 2 minutes in 
specifically designed buckets (Sorvall Legend and Heraeus). Centrifugation delivered 
1µl of total RNA into each of the 384 wells on the card, significantly reducing the 
amount of bench time required to run multiple quantitative PCR analyses. Cards 
were run on the ABI Fast Cycler (7900HT) at 50oC for 30 minutes for the reverse 
transcriptase reaction, 94.5oC for 15 minutes to initiate the PCR reaction, and 40 
cycles of 97oC for 30 seconds and 59.7oC for 1 minute.  
 
Targets were selected to assess changes in protein synthesis, the negative regulation 
of skeletal protein synthesis, muscle atrophy, apoptotic potential, fatty acid 
metabolism, glucose metabolism, and the expression of proteins associated with 
metabolic status (TABLE 3.1). 
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TABLE 3.1  W Low-density array targets 
Function Symbol Gene Name 
Protein IRS1 Insulin receptor substrate 
Synthesis Pik3cd Phosphoinositide 3-kinase 
 Akt Akt 
 Gsk3B 'ůǇĐŽŐĞŶƐǇŶƚŚĂƐĞŬŝŶĂƐĞ ?ɴ 
 Frap1 Mammalian target of rapamycin 
 Eif2b Elongation factor 2B 
 Eif4e Elongation factor 4E 
Negative Rela E&ʃɴ 
Regulation Tnfsf12 TNF like weak inducer of apoptosis 
and Trim63 Muscle RING-finger protein 1 
Degradation Dusp1 Dual specificity protein phosphatase 1 
 MAPK14 p38 
 FBox32 MAFBx 
 Psma5 Proteosome subunit 5 
Muscle Gdf8 Myostatin 
Atrophy Ctsl Cathepsin L 
 Capn1 Calpain I 
 Capn2 Calpain II 
 Capn3 Calpain III 
Apoptosis Bax Bax 
 Bcl2 Bcl2 
 Casp3 Caspase III 
 Casp12 Caspase XII 
Fatty Acid  Cpt1a Carnitine palmitoyltransferase 
Oxidation Lpin1 Lipin 
 Adipor1 Adiponectin receptor 1 
 Adipor2 Adiponectin receptor 2 
 UCP3 Uncoupling protein 3 
Glycolysis Hk1 Hexokinase 
Metabolic Ppargc1a PPAR gamma coactivator 1 alpha 
Regulators Ppargc1b PPAR gamma coactivator 1 beta 
 Ppara Peroxisome proliferator activated receptor alpha 
 Ppard Peroxisome proliferator activated receptor delta 
 Prkaa1 AMP Kinase 1 
 Prkaa2 AMP Kinase 2 
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Of the 48 genes arrayed onto each card, 5 were designated as potential 
housekeeping genes and included 18S, TBP, ACTB, PPIA and HPRT (TABLE 3.2). 
 
 
TABLE 3.2  W Low-density array potential housekeeping genes 
Function Symbol Gene Name 
Housekeeping 18S 18S ribosomal subunit  
Genes ActB Beta Actin 
 Hprt Hypoxanthine phosphoribosyltransferase 1 
 Ppia Cyclophilin A 
 TBP TATA box binding protein 
 
 
Relative expression data was derived using the comparative CP / dCT method 
(Schmittgen and Livak 2008). The raw crossing point (CP) value was taken for each 
sample and expressed relative to the first sample, defined as the calibrator (CP 
sample  W CP calibrator). The calibrator could have been any sample from the data 
set, the first being selected for ease of analysis in Excel (Microsoft). Contrary to 
standard curve based methodologies (METHOD 2.1.7.2) whereby the amplification 
efficiency is calculated based up a standard curve of known dilutions of cDNA, the 
low-density array did not include space to accommodate a standard curve and 
therefore the amplification efficiency was set at 2 (or 100%) for all genes of interest. 
The relative CP value (relative to the control sample) was linearised by the formula; 
 
 2^-(CP Sample  W CP Calibrator)   
 
In order to normalise the expression data effectively, the expression of all 5 
housekeeping genes was analysed using validated normalisation software (GeNorm). 
The average stability of each housekeeping gene (termed M) was assessed 
independently according to the method of Vandesompele, 2002 (Vandesompele, De 
Preter et al. 2002). Taking the two most stable genes; the 3rd, 4rd and 5th gene was 
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sequentially added and the variance (V) calculated following each addition. The 
number of housekeeping genes employed was based on the lowest V value. A 
normalisation factor was derived based on the geometric means of the 
recommended number of housekeeping genes. All analysis was carried out 
automatically using GeNorm software version 3.5. Vandesompele, 2002 
(Vandesompele, De Preter et al. 2002) includes a full explanation of the formulae 
used to calculate M and V. 
 
Finally, the linearised expression value was normalised by dividing the dCT value (as 
calculated above) by the normalisation factor (also linear) based upon the geometric 
means of a number of housekeeping genes. 
 
3.2.8  ? Biospecimens 
Whole bilateral quadriceps muscle samples, inclusive of the rectus femoris, were 
dissected, weighed and immediately snap frozen in isopentane cooled with liquid 
nitrogen. Care was taken to avoid inclusion of any adipose tissue or additional 
muscle, most importantly the tensor fasciae latae and sartorius which are located 
within the dissected area. Whole blood was drawn via cardiac puncture into clot-
activator tubes (Sarstedt) and serum obtained by centrifugation. All serum was kept 
at -80oC prior to analysis. 
 
3.2.9 - Statistical analysis 
All data are reported as means + standard error of the mean (S.E.M).  Comparisons 
were performed using the independent samples t-test between two groups, or 
analysis of variance (ANOVA) between multiple groups. Where statistical significance 
of the ANOVA permitted, the Bonferroni test was used to test for significance, with 
significance accepted as P < 0.05. All statistical analyses were performed using SPSS 
17.0. Symbols used to indicate statistical significance were; * P < 0.05; ** P < 0.01; 
*** P < 0.001. # P = < 0.1 was regarded as a trend (Tominaga, Ndu et al. 2006; Jung, 
Reichstein et al. 2010). 
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3.3  ? Results 
 
For enhanced clarity, the results are presented here in two parts. 3.3.1 Reports the 
effects of clenbuterol administration on weight parameters and quadriceps muscle 
function whilst 3.3.2 reports the effects of induced OA on quadriceps muscle 
function, and the modulatory effects of clenbuterol pre-treatment in this setting. 
 
3.3.1  ? Preliminary effects of clenbuterol administration 
 
3.3.1.1 - Weight parameters 
Subcutaneous administration of clenbuterol at a dosage of 1.5mg/kg/day resulted in 
an approximate 35% elevation in bodyweight gain (P = < 0.001) following 14 days of 
treatment compared to saline control treated animals. Clenbuterol-treated animals 
had visibly reduced adipose deposits, and larger more defined skeletal musculature, 
suggesting that increased animal weight was likely due to lean tissue deposition.  In 
addition to bodyweight, quadriceps mass (wet weight) was also elevated (+ 40%) 
following clenbuterol treatment (6.52 + 0.21g) compared with saline treated controls 
(4.64 + 0.21g), (P = <0.001) (FIGURE 3.1). Statistical significance was maintained 
when quadriceps mass was normalised to total bodyweight (P = 0.020). 
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FIGURE 3.1  ? The effects of 14 days administration of clenbuterol hydrochloride on % 
bodyweight change from the first day of pre-treatment (A) and quadriceps mass (B). 
Data are mean + S.E.M; n = 5. 
 
3.3.1.2 - Contractile and metabolic potential of the quadriceps muscle 
Quadriceps muscles were characterised with respect to their contractile and 
metabolic potential. Myosin Heavy Chain (MHC) composition of the quadriceps 
muscle was determined as an index of contractile capacity by high-resolution SDS 
PAGE. Control material from rat soleus (predominance of MHC I) and diaphragm 
(absence of MHC IIB) was included for reference. Electrophoretic separation revealed 
ƚŚĞƌĂƚƋƵĂĚƌŝĐĞƉƐŵƵƐĐůĞƚŽďĞĐŽŵƉŽƐĞĚƉƌĞĚŽŵŝŶĂŶƚůǇŽĨ “ĨĂƐƚƚǁŝƚĐŚ ?D, ?ǁŝƚŚ
a composition of 4.85% type I, 7.25% type IIA, 22.34% type IIX and 66.55% type IIB. 
Clenbuterol administration did not induce any significant changes to the composition 
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of the quadriceps muscle following 14 days treatment (FIGURE 3.2). Representative 
photomicrographs, and associated control data are included in APPENDIX B. 
  
 
 
FIGURE 3.2  ? The effects of 14 days administration of clenbuterol hydrochloride on 
MHC isoforms I, IIA, IIX and IIB. Data are mean densitometric value of each isoform 
expressed as a percentage of the total MHC signal + S.E.M; n = 5. Saline x Clenbuterol 
P = 0.988, 0.963, 0.631, 0.586 for MHC I, IIA, IIX and IIB respectively. Representative 
photomicrographs are included within APPENDIX B. 
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As an indication of oxidative metabolic potential, associated with slow-twitch muscle 
fibres, isocitrate dehydrogenase (ICDH) enzyme activity was determined. Similarly, 
glycolytic metabolic capacity, associated with faster-twitch fibres was assessed by 
the determination of lactate dehydrogenase (LDH) activity. Enzyme activities were 
normalised to extractable protein concentration and expressed as mOD/min/µg total 
protein.  Clenbuterol administration had no effect on ICDH or LDH activity within the 
quadriceps muscle (FIGURE 3.3) following 14 days pre-treatment. 
 
 
FIGURE 3.3  ? The effects of 14 days administration of clenbuterol hydrochloride on 
ICDH and LDH activity in whole quadriceps homogenates. Data are mean mOD/min 
normalised to total extractable protein + S.E.M; n = 5. Saline x Clenbuterol P = 0.107 
and 0.278 for ICDH and LDH activity respectively.  
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3.3.1.3 - Analysis of 4EBP1 expression in quadriceps muscle samples 
As an index of protein synthetic potential, phosphorylated and total 4EBP1 protein 
was quantified by western blot. 4EBP1 is the elongation factor 4E (elF4E) binding 
protein that regulates mRNA translation by regulating the formation of the cap-
initiation complex. When 4EBP1 is hyperphosphorylated by mTOR (mammalian 
target of rapamycin), its binding to elF4E is inhibited thereby enhancing protein 
synthesis (Connolly, Braunstein et al. 2006). Clenbuterol administration did not result 
in any significant changes to total, phosphorylated 4EBP1 or the ratio of 
phosphorylated to total 4EBP1 (P = 0.443, 0.171 and 0.683 respectively) (FIGURE 
3.4). 
 
 
 
FIGURE 3.4  ? The effects of 14 days administration of clenbuterol hydrochloride on 
the ratio of phosphorylated to total 4EBP1 protein. Data are mean densitometric 
units, normalised to total protein load + S.E.M; n = 5. Inset  W Representative western 
blot - lanes 1 and 2 comprise animals from groups Saline 14d and Clenbuterol 14d 
respectively.  
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3.3.1.4 - Analysis of the quadriceps transcriptome 
Transcriptome analysis of the treated quadriceps muscle specimens was conducted 
using custom low-density array as described in (3.2.7) and details of which can be 
found in TABLE 3.1. GeNorm software (v 3.5) was used to determine the most 
suitable housekeeping gene according to the method of Vandesompele, 2002 
(Vandesompele, De Preter et al. 2002). Analysis revealed that beta-actin (ActB) and 
cyclophilin A (Ppia) were the most stable housekeeping genes in response to 
clenbuterol administration, and therefore most suitable for data normalisation. Both 
housekeeping genes displayed a stability index (M) of 0.229 which was considerably 
less than the suggested cut-off of M <1.5. Raw CP values were converted to relative 
expression values using the comparative CP method (Schmittgen and Livak 2008) and 
these values divided through by the normalisation factor determined from the 
geometric means of ActB and Ppia expression to derive normalised mRNA expression 
values.  
 
As described in (3.2.7), targets were selected to assess changes in protein synthesis, 
negative regulation of skeletal protein, muscle atrophy, apoptotic potential, fatty 
acid metabolism, glucose metabolism, and the expression of nuclear receptors 
associated with metabolic status.  
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Markers of protein synthesis were generally unaffected by clenbuterol 
administration. Statistically, members of the PI3K / Akt family remained constant 
irrespective of treatment with the exception of mammalian target of rapamycin 
(mTOR) which displayed a trend towards increased mRNA in clenbuterol pre-treated 
quadriceps muscle (P = 0.058). 
 
 
 
 
FIGURE 3.5  ? The effects of clenbuterol administration on quadriceps muscle mRNA 
expression of markers of protein synthesis. Data are normalised expression values + 
S.E.M; n = 5. 
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Negative regulators of skeletal muscle protein were assessed by the determination of 
factors involved in proteosomal degradation. Analytes included the E3 ligases 
(MuRF1, MAFBx), the proteosome (subunit 5) in addition to upstream factors 
involved in the initiation of these (TWEAK, NFKB, DUSP1 and p38 MAPK). Clenbuterol 
administration decreased TWEAK mRNA (P = 0.059), increased DUSP1 mRNA 
expression (P = 0.013) and decreased MURF1 expression (P = 0.054). 
 
 
 
FIGURE 3.6  ? The effects of clenbuterol administration on quadriceps muscle mRNA 
expression of negative regulators of protein synthesis. Data are normalised 
expression values + S.E.M; n = 5. 
 
77 
 
Factors implicated in muscle atrophying conditions were assessed and included 
myostatin, cathepsin L, and calpain members I  W III. Both calpain I and muscle specific 
calpain III were up-regulated in clenbuterol pre-treated quadriceps specimens (P = 
0.08 and 0.07 respectively). Clenbuterol administration had no effect on myostatin or 
cathepsin L mRNA expression. 
 
 
 
FIGURE 3.7  ? The effects of clenbuterol administration on quadriceps muscle mRNA 
expression of atrophy associated factors. Data are normalised expression values + 
S.E.M; n = 5. 
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The apoptotic response potential was assessed by quantifying the mRNAs of pro-
apoptotic Bax and anti-apoptotic Bcl2 in addition to the cysteine-dependent 
aspartate directed proteases III and XII (Caspases III, XII). Clenbuterol administration 
had no effect on the expression of apoptosis response related factors in quadriceps 
muscle specimens. 
 
 
FIGURE 3.8  ? The effects of clenbuterol administration on quadriceps muscle mRNA 
expression of apoptosis associated factors. Data are normalised expression values + 
S.E.M; n = 5. 
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Oxidative metabolic potential was assessed in quadriceps muscle specimens via the 
expression of mRNAs pertaining to Cpt1a, Lipin, Adiponectin receptor 1/2, and UCP3. 
Clenbuterol administration had no significant effects on the expression of any of 
these factors. 
 
 
 
FIGURE 3.9  ? The effects of clenbuterol administration on quadriceps muscle mRNA 
expression of factors associated with oxidative potential. Data are normalised 
expression values + S.E.M; n = 5. 
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Glycolytic potential was assessed by the sole expression of mRNA transcripts 
pertaining to hexokinase I  W the enzyme responsible for catalysing the conversion of 
glucose to glucose-6-phosphate during the initial phase of glycolysis. Clenbuterol 
administration did not affect hexokinase I mRNA over the course of the study (P = 
0.147).  
 
 
FIGURE 3.10  ? The effects of clenbuterol administration on quadriceps muscle mRNA 
expression of hexokinase I. Data are normalised expression values + S.E.M; n = 5. 
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To detect potential changes in metabolite signalling, members from the PGC1, PPAR 
and AMP-activated protein kinase family were assessed with respect to clenbuterol 
treatment. None of the factors assessed were affected by clenbuterol pre-treatment. 
 
 
 
FIGURE 3.11  ? The effects of clenbuterol administration on quadriceps muscle mRNA 
expression of metabolite signalling factors. Data are normalised expression values + 
S.E.M; n = 5. 
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TABLE 3.3  W Summary of Quadriceps mRNA expression changes following clenbuterol 
administration. Data are mean normalised expression + S.E.M; n = 5. 
 
Function Symbol Saline Clenbuterol P = 
Protein IRS1 52.822 ± 7.315 42.852 ± 7.500 0.369 
Synthesis PI3K 23.132 ± 3.246 20.608 ± 2.744 0.569 
 Akt 18.570 ± 1.575 20.938 ± 0.754 0.212 
 Gsk3B 23.544 ± 3.089 23.410 ± 1.753 0.953 
 mTOR 8.966 ± 0.546 13.120 ± 1.795 0.058 
 EIF2B 8.720 ± 0.774 10.825 ± 2.30 0.467 
 EIF4E 30.680 ± 3.927 28.455 ± 5.401 0.664 
Negative E&ʃɴ 6.580 ± 0.436 9.666 ± 4.463 0.304 
Regulation TWEAK 22.576 ± 0.620 19.454 ± 1.274 0.059 
and MuRF 33.710 ± 3.459 23.200 ± 3.133 0.054 
Degradation Dusp1 7.250 ± 0.364 13.076 ± 1.799 0.013 
 P38 13.620 ± 1.151 14.164 ± 1.521 0.783 
 MAFBx 33.202 ± 4.932 26.520 ± 3.686 0.325 
 Proteosome 21.296 ± 2.082 20.662 ± 1.202 0.799 
Muscle Myostatin 32.628 ± 5.116 27.402 ± 6.489 0.525 
Atrophy Cathepsin L 28.188 ± 1.689 27.526 ± 3.769 0.877 
 Calpain I 9.066 ± 0.642 12.614 ± 1.647 0.080 
 Calpain II 55.110 ± 4.060 48.282 ± 8.180 0.476 
 Calpain III 8.024 ± 0.650 11.932 ± 1.751 0.070 
Apoptosis Bax 100.144 ± 10.142 71.550 ± 16.684 0.181 
 Bcl2 22.564 ± 4.878 20.136 ± 3.736 0.703 
 Caspase III 1.062 ± 0.088 4.540 ± 3.473 0.376 
 Caspase XII 41.580 ± 7.362 29.266 ± 5.726 0.223 
Fatty Acid Cpt1a 15.008 ± 2.385 13.396 ± 1.710 0.598 
Oxidation Lipin 16.860 ± 1.433 16.256 ± 2.413 0.835 
 Adipor1 28.972 ± 4.610 29.292 ± 3.133 0.956 
 Adipor2 28.242 ± 2.667 25.368 ± 2.518 0.456 
 UCP3 33.448 ± 7.678 28.282 ± 10.376 0.447 
Glycolysis Hk1 11.420 ± 0.616 15.358 ± 2.370 0.147 
Metabolic W' ?ɲ 67.720 ± 14.140 50.248 ± 12.346 0.379 
Regulators W' ?ɴ 30.743 ± 3.484 25.930 ± 3.852 0.439 
 WWZɲ 25.168 ± 3.836 20.078 ± 3.793 0.431 
 WWZɷ 131.388 ± 12.893 96.485 ± 25.054 0.310 
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 AMPK1 3.312 ± 0.515 6.768 ± 2.957 0.241 
 AMPK2 307.60 ± 68.300 181.450 ± 73.164 0.243 
 
 
 
3.3.1.5  ? Summary of the effects of clenbuterol on skeletal muscle characteristics 
Clenbuterol administration over 14 days resulted in significant increases in 
bodyweight and quadriceps skeletal muscle mass. Assessment of the quadriceps 
skeletal muscle revealed that neither fibre-type nor metabolic potential were directly 
affected by Clenbuterol. Assessment of numerous mRNA transcripts associated with 
protein synthesis, degradation and metabolic signalling demonstrated a tendency 
towards decreased protein degradative signalling (MuRF / TWEAK) and increased 
calpain I and III activity indicative of skeletal muscle remodelling. Protein synthetic 
potential appeared unaltered. 
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3.3.2  ? The effects of meniscectomy-induced OA and clenbuterol administration on 
parameters of quadriceps function 
 
3.3.2.1 - Histopathological examination 
Of those animals subjected to meniscectomy surgery, histopathological examination 
was performed as per METHOD 3.2.5. Microscopy of toluidine blue stained sections 
from the ipsilateral limbs revealed evidence of OA-like lesions, predominantly 
localised at the tibial condyle. Microscopically, meniscectomised tibias presented 
with proteoglycan and chondrocyte loss, erosion and ulceration of the articular 
surface, but limited evidence of subchondral degeneration. Femoral condyles 
showed evidence of proteoglycan loss; however this was less severe than that noted 
on the respective tibial condyles.  No femoral erosion, ulceration or subchondral 
degeneration was noted within the experimental timeframe. Pre-treatment with 
clenbuterol prior to the surgical induction of OA had no effect on tibial or femoral 
pathology 21 days post surgery when compared with saline pre-treated animals. 
Microscopically, the severity of proteoglycan and chondrocyte loss, ulceration and 
subchondral degeneration remain unchanged irrespective of pre-treatment regime.  
All sham operated control animals were free from OA at 21 days post surgery (TABLE 
3.4) validating their use as a suitable surgical control.  
 
 
TABLE 3.4  W The effects of meniscectomy-induced OA and clenbuterol administration 
on joint histopathology. Data are mean pathological scores + S.E.M; n = 10 
 
Parameter Sham Saline MNX Clen MNX P = 
Proteoglycan loss (TIB) 0 1.90 + 0.18 2.10 + 0.23 0.491 
Erosion / ulceration (TIB) 0 1.10 + 0.35 1.30 + 0.34 0.663 
Subchondral degeneration (TIB) 0 0.20 + 0.13 0.50 + 0.27 0.485 
Proteoglycan loss (FEM) 0 0.40 + 0.22 0.80 + 0.25 0.202 
Erosion / ulceration (FEM) 0 0 + 0 0 + 0 - 
Subchondral degeneration (FEM) 0 0 + 0 0 + 0 - 
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FIGURE 3.12  W Representative photomicrographs of tibiofemoral joints stained with 
toluidine blue and visualised at 4 x magnification. A  W Saline MNX, lateral 
tibiofemoral joint; B  W Saline MNX, medial tibiofemoral joint; C  W  Clen MNX, lateral 
tibiofemoral joint; D  W Clen MNX, medial tibiofemoral joint. FEM  W femoral condyle; 
TIB  W tibial condyle. 
 
Photomicrographs A + C show proteoglycan-rich lateral joint margins with no 
macroscopic defects. The articular joint surfaces are smooth and free from 
irregularities.  
 
Photomicrographs B + D show pathological medial joint margins with proteoglycan 
loss (dashed arrow), joint fracture (black arrow), and fibrillation (grey arrow). Medial 
predominance is noted in this model due to transection of the medial meniscus 
whilst the lateral meniscus is left intact. 
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3.3.2.2 - Weight parameters 
Daily weight records revealed that surgically-induced OA was associated with a 
reduction in bodyweight gain over the course of the study (d1  W d35) (16.92 + 1.12%) 
compared with those animals undergoing the sham control procedure (24.03 + 
0.98%) P= 0.019. Clenbuterol pre-treatment suppressed the reduction in bodyweight 
gain post meniscectomy, leading to similar weight gain to those animals undergoing 
the sham control procedure (Clen MNX: 20.16% + 1.11, Sham: 24.03% + 0.98). The 
quadriceps from those animals with surgically induced OA (5.32 + 1.72g) were 
numerically smaller than animals undergoing the sham control procedure (5.91 + 
1.19g) P = 0.089. However, when corrected for bodyweight, the reduction in 
quadriceps mass in response to OA induction was no longer evident (ANOVA P = 
0.154) (TABLE 3.5). The previously noted hypertrophic effects of clenbuterol on 
quadriceps mass immediately following pre-treatment were no longer apparent at 
the study end point (d35), with clenbuterol pre-treated animals presenting with 
similar quadriceps mass relative to bodyweight to saline re-treatment animals.  
 
 
TABLE 3.5  W The effects of meniscectomy-induced OA and clenbuterol administration 
on percentage bodyweight gain over the course of the study, quadriceps mass (g), 
and quadriceps relative to bodyweight mass (%). Data are mean + S.E.M; Sham n = 5, 
Saline/Clen MNX n = 10. 
 
Parameter Sham Saline MNX Clen MNX P = 
Bodyweight gain (%) 24.03 + 0.98a 16.92 + 1.12 20.16 + 1.11 0.021 
Quadriceps mass (gram) 5.91 + 1.19 5.32 + 1.72 5.60 + 1.57 0.099 
Quadriceps mass (% ) 1.69 + 0.02 1.60 + 0.05 1.70 + 0.02 0.154 
aSham x Saline MNX (P = 0.019); Sham x Clen MNX (P = 0.236) 
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3.3.2.3 - Incapacitance assessment 
With the aim of assessing behavioural joint pain in the operated animals, 
incapacitance assessment was performed throughout the study.  Data revealed a 
50:50 load distribution between the hind limbs prior to surgery (Grey Bar - FIGURE 
3.9). Following meniscectomy surgery on study day 15, significantly less weight was 
placed on the ipsilateral limb (day 14 versus day 21, day 28, day 35; P = < 0.001). 
Weight distribution between the hind limbs of the meniscectomy treated animals 
resolved over a period of 14 days post surgery, although equal distribution was not 
achieved within the experimental timeframe. Pre-treatment with clenbuterol prior to 
the induction of OA had no effect of markers of behavioural joint pain (FIGURE 3.13 
grey line vs. black line).  
 
 
 
 
FIGURE 3.13  W The effects of MNX Surgery and pre-treatment regime on weight 
bearing. Data are percentage standing weight on the ipsilateral (operated) limb + 
S.E.M n = 10 for operated animals only. No significant effect of pre-treatment regime 
noted. 
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3.3.2.4 - Contractile and metabolic characteristics of the quadriceps muscle 
Electrophoretic examination of the quadriceps muscles at 21 days post surgery was 
performed to examine changes in the MHC expression profile.  Compared to the 
sham control animals, meniscectomy operated (saline pre-treated) animals exhibited 
a 115% increase in the protein expression of the slow twitch MHC I (P = 0.080), 
numerically in lieu of fast twitch MHC IIB. Pre-treatment with clenbuterol suppressed 
the OA associated increase in MHC I protein and numerically, maintained the MHC 
IIB complement. 
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FIGURE 3.14  ? The effects of meniscectomy-induced OA and clenbuterol 
administration on MHC isoforms I, IIA, IIX and IIB. (A) Silver stained electrophoretic 
MHC separation (50ng protein load) demonstrating the presence of four well-
resolved bands in the rat quadriceps (Lane 1). Lanes 2 and 3 contain control material 
from rat diaphragm and soleus respectively with known MHC protein expression 
profiles. (B) Representative quadriceps muscle samples (50ng total protein) from 
each experimental group following termination. (C) Mean densitometry values of 
each isoform expressed as a percentage of the total MHC signal + S.E.M; Sham n = 5, 
Saline MNX / Clen MNX n = 10. 
 
The metabolic potential of the quadriceps muscle samples was assessed by the 
quantification of ICDH and LDH enzyme activities in whole muscle homogenates.  The 
surgical induction of OA had no effect on ICDH activity or LDH activity. Clenbuterol 
pre-treated animals undergoing MNX surgery had significantly elevated LDH activity 
(Sham x Clen MNX; P = 0.028), suggesting an interaction between the surgical 
induction of OA and clenbuterol pre-treatment. 
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FIGURE 3.15  ? The effects of meniscectomy-induced OA and clenbuterol 
administration on ICDH and LDH activity in whole quadriceps homogenates. Data are 
mean mOD/min normalised to extractable protein + S.E.M; Sham n = 5, Saline/Clen 
MNX n = 10. P = 0.495 and 0.018 for ICDH and LDH activity respectively; * indicates P 
= < 0.05. 
 
3.3.2.5 - Analysis of 4EBP1 expression in quadriceps muscle samples 
As an index of protein synthesis, phosphorylated and total 4EBP1 protein was 
quantified by western blot.  Neither total nor phosphorylated 4EBP1 was affected by 
the induction of OA or clenbuterol pre-treatment. The ratio of phosphorylated to 
total 4EBP1 also remained constant (P = 0.287) (FIGURE 3.16).  
 
 
 
 
FIGURE 3.16  ? The effects of meniscectomy-induced OA and clenbuterol 
administration on the ratio of phosphorylated to total 4EBP1 protein. Data are mean 
densitometric units, normalised to total protein load + S.E.M; Sham n = 5, Saline/Clen 
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MNX n = 10. Inset  W Representative western blot - lanes 1, 2 and 3 comprise animals 
from groups Sham, Saline MNX and Clen MNX respectively.  
 
3.3.2.6 - Analysis of the quadriceps transcriptome 
As described in (CHAPTER 3.2.7), targets were selected to assess changes in protein 
synthesis, negative regulation of skeletal protein, muscle atrophy, apoptotic 
potential, fatty acid metabolism, glucose metabolism, and the expression of nuclear 
receptors associated with metabolic status in post-surgical quadriceps muscle 
specimens. GeNorm analysis revealed that HPRT and TATA binding protein (TBP) 
were most stable in response to the surgical induction of OA and clenbuterol pre-
treatment and therefore the most suitable housekeeping genes for data 
normalisation. Both housekeeping genes displayed a stability index (M) of 0.273 
which was considerably less than the suggested cut-off of M <1.5. Raw CP values 
were converted to relative expression values using the comparative CP method 
(Schmittgen and Livak 2008) as described previously (CHAPTER 3.2.7). 
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Markers of protein synthesis were generally unaffected by the surgical induction of 
OA or pre-treatment regime (FIGURE 3.17). IRS1 mRNA was unaffected by the 
induction of OA per se however, was reduced in animals pre-treated with clenbuterol 
prior to the induction of OA (P = 0.013 sham x Clen MNX). 
 
 
 
 
FIGURE 3.17  ? The effects of meniscectomy-induced OA and clenbuterol 
administration on markers of protein synthetic potential. Data are normalised 
expression values + S.E.M; n = 5. 
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Negative regulators of skeletal muscle protein were assessed by the determination of 
factors involved in proteosomal degradation. None of the factors studied were 
modulated by in the surgical induction of OA, or pre-treatment with clenbuterol.  
 
 
 
 
FIGURE 3.18  ? The effects of meniscectomy-induced OA and clenbuterol 
administration on negative regulators of protein synthesis. Data are normalised 
expression values + S.E.M; n = 5. 
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Factors implicated in muscle atrophying conditions were assessed and included 
myostatin, cathepsin L, and calpain members I  W III. None of the atrophy associated 
factors studies were modulated by the surgical induction of OA or clenbuterol pre-
treatment. 
  
 
 
 
FIGURE 3.19  ? The effects of meniscectomy-induced OA and clenbuterol 
administration on factors associated with muscle atrophying conditions. Data are 
normalised expression values + S.E.M; n = 5. 
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None of the apoptosis associated factors studies were modulated by the surgical 
induction of OA or clenbuterol pre-treatment.  
 
 
 
 
FIGURE 3.20  ? The effects of meniscectomy-induced OA and clenbuterol 
administration on factors associated with the apoptotic response. Data are 
normalised expression values + S.E.M; n = 5. 
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Oxidative potential was assessed in quadriceps muscle specimens. Adiponectin 
receptor 2 (AdiporR2) was elevated in response to OA induction (P = 0.080). Pre-
treatment with clenbuterol suppressed the OA associated increase in AdipoR2 with 
mRNA expression restored to that of sham control levels (P = 0.363). All other factors 
assessed were unaffected by surgery or pre-treatment regime. 
 
 
 
FIGURE 3.21  ? The effects of meniscectomy-induced OA and clenbuterol 
administration on factors associated with fatty acid oxidation. Data are normalised 
expression values + S.E.M; n = 5. 
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Glycolytic potential was assessed by examining the expression of hexokinase I mRNA. 
Hexokinase I expression was unaffected by surgery or pre-treatment regime. 
 
 
 
 
FIGURE 3.22  ? The effects of meniscectomy-induced OA and clenbuterol 
administration on hexokinase I mRNA expression. Data are normalised expression 
values + S.E.M; n = 5. 
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When the expression of genes associated with metabolic signalling were assessed, 
W' ?ɲĂŶĚɴĚŝƐƉůĂǇĞĚƐŝŵŝůĂƌĞǆƉƌĞƐƐŝŽŶƉƌŽĨŝůĞƐďƵƚǁĞƌĞƐƚĂƚŝƐƚŝĐĂůůǇƵŶĂĨĨĞĐƚĞĚďǇ
OA induction (Saline MNX) or pre-treatment (Clen MXN) ? ^ŝŵŝůĂƌůǇ ? WWZ ɲ ĂŶĚ ɷ
ĞǆŚŝďŝƚĞĚƐŝŵŝůĂƌĞǆƉƌĞƐƐŝŽŶƉƌŽĨŝůĞƐŚŽǁĞǀĞƌƚŚĞĞǆƉƌĞƐƐŝŽŶŽĨWWZɲǁĂƐƌĞĚƵĐĞĚ
following the induction of OA (P = 0.096). AMP kinase I was unaffected by the 
induction of OA or pre-treatment regime whereas numerically, AMP kinase 2 was 
reduced following the induction of OA and rescued to sham levels with pre-
treatment (P = 0.134). AMP Kinase I and 2 displayed differential responses to 
clenbuterol administration with mean AMP kinase I expression increased and AMP 
Kinase 2 reduced in response to treatment however these changes were not 
statistically significant.  
 
 
FIGURE 3.23  ? The effects of meniscectomy-induced OA and clenbuterol 
administration on factors involved in metabolite signalling. Data are normalised 
expression values + S.E.M; n = 5. 
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TABLE 3.6  W Summary of Quadriceps mRNA expression changes following MNX and 
clenbuterol administration. Data are mean normalised expression + S.E.M; n = 5. 
 
Gene Sham Saline MNX Clen MNX P = 
IRS1 153.422 ± 13.171 123.546 ± 10.175 98.718 ± 10.404 0.017 
PI3K 53.966 ± 3.305 56.364 ± 6.162 46.672 ± 4.187 0.346 
Akt 45.560 ± 4.350 37.408 ± 2.078 36.848 ± 2.685 0.197 
Gsk3B 72.548 ± 15.004 51.445 ± 2.871 66.314 ± 3.953 0.280 
mTOR 22.866 ± 4.092 17.322 ± 1.439 19.728 ± 1.025 0.344 
EIF2B 18.315 ± 2.111 14.670 ± 0.471 16.086 ± 0.603 0.223 
EIF4E 64.095 ± 1.758 93.736 ± 35.742 55.042 ± 5.768 0.522 
E&ʃɴ 17.676 ± 3.968 12.480 ± 0.986 13.776 ± 1.316 0.318 
TWEAK 54.470 ± 6.178 40.728 ± 4.293 50.538 ± 2.595 0.179 
MuRF 79.732 ± 11.358 77.615 ± 6.483 76.572 ± 5.376 0.963 
Dusp1 18.385 ± 6.291 21.733 ± 5.649 18.340 ± 2.468 0.878 
P38 28.610 ± 3.247 23.890 ± 1.189 23.506 ± 1.710 0.237 
MAFBx 86.384 ± 19.323 78.373 ± 6.480 95.190 ± 6.911 0.510 
Proteosome 48.015 ± 5.524 45.635 ± 2.796 51.622 ± 3.284 0.610 
Myostatin 53.576 ± 8.011 59.310 ± 7.385 68.402 ± 11.855 0.600 
Cathepsin L 57.522 ± 5.837 59.815 ± 4.894 61.38 ± 5.352 0.883 
Calpain I 19.730 ± 1.989 18.936 ± 1.400 19.650 ± 1.678 0.937 
Calpain II 127.872 ± 14.846 107.288 ± 8.316 116.354 ± 4.481 0.386 
Calpain III 18.010 ± 2.652 14.515 ± 1.277 15.800 ± 0.859 0.445 
Bax 198.236 ± 9.852 226.244 ± 9.444 234.390 ± 15.217 0.104 
Bcl2 47.040 ± 11.977 50.166 ± 6.532 59.200 ± 1.736 0.548 
Caspase III 2.000 ± 0.347 2.478 ± 0.309 2.348 ± 0.412 0.626 
Caspase XII 98.550 ± 10.700 90.513 ± 10.273 105.918 ± 10.566 0.634 
Cpt1a 27.683 ± 7.500 22.296 ± 2.072 23.844 ± 3.274 0.731 
Lipin 32.270 ± 5.252 32.758 ± 0.922 33.952 ± 2.039 0.934 
Adipor1 58.508 ± 7.899 54.822 ± 2.897 53.182 ± 2.472 0.754 
Adipor2 52.382 ± 3.106 68.240 ± 6.011 58.846 ± 4.470 0.094 
UCP3 49.824 ± 6.371 52.602 ± 7.691 57.762 ± 4.719 0.581 
Hk1 21.824 ± 1.194 20.342 ± 1.643 21.766 ± 2.296 0.802 
W' ?ɲ 237.053 ± 51.066 152.933 ± 15.560 183.482 ± 7.450 0.239 
W' ?ɴ 90.010 ± 13.180 69.353 ± 3.102 77.028 ± 8.553 0.389 
WWZɲ 81.065 ± 10.965 53.493 ± 6.871 60.244 ± 3.643 0.096 
WWZɷ 284.215 ± 20.425 257.553 ± 24.292 271.034 ± 25.198 0.776 
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AMPK1 5.376 ± 0.672 6.720 ± 0.599 6.112 ± 0.575 0.313 
AMPK2 815.622 ± 74.528 660.334 ± 38.018 810.230 ± 35.770 0.099 
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3.4  ? Discussion 
 
This is the first study to report the role of the quadriceps muscle and the effects of 
induced skeletal muscle hypertrophy on the severity of joint pathology in an animal 
model of osteoarthritis. Clenbuterol administration, for 14 days, resulted in marked 
skeletal muscle hypertrophy in the rat. Previous studies have reported that 
clenbuterol-induced hypertrophy is commonly associated with increased expression 
of the fast isoforms of MHC (Oishi, Imoto et al. 2002), and therefore an assessment 
of MHC composition following clenbuterol administration was undertaken. 
Clenbuterol did not induce any changes to the MHC protein composition of the 
quadriceps muscle in this study, suggesting that the contractile properties of this 
skeletal muscle were unaltered.  
 
Clenbuterol administration was further associated with the expression of several key-
modulators of muscle mass. Pro-synthetic mammalian target of rapamycin (mTOR) 
mRNA abundance was increased with clenbuterol treatment, inferring increased 
protein synthetic signalling. Conversely, the expression of the E3 ligase MuRF was 
decreased at the level of mRNA. An mTOR mediated decrease in MuRF and MAFBx 
expression may present one possible route via which clenbuterol may induce muscle 
hypertrophy (Kline, Panaro et al. 2007). Moreover, the mRNA of Dusp1, which 
antagonises the activation of MAFBx expression by p38 (Franklin and Kraft 1997), 
was increased by clenbuterol treatment. Additionally, tumour necrosis factor-like 
weak inducer of apoptosis (TWEAK) which ĂĐƚŝǀĂƚĞƐDƵZ& ?ĞǆƉƌĞƐƐŝŽŶǀŝĂE&ʃɴ(Cai, 
Frantz et al. 2004) was decreased following clenbuterol administration. By inference, 
the reduced expression of TWEAK may reason the decrease in MuRF1 expression 
noted in response to clenbuterol. 
 
Clenbuterol administration was further associated with changes in calpain 
expression. Whilst calpain II remained unaltered by treatment, both calpain I and 
calpain III were modestly up-regulated. Previous studies have reported that exercise 
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induced hypertrophy is associated with the increased expression of calpain I (Higgins, 
Lasslett et al. 1988). Such data are consistent with the findings of this study, with the 
exception that hypertrophy was induced by clenbuterol rather than targeted 
exercise.  Calpain II expression has been previously shown to be induced by both 
clenbuterol administration (Higgins, Lasslett et al. 1988) and exercise following 
immobilisation (Jones, Hill et al. 2004) however this finding was not replicated in this 
study, with clenbuterol treated animals presenting with similar calpain II expression 
to control animals. The function of calpain III is less clear with regards skeletal muscle 
atrophy and hypertrophy. Whilst mutations in the calpain III gene, leading to the loss 
of calpain III protein expression, have been found to be responsible for Limb Girdle 
Muscular Dystrophy type IIA (LGMDIIA), an autosomal recessive disorder 
characterised by progressive weakness and skeletal muscle atrophy (Jones, Hill et al. 
2004), the stable over-expression of calpain III in mice had no effect on skeletal 
muscle morphology or function (Spencer, Guyon et al. 2002). Previous studies have 
however noted increased calpain III expression following the induction of skeletal 
muscle hypertrophy (Yang, Chen et al. 2007). As calpain III is intrinsically linked with 
sarcomeric remodelling (Kramerova, Kudryashova et al. 2005), it is one possibility 
that the increase in expression noted here was associated with the marked skeletal 
muscle hypertrophy noted in response to clenbuterol administration. 
 
On balance, clenbuterol appeared to reduce skeletal muscle atrophy signalling and 
increase factors associated with skeletal muscle remodelling. That said, the effects of 
clenbuterol on protein synthetic signalling were less apparent than those on muscle 
atrophy signalling and limited to increased mTOR mRNA, with no overall effect on 
4EBP1 activation. 
 
The surgical induction of knee OA was associated with reduced weight gain, evidence 
of behavioural joint pain and the induction of MHC I protein in the quadriceps 
muscle. In this instance, the increase in MHC I protein was not associated with a 
concurrent increase in oxidative ICDH enzyme activity, which remained unaltered by 
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surgery. The induction of OA via MNX surgery was also associated with decreased 
WWZɲĂŶĚ ŝŶĐƌĞĂƐĞĚĚŝƉŽZ ?ĞǆƉƌĞƐƐŝŽŶ ?WWZɲ ŝƐƌĞƉŽƌƚĞĚƚŽĐŽƌƌĞůĂƚĞƉŽƐŝƚŝǀĞůǇ
with MHC type I fibres, and negatively with MHC type IIB fibres (Krämer, Ahlsén et al. 
2006). In this instance hŽǁĞǀĞƌ ?WWZɲĞǆƉƌĞƐƐŝŽŶĂƉƉĞĂƌĞĚ to correlate negatively 
with MHC I protein expression, the reason for which is unclear at this stage. Pre-
treatment with clenbuterol prior to the initiation of OA countered the induction of 
MHC I protein, numerically maintained MHC IIB protein, and elevated glycolytic LDH 
enzyme activity (P = 0.028). However, clenbuterol pre-treatment was unable to 
modulate the severity of joint pathology or subsequent behavioural pain in this 
model. 
 
The use of clenbuterol to induce skeletal muscle hypertrophy and promote lipolysis is 
well characterised across multiple species (Lynch and Ryall 2008). In this current 
study, following 2 weeks of clenbuterol treatment, a significant increase in the 
quadriceps muscle mass (+40%) was attained. However, at the study endpoint, the 
hypertrophic effect of clenbuterol was no longer apparent in the pre-treated 
animals, which presented with comparable quadriceps mass to bodyweight ratios. To 
determine the muscle fibre-type composition of the quadriceps, MHC protein 
expression was monitored. Of interest, it was found that although no changes to the 
MHC protein composition were noted in response to clenbuterol prior to surgery, 
subtle effects of clenbuterol on MHC protein expression and metabolic potential 
were observed in the period post surgery where clenbuterol suppressed the trend 
towards a meniscectomy surgery induced increase in MHC I and elevated LDH 
enzyme activity. Although only a trend association was noted between pre-treatment 
with clenbuterol and suppression of the increase in MHC I protein observed post 
surgery (p = 0.081), this is supported by several studies that report the slow to fast 
fibre inducing effects of clenbuterol in rodents (Lynch and Ryall 2008). The fact that 
these changes were not observed in the pre-treatment period may be due to the 
length of drug exposure and / or the muscle studied. The latter may be related to the 
natural distribution of MHC protein isoforms within the quadriceps muscle which is 
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comprised of over 85% fast MHC IIX / MHC IIB, and less than 15% slower MHC I / 
MHC IIA. Such a high baseline complement of fast MHC may reduce the impact of ɴ-
agonist administration with regards to its effect in inducing slow to fast fibre type 
transitions. Previous studies noting such changes were often conducted over a longer 
timeframe and tended to study the slow twitch soleus muscle, which is particularly 
susceptible to fibre type shifts. It is also possible however, that these changes were 
simply more evident in the predominantly slow soleus when compared with the 
predominantly fast quadriceps.  
 
As previously noted, meniscectomy surgery was associated with a trend towards 
increased MHC I, indicative of a switch towards a slower more oxidative and fatigue 
resistant muscle type, more commonly associated with postural, anti-gravity muscles 
(Adams, Haddad et al. 1994). Such changes in muscle fibre type following 
meniscectomy may have important implications for rehabilitation, in particular the 
type of muscle strengthening program recommended.  One possible reason for this 
change in MHC composition in response to meniscectomy surgery might be that it is 
a physiological attempt to increase the stability of the operated joint by increasing 
the complement of fatigue resistant, slow muscle fibres that surround it. A further 
possibility is that surgery-induced changes in weight bearing led to disuse atrophy of 
fast MHC IIB fibres, resulting in an increase in the relative proportion of slower MHC I 
fibres as noted previously (Gardiner, Favron et al. 1992).  Noteworthy is that only 
mild changes to weight bearing were noted (approximately 4%) and it is unclear 
whether such modest perturbations are capable of inducing changes to the relative 
distribution of MHC.  
 
A number of previous studies suggest that modulating muscle function through 
exercise may have an impact on the development and severity of OA in humans; 
therefore it must be considered why no effect was noted in this experimental model. 
The experimental approach chosen in the present study was to dose with clenbuterol 
for up to 2 weeks prior to surgical induction of OA, but to stop administration 
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immediately after surgery.  This approach avoided any potential confounding factors 
of direct clenbuterol action at the joint or direct cardiovascular effects, and allowed 
the physiological impact of a hypertrophic quadriceps muscle on OA severity to be 
modelled. However, although clenbuterol resulted in marked increases in quadriceps 
mass during the pre-treatment period, this effect was not maintained throughout the 
time course of the study and may explain the lack of effect on OA severity reported.  
Another possibility might be the agent of choice used in this study to induce muscle 
hypertrophy.  Although clenbuterol is effective in this regard, it also leads to an 
overall increase in animal bodyweight due to the induction of lean mass, a 
concurrent decline in fat mass and the relatively high mass of skeletal muscle 
compared to that of adipose tissue (Rothwell and Stock 1987). It is well known that 
weight is a risk factor for knee OA (Arden and Nevitt 2006).  Moreover, bodyweight 
has been associated with the severity of OA in the Dunkin Hartley guinea pig where a 
28% reduction in bodyweight led to a marked 40% decrease in OA severity (Bendele 
and Hulman 1991).  By inference, it is therefore possible that this increased 
bodyweight in the clenbuterol treated animals compared to the control animals, at 
the time of induction, may have negated any potential beneficial effect of a 
strengthened quadriceps, and thus explains the lack of positive modulation noted 
during this study. A further possibility is that quadriceps muscle mass is not the sole 
determinant of the role of muscles in OA. Instead, it is likely that it is the coordinate 
modulation of several muscle parameters such as muscle fibre type composition and 
size of motor units recruited during exercise that together with mass, are key in 
eliciting an impact on OA pathology.  
 
In addition it is also important to note that clenbuterol has greater hypertrophic 
effects on slow twitch muscles compared with faster twitch muscles (Stevens, Firinga 
et al. 2000; Herrera, Zimmerman et al. 2001).  In the intact knee, agonist force is 
generated by the quadriceps muscle in tandem with antagonist force generation by 
the hamstrings producing joint stability (Hortobagyi, Westerkamp et al. 2005). If one 
considers the quadriceps / hamstrings balance (Q/H ratio) and that anabolic steroid 
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induced hypertrophy might elicit a greater strength increases in leg flexion over leg 
extension (Schroeder, Terk et al. 2003), it is possible that clenbuterol administration 
induced skeletal muscle hypertrophy disproportionately across the various muscles 
surrounding the knee joint, disrupting the fine balance of agonist and antagonist 
forces, leading to decreased joint stability.  This could have a detrimental effect on 
the formation of joint pathology in a similar way to that observed in man with joint 
instability due to joint mal-alignments (Kalichman, Zhang et al. 2007). In this respect, 
ɴ-agonist administration appears not to mimic strength training in which contractile 
movements impose work, and therefore hypertrophy, on both antagonistic muscles 
maintaining muscle synergy. 
 
In summary, this study confirmed that the meniscectomy surgery protocol utilised 
resulted in the formation of consistent OA-like lesions in the rat which appeared 
morphologically similar to OA of the human knee. Moreover, the administration of 
clenbuterol was effective in the induction of marked skeletal muscle hypertrophy 
following administration for 14 days. Given the high baseline complement of fast-
twitch muscle fibres in the quadriceps skeletal muscle, clenbuterol administration 
was not associated with changes to the fibre-type composition nor was it associated 
with changes indicative of an altered metabolic profile. Clenbuterol-induced skeletal 
muscle hypertrophy and a trend towards increased glycolytic potential, prior to the 
induction of OA, did not appear to modulate the severity of OA in this experimental 
model.  
 
Although the MNX model of OA was beneficial in the assessment of OA and 
indispensible for the testing of muscle hypertrophy inducing agents, it was felt that 
the enhanced rate at which disease occurred may have precluded any beneficial 
effects of increased skeletal muscle mass. It was therefore proposed that animal 
models of OA that better mimic the human condition in terms of initiation and 
progression rates, may provide a more suitable platform on which to observe subtle 
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changes in disease progression brought about through modulating skeletal muscle 
function.  
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CHAPTER 4  ? ELUCIDATING MYOSIN HEAVY CHAIN (MHC) SPECIFIC 
CDNA SEQUENCES IN THE DUNKIN HARTLEY GUINEA PIG 
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4.1  ? Introduction and Rationale 
 
In attempting to examine skeletal muscle in an animal model of knee-OA that better 
emulates the human condition, the spontaneous Dunkin Hartley guinea pig model 
was considered. However, quantifying skeletal muscle changes by the assessment of 
MHC in the guinea pig has proved problematic to date.  
 
Several chronic conditions leading to skeletal muscle dysfunction are known to be 
associated with changes in muscle fibre-type (reviewed in CHAPTER 1.3.7) as 
determined by the expression of myosin heavy chain (MHC) isoforms at both the 
mRNA and protein level. Furthermore, many of these conditions are modelled, pre-
clinically, in the guinea pig due to similar disease onset and progression to the human 
condition, and their generally well-characterised anatomy.  
 
As described in CHAPTER 1.3.2, MHC composition is amenable to determination by 
protein and mRNA based methodologies, the latter quantifying the expression of 
MHC isoform-specific gene transcripts allowing the detection of earlier, and more 
subtle changes. As such, the MHC mRNAs, and associated specific oligonucleotide 
primers for PCR of all common laboratory species, such as the rat and mouse, have 
been available for some time. To date, it has not been possible to resolve guinea pig 
MHC isoforms using SDS PAGE. Moreover, due to incomplete genomic annotation, 
the assessment of guinea pig MHC mRNA expression has not been possible either, 
thus precluding full characterisation of the early changes in skeletal muscle in 
response to disease and disease modulation.  
 
Therefore, the purpose of this study was to characterise the multigenic structure of 
the sarcomeric MHC family in the guinea pig, and to design and validate specific 
oligonucleotide primers to enable the assessment of MHC mRNA expression in 
relevant disease models. The molecular tools developed here were subsequently 
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utilised to assess changes in the quadriceps skeletal muscle in response to 
developing knee osteoarthritis in the laboratory guinea pig (CHAPTER 5).    
 
 
4.1.1  ? Hypotheses and aims  
The structure of the sarcomeric MHC family in the laboratory guinea pig will be 
clustered in a head-to-tail fashion, consistent with that of other species which have 
been previously described (CHAPTER 1.3.2). Furthermore, enough sequence 
variability will exist between the various isoforms of MHC, at the mRNA level, as to 
allow the design and validation of isoform-specific oligonucleotide primers for 
expression studies by quantitative PCR. 
 
The following specific aims will be addressed; 
 
 Elucidate genes encoding for the various isoforms of MHC in the guinea pig  
 Accurately determine the gene boundaries of each MHC isoform 
 Derive novel partial coding sequence for each of the sarcomeric MHC isoforms 
 Design and validate specific oligonucleotide primers for mRNA expression by 
quantitative PCR 
 Perform promoter analysis in comparison to other well-characterised species 
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4.2  ? Experimental Protocol 
 
4.2.1  ? Experimental approach 
The experimental approach taken was to locate regions of cDNA sequence conserved 
ďĞƚǁĞĞŶ ƚŚĞ  “ĨĂƐƚ ? ŝƐŽĨŽƌŵƐ ŽĨ D, ŝŶ ƚŚĞ ƌĂƚ ĂŶĚ ŵŽƵƐĞ ďǇ alignment. Primers 
were designed in the conserved regions, and used to amplify a region of novel 
sequence coding for MHC from guinea pig quadriceps cDNA. The resulting PCR 
products were cloned and sequenced bi-directionally.  The novel guinea pig-derived 
sequence was subsequently used to query the partially annotated guinea pig 
genomic DNA database to locate the region of sequenced genome likely to encode 
the MHC gene family. Using the well-studied structure of the MHC family in 
numerous species as a reference, it was possible to advance along the guinea pig 
genomic sequence, and locate genes encoding each of the remaining MHC isoforms 
of interest.  
 
hƐŝŶŐ ?ĂŶĚ ? ?ZŵĞƚŚŽĚŽůŽŐǇ ?ƚŚĞďŽƵŶĚĂƌŝĞƐƌĞůĂƚŝŶŐƚŽƚŚĞĞǆƉƌĞƐƐĞĚƌĞŐŝŽŶƐ
of each of the MHC-associated genes were described, and specific oligonucleotide 
primers designed within areas of divergence. This approach was utilised to design 
isoform-specific primers for quantitative PCR, capable of determining the transcript 
abundance of each skeletal muscle-associated MHC with reference to muscle fibre-
type.  
 
4.2.2  ? Biospecimens 
Extensor digitorum longus, soleus and quadriceps femoris were dissected from 3 
month old Dunkin Hartley strain guinea pigs (Harlan, UK) and immediately snap 
frozen in liquid nitrogen. Total RNA was extracted from 100mg of sample using TRIzol 
regent (Invitrogen). Contaminating genomic DNA was removed via DNase digestion 
(Promega), and the resulting RNA resuspended in DNase / RNase-free water. All RNA 
was stored at -80oC prior to use. For standard PCR applications, complimentary DNA 
was generated by reverse transcription of 500ng total RNA using MMLV (Promega) 
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using a standard protocol and stored at -20oC prior to analysis (METHODS 2.1.1  ? 
2.1.5) . 
 
4.2.3  ? cDNA sequence alignment and bioinformatics 
All cDNA sequences were obtained from Ensemble Release 56 (Ensemble), and 
aligned using the ClustalW2 application (Larkin, Blackshields et al. 2007) configured 
for DNA analysis where indicated. Novel sequence data was compared to the 
partially annotated Cavia porcellus database using the BLAT utility (Kent 2002) 
available from Ensemble Release 56 (Ensemble). 
 
4.2.4  ? Rapid amplification of cDNA ends (RACE) 
 ? ?ZĂƉŝĚĂŵƉůŝĨŝĐĂƚŝŽŶŽĨĐEĞŶĚƐ ? ? ?Z ?ǁĂƐĐĂƌƌŝĞĚŽƵƚƵƐŝŶŐƚŚĞ'ĞŶĞZĂĐĞƌ ?
system (Invitrogen). DNase digested total RNA (3000ng) was incubated with 10U calf 
intestinal phosphatase (CIP), 1µl CIP buffer (0.5M Tris-HCl pH 8.5, 1mM EDTA) and 
40U RNaseOut (Invitrogen) at 50oĨŽƌ ? ?ŵŝŶƵƚĞƐ ? ? ?ĚĞƉŚŽƐƉŚŽƌǇůĂƚŝŽŶƐƉĞĐŝĨŝĐĂůůǇ
targets partial length, un-capped transcripts thus preventing their inclusion in this 
assay. RNA was precipitated by the addition of 90µl RNase/DNase-free water and 
100µl phenol: chloroform (1:1) and vortexed vigorously for 30 seconds. Following 
centrifugation (Accuspin Micro, Fisher) at 16,000g for 5 minutes at room 
temperature, 100µl of the resulting aqueous phase was removed to a separate tube. 
To the resulting aqueous phase, 20µg mussel glycogen, 10µl 3M sodium acetate (pH 
5.2) and 220µl 95% (v/v) ethanol were added and vortexed briefly. The precipitated 
RNA was centrifuged at 16,000g for 20 minutes (+4oC), washed with 70% (v/v) 
ethanol and resuspended in 7µl RNase/DNase-free water. Following 
dephosphorylation, RNA was treated with tobacco acid pyrophosphatase (TAP) to 
ƌĞŵŽǀĞ ƚŚĞ  ? ? ĐĂƉ ƐƚƌƵĐƚƵƌĞ ĂŶĚ ĞǆƉŽƐĞ ƚŚĞ ƚĞƌŵŝŶĂů  ? ? ƉŚŽƐƉŚĂƚĞ ŝŶ Ă ƌĞĂĐƚŝŽŶ
containing 0.5U TAP, 1µl buffer (0.5 M sodium acetate, pH 6.0, 10 mM EDTA, 1% v/v 
ɴ-mercaptoethanol, 0.1% v/v Triton® X-100), 40U RNaseOut, and incubated at 37oC 
for 60 minutes. The resulting dephosphorylated, de-capped RNA was precipitated as 
ĂďŽǀĞ ?&ŝŶĂůůǇ ?ĂŶZEŽůŝŐŽŶƵĐůĞŽƚŝĚĞǁĂƐůŝŐĂƚĞĚƚŽƚŚĞĞǆƉŽƐĞĚ ? ?ƉŚŽƐƉŚĂƚĞƵƐŝŶŐ
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T4 ligase in a reaction containing 5U T4 ligase, 1µl 10mM ATP, 40U RNaseOut in a 
buffer comprising (330 mM Tris-Acetate, pH 7.8, 660 mM potassium acetate, 100 
mM magnesium acetate 5 mM DTT) at 37oC for 60 minutes.  Complimentary DNA 
was reverse transcribed from modified RNA using the GeneRacer modified Oligo dT 
ƉƌŝŵĞƌ  ? ?ƉŵŽůĞ ? ĂŶĚ ^ƵƉĞƌƐĐƌŝƉƚ ///  ?/ŶǀŝƚƌŽŐĞŶ ? ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ
ƉƌŽƚŽĐŽů ?dŚĞƌĞƐƵůƚŝŶŐĐEŝƐƐƵďƐĞƋƵĞŶƚůǇƌĞĨĞƌƌĞĚƚŽĂƐ “ZƌĞĂĚǇĐE ? ? 
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4.3  ? Results 
 
4.3.1  ? Identification of conserved regions 
In order to generate a region of guinea pig cDNA encoding part the MHC multigenic 
family, all available MHC mRNAs were obtained from the mouse (Mus musculus) and 
rat (Rattus norvegicus) cDNA libraries, Ensemble release 56. Search terms comprised 
the official gene name as listed in TABLE 4.1. For the identification of conserved 
regions in which oligonucleotide primers for quantitative PCR could be designed, 
MyH1, MyH2 and MyH4 (MHC IIA, IIX and IIB respectively) cDNA sequences were 
aligned uƐŝŶŐůƵƐƚĂůt ? ?/ ? ?^ĞƋƵĞŶĐĞƐǁĞƌĞƚƌƵŶĐĂƚĞĚĂƚƚŚĞ ? ?ƚĞƌŵŝŶŝƚŽĞǆĐůƵĚĞ
ĂŶǇƐĞƋƵĞŶĐĞ ĨƌŽŵ ƚŚĞ  ? ? ƵŶƚƌĂŶƐůĂƚĞĚ ƌĞŐŝŽŶĂŶĚ ŝŶĐůƵĚĞŽŶůǇ ƐĞƋƵĞŶĐĞ ĨƌŽŵƚŚĞ
ŝŶŝƚŝĂƚŝŶŐ  “d' ? ŽŶǁĂƌĚƐ ? ^ĞƋƵĞŶĐĞ ĂůŝŐŶŵĞŶƚ ƌĞǀĞĂůĞĚĂ ĐŽŶƐĞƌǀĞĚ ƌĞŐŝŽŶ ? ĂĐƌŽƐƐ
both MHC isoform and species, between exons 5 and 10 (FIGURE 4.1) large enough 
to accommodate a pair of oligonucleotide primers. These primers were named 
GP_626bp after their theoretical amplicon size. 
 
 
TABLE 4.1  W Gene names, cDNA sequence attributes and accession numbers 
Species Gene Name MHC Isoform Accession Number Comments 
Mus  MyH1 IIX NM_030679.1 Full Length cds 
musculus MyH2 IIA NM_001039545.2 Full Length cds 
 MyH3 Embryonic NM_001099635.1 Full Length cds 
 MyH4 IIB NM_010855.2 Full Length cds 
 MyH8 Neonatal NM_177369.3 Full Length cds 
 MyH13 Extra-ocular NM_001081250.1 Full Length cds 
Rattus  MyH1 IIX NM_001135158.1 Full Length cds 
norvegicus MyH2 IIA NM_001135157.1 Full Length cds 
 MyH3 Embryonic NM_012604.1 Full Length cds 
 MyH4 IIB NM_019325.1 Full Length cds 
 MyH8 Neonatal XM_001080186.1 Full Length cds 
 MyH13 Extra-ocular XM_001078857.1 Full Length cds 
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MyH2_Mus         TCCGGGGCCGGGAAGACTGTGAACACGAAGCGTGTCATCCAGTACTTTGCAACAATTGCA 600 
MyH2_Rattus      TCCGGGGCCGGGAAGACTGTGAACACGAAGCGTGTCATCCAGTACTTTGCAACAATTGCA 600 
MyH1_Mus         TCCGGGGCCGGGAAGACTGTGAACACGAAACGTGTCATCCAGTACTTTGCAACAATTGCA 600 
MyH1_Rattus      TCCGGGGCCGGGAAGACTGTGAACACGAAGCGTGTCATCCAGTACTTTGCAACAATTGCA 600 
MyH4_Mus         TCCGGGGCCGGGAAGACTGTGAACACGAAGCGTGTCATCCAGTACTTTGCAACAATTGCA 600 
MyH4_Rattus      TCCGGGGCCGGGAAGACTGTGAACACGAAGCGTGTCATCCAGTACTTTGCAACAATTGCA 600 
                 ***************************** ****************************** 
 
MyH2_Mus         GTCACTGGGGACAAGAAGAAGGAGGAGGCAACTTCTGGCAAAATGCAGGGGACGCTGGAG 660 
MyH2_Rattus      GTCACTGGGGAGAAAAAGAAGGAGGAGGTGACTTCTGGCAAAATGCAGGGGACCCTGGAA 660 
MyH1_Mus         GTCACTGGGGAGAAAAAGAAGGAGGAGGCAACTTCTGGCAAAATGCAGGGGACGCTGGAG 660 
MyH1_Rattus      GTCACTGGGGAGAAAAAGAAGGAGGAGGTGACTTCTGGCAAAATGCAGGGGACCCTGGAA 660 
MyH4_Mus         GTCACTGGGGACAAGAAGAAGGAGGAGGCGACTTCTGGCAAAATGCAGGGGACCCTTGAA 660 
MyH4_Rattus      GTCACCGGGGACAAGAAGAAGGAGGAAGCACCTTCTGGCAAAATGCAGGGGACCCTTGAA 660 
                 ***** ***** ** *********** *   ********************** ** **  
 
---------------------------------------------------------------------------------- 
 
MyH2_Mus         ATTTTGGGCTTTACAAATGATGAAAAAGTCTCCATCTATAAGCTCACCGGTGCTGTGATG 1080 
MyH2_Rattus      ATTCTGGGCTTTACAAATGATGAAAAGGTCTCCATCTATAAGCTCACGGGAGCTGTGATG 1080 
MyH1_Mus         ATTCTGGGCTTCACTTCTGATGAAAGAGTCTCCATCTATAAGCTCACAGGGGCTGTGATG 1080 
MyH1_Rattus      ATTCTGGGCTTCACTTCTGATGAAAGAGTCTCCATCTATAAGCTCACGGGGGCTGTGATG 1080 
MyH4_Mus         ATCCTGGGATTCAGTGCAGATGAAAAGGTGGCCATTTACAAGCTCACAGGCGCTGTGATG 1080 
MyH4_Rattus      ATCCTGGGGTTCACTGCAGATGAAAAAGTGGCCATTTACAAGCTCACTGGTGCTGTGATG 1080 
                 **  **** ** *     *******  **  **** ** ******** ** ********* 
 
MyH2_Mus         CATTATGGGAACATGAAGTTCAAGCAGAAGCAGCGGGAGGAGCAGGCAGAGCCAGATGGC 1140 
MyH2_Rattus      CATTATGGGAACATGAAGTTCAAGCAGAAGCAGCGGGAAGAACAGGCTGAGCCGGATGGC 1140 
MyH1_Mus         CATTATGGGAACATGAAATTCAAGCAGAAGCAACGAGAGGAGCAGGCTGAGCCAGACGGC 1140 
MyH1_Rattus      CATTATGGGAACATGAAGTTCAAGCAGAAGCAACGTGAGGAGCAGGCTGAGCCGGATGGC 1140 
MyH4_Mus         CATTATGGGAACATGAAATTCAAGCAAAAGCAAAGGGAAGAGCAGGCTGAGCCAGACGGC 1140 
MyH4_Rattus      CACTATGGGAACATGAAATTCAAGCAAAAGCAAAGGGAAGAGCAGGCTGAGCCAGACGGC 1140 
                 ** ************** ******** *****  * ** ** ***** ***** ** *** 
 
MyH2_Mus         ACCGAAGTTGCTGACAAAGCTGCCTATCTTCAGGGTCTGAACTCTGCTGACCTGCTCAAA 1200 
MyH2_Rattus      ACGGAAGTGGCTGACAAGGCTGCCTATCTTCAGGGTCTGAACTCTGCTGACCTGCTCAAA 1200 
MyH1_Mus         ACCGAAGTTGCTGACAAGGCTGCCTATCTCCAAAATCTGAACTCTGCTGACCTGCTCAAA 1200 
MyH1_Rattus      ACGGAAGTGGCTGACAAGGCTGCCTATCTCCAAAATCTGAACTCTGCTGACCTGCTCAAA 1200 
MyH4_Mus         ACCGAAGTTGCTGACAAGGCTGCCTATCTGACAAGTCTGAACTCTGCTGACCTGCTCAAA 1200 
MyH4_Rattus      ACTGAAGTGGCTGACAAGGCTGCCTATCTGACAAGTCTGAACTCTGCTGACCTGCTCAAA 1200 
                 ** ***** ******** ***********      ************************* 
 
FIGURE 4.1  W cDNA sequence alignment of MHC (fast) mRNAs of mouse (Mus) and 
rat (Rattus) origin as indicated. Asterisks indicate nucleotides which are conserved 
across all 6 sequences.  Primer pair GP_646bp are indicated in blue (forward) and 
grey (reverse) boxes. 
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4.3.2  ? Generating a fragment of guinea pig sequence 
In order to generate a region of guinea pig cDNA sequence encoding part the MHC 
multigenic family with which to query the gDNA database and locate the region in 
which it was encoded, quadriceps cDNA was subjected to endpoint PCR using primer 
pair GP_626bp (METHOD 2.1.7). PCR revealed the presence of an abundant 
transcript of the expected size (FIGURE 4.2).  
 
 
 
 
FIGURE 4.2  W Fragment of Guinea Pig sequence pertaining to MHC. 1Kb: 1Kb DNA 
ladder, 100bp: 100bp DNA ladder, 626bp: guinea pig quadriceps cDNA following PCR 
with GP_626bp primers; annealing temperature = 55oC, NEG: no template control 
 
 
In order to determine which MyH transcript the PCR amplicon was derived from, the 
resulting amplicon was cloned into the pGEM T-Easy vector system according to the 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛinstructions (Promega) (METHOD 2.2.2). Following transformation 
into JM109 competent cells (Promega), 5 clones were selected at random for DNA 
sequencing using M13 primers targeting the vector sequence to obtain full-length 
sequencing of the inserts. All 5 clones were identical; therefore the novel sequence 
was used to query the partially annotated Cavia porcellus gDNA database using BLAT 
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(Ensemble release 56) to include sequences from Rattus norvegicus, Mus musculus 
and Cavia porcellus with the intention of confirming the identity of the clone, and 
locating the genomic region in which it was encoded.  BLAT analysis revealed the 
ĐůŽŶĞĚƐĞƋƵĞŶĐĞƚŽďĞůŽĐĂƚĞĚƚŽǁĂƌĚƐƚŚĞ ? ?ƚĞƌŵŝŶŝŽĨŐĞŶe MyH2 in both Rattus 
norvegicus and Mus musculus. BLAT also revealed a sequence match in the un-
annotated guinea pig gDNA database - this was assumed to correspond to MyH2 
also.  
 
4.3.3  ? Determining the genomic location of other members of the MHC gene 
family 
In all other species described, the MHC family of genes is located across two separate 
chromosomes. One chromosome encodes (in order) MyH3/MyH2, MyH1/MyH 4 and 
MyH8/MyH13 arranged in a head-to-tail fashion. The other chromosome encodes 
the cardiac (MǇ, ?ɲ ? ĂŶĚ ƐůŽǁ ƐŬĞůĞƚĂů ŵƵƐĐůĞ ŝƐŽĨŽƌŵƐ  ?DǇ, ?ɴ ?(Weiss and 
Leinwand 1996). Using this knowledge, and the previously determined location of the 
guinea pig MyH2 gene as a starting point, it was possible to advance along the 
genomic sequence data (Ensemble release 56) in both the 5- ? ? ĂŶĚ  ?-  ? ĚŝƌĞĐƚŝŽŶ ?
aligning individual exons from both Rattus norvegicus and Mus musculus MyH1, 
MyH2, MyH3, MyH4, MyH8 and MyH13 cDNAs (TABLE 4.1) to the guinea pig gDNA 
database, thus spatially mapping out the arrangement of genes in the guinea pig 
(FIGURE 4.3). During the course of this study, a full length cDNA pertaining to Cavia 
porcellus MyH7, known to encode the slow skeletal muscle isoform MHC I, was 
annotated in Ensemble release 56. MyH7 was therefore not analysed in any further 
detail, and the focus maintained on characterising the fast-twitch associated MHC 
genes (MyH1, MyH2 and MyH4). 
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FIGURE 4.3  ? Spatial arrangement of the multigenic myosin heavy chain (MHC) family in the laboratory guinea pig (Cavia porcellus) as 
determined through the retrieval of MHC isoform specific genes (MyH) from various species using multiple BLAT and subsequent 
alignment (ClustalW2). I.G  W Intergenic region size (Kb); Protein  W protein product of each gene. 
 
 
 
 
 
119 
 
4.3.4  ? ĞƚĞƌŵŝŶĂƚŝŽŶŽĨƚŚĞŐĞŶĞďŽƵŶĚĂƌŝĞƐŽĨDǇ, ? ? ?ĂŶĚ ?ďǇ ? ?ĂŶĚ ? ?Z 
To accurately determine the transcriptome boundaries of each of the adult skeletal 
muscle associated MHC isoforms, the untranslated regions of each mRNA were 
extended using  ? ? ĂŶĚ  ? ? Z ? dŚĞ ŵƵůƚŝƉůĞ ĞǆŽŶŝĐ ĂůŝŐŶŵĞŶƚƐ  ?ĂƐ ƉƌĞǀŝŽƵƐůǇ
described) from MyH1, MyH2 and MyH4 were obtained from the guinea pig genomic 
sequence, and the newly annotated putative cDNA sequence data (manually spliced 
from the genomic sequence) aligned using ClustalW2 (FIGURE 4.4).  
 
Sequence homology across the coding sequence of the three guinea pig isoforms of 
MHC showed a particularly high level of conservation. As such, it was not possible to 
design isoform-specific RACE primers (to extend the untranslated regions), nor 
standard oligonucleotide PCR primers with which to conduct expression studies. The 
issue of extending the untranslated regions, and therefore demarcating the gene 
ďŽƵŶĚĂƌŝĞƐǁĂƐŽǀĞƌĐŽŵĞďǇĚĞƐŝŐŶŝŶŐ  ? ?ĂŶĚ  ? ?ZƉƌŝŵĞƌƐ ƚŽĂŵƉůŝĨǇ all three 
isoforms of MHC as indicated in FIGURE 4.4. RNA derived from three different 
ŵƵƐĐůĞƐǁĂƐƵƐĞĚŝŶƚŚĞ ? ?ĂŶĚ ? ?ZƉƌŽƚŽĐŽůƚŽĞŶƌŝĐŚĨŽƌƚŚĞǀĂƌŝŽƵƐD,ŐĞŶĞ
transcripts since extensor digitorum longus is known to predominantly express MyH1 
and MyH4; soleus MyH2 and MyH7 whilst quadriceps is thought to express all four 
isoforms. With regards the design of PCR primers for analysis of expression, it was 
hypothesised that the sequence data from the un-translated region (derived through 
RACE) would likely be less well-conserved and therefore permit the design of gene-
specific primers.  
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MyH1_Cavia      GTGACAGCCAAGACAGAAGGCGGAGCTACTGTAACAGTGAAGGATGACCAGGTGTTCCCC 237 
MyH2_Cavia      GTAACTGTGAAAACCGAAGCGGGAGCGACCTTGACAGTGAAGGATGACCAGGTGTTCCCC 240 
MyH4_Cavia      GTGACAGCCAAGACAGAAGGCGGAGCTACTGTCACAGTTAAGGAAGACCAAGTCTTTTCC 237 
                ** ** *  ** ** ****  ***** **  * ***** ***** ***** ** **  ** 
 
MyH1_Cavia      ATGAACCCTCCCAAATACGACAAGATCGAGGACATGGCCATGATGACCCACCTGCACGAG 297 
MyH2_Cavia      ATGAACCCTCCCAAATTTGACAAGATCGAGGACATGGCCATGATGACCCACCTGCACGAG 300 
MyH4_Cavia      ATGAACCCTCCCAAATATGACAAGATCGAGGACATGGCCATGATGACCCACCTGCACGAG 297 
                ****************  ****************************************** 
 
MyH1_Cavia      CCTGCGGTGCTGTACAACCTCAAAGAGCGTTACGCAGCCTGGATGATCTACACCTACTCG 357 
MyH2_Cavia      CCTGCGGTGCTGTACAACCTCAAAGAGCGTTACGCAGCCTGGATGATCTACACCTACTCG 360 
MyH4_Cavia      CCTGCCGTGCTGTACAACCTCAAAGAGCGTTACGCAGCCTGGATGATCTACACCTACTCG 357 
                ***** ****************************************************** 
 
------------------------------------------------------------------------------------------------------------ 
 
MyH1_Cavia      AGAAGGCCAAGAAGGCCATCACTGATGCCGCCATGATGGCCGAGGAGCTGAAGAAGGAGC 5325 
MyH2_Cavia      AGAAGGCCAAGAAGGCCATCACCGATGCCGCCATGATGGCCGAGGAGCTGAAGAAGGAGC 5335 
MyH4_Cavia      AGAAGGCCAAGAAGGCCATCACTGATGCCGCCATGATGGCCGAGGAGCTGAAGAAGGAGC 5331 
                ********************** ************************************* 
 
MyH1_Cavia      AGTGACAGCAGCGCCCACCTGGGAGCGCATGAAGAAGAACCTGGAGCAGACGGTCAAGGA 5385 
MyH2_Cavia      AG-GACACCAGCGCCCACCTGG-AGCGCATGAAGAAGAACATGGAGCAGACGGTCAAGGA 5393 
MyH4_Cavia      AG-GACACCAGCGCCCACCTGG-AGCGCATGAAGAAGAACCTGGAGCAGACGGTCAAGGA 5389 
                ** **** ************** ***************** ******************* 
 
MyH1_Cavia      CCTGCAGCACCGGCCTGGACGAGGCCGAGCAGCTGGCGCTGAAGGGCGGCAAGAAGCAGA 5445 
MyH2_Cavia      CCTGCAGCTCCG-TTTGGACGAGGCCGAGCAGCTGGCGCTGAAGGGCGGCAAGAAGCAGA 5452 
MyH4_Cavia      CCTGCAGCACCG-GCTGGACGAGGCCGAGCAGCTGGCGCTGAAGGGCGGCAAGAAGCAGA 5448 
                ******** ***   ********************************************* 
 
MyH1_Cavia      TCCAGAAGCTGGAGGCCAGG----GTACGTGAACTTGAAGGGGAAGTGGAAAGCGAACAG 5501 
MyH2_Cavia      TCCAGAAGCTGGAGGCCAGG----GTGCGTGAGCTGGAAGGCGAGGTAGAGAGTGAGCAA 5508 
MyH4_Cavia      TCCAGAAGCTGGAGGCCAGGCCAGGTGAGGGAACTTGAAAACGAAGTTGAAAATGAGCAG 5508 
                ********************    **  * ** ** ***   ** ** ** *  ** **  
 
 
FIGURE 4.4  W Guinea pig cDNA coding sequence alignment of theoretical guinea pig 
MHC isoforms MyH1, 2, and 4 derived from the guinea gDNA sequence as located by 
multiple sequence alignment (FIGURE 4.3). Asterisks indicate nucleotides which are 
conserved across all sequences. Oligonucleotide primers indicated are RevGSP (blue 
box), RevNestedGSP (blue underline), ForGSP (grey box), and ForNestedGSP (grey 
underline). 
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4.3.4.1  ? Rapid amplification of cDNA ends (RACE) 
&Žƌ  ? ?ĂŶĚ ? ?ZƌĞĂĐƚŝŽŶƐ ?ƚŽƚĂůZEĨƌŽŵƐŽůĞƵƐ ?ĞǆƚĞŶƐŽƌdigitorum longus and 
quadriceps specimens was modified by adding a region of ŬŶŽǁŶƐĞƋƵĞŶĐĞĂƚƚŚĞ ? ?
terminus in accordance with (CHAPTER 4.2.4). First-strand complimentary DNA was 
generated using a modified Oligo dT primer, thus adding a region of known sequence 
Ăƚ ƚŚĞ  ? ?terminus (FIGURE 4.5A ? ?  ? ? Z ƌĞĂĐƚŝŽŶƐ ǁĞƌĞƉĞƌĨŽƌŵĞĚinitially using 
ƉƌŝŵĞƌƐ 'ĞŶĞZĂĐĞƌ  ? ? ĂŶĚ ZĞǀ'^W ƚŽ ŐĞŶĞƌĂƚĞ ĂƉƉƌŽǆŝŵĂƚĞůǇ  ? ? ?ďƉ ŽĨ ĐŽĚŝŶŐ
ƐĞƋƵĞŶĐĞ ƉůƵƐ ƚŚĞ ŶŽǀĞů  ? ? hdZ ? ǁŚŝůƐƚ  ? ? Z ƌĞĂĐƚŝŽŶƐ ǁĞƌĞ ƉĞƌĨŽƌŵĞĚ ƵƐŝŶŐ
ƉƌŝŵĞƌƐ'ĞŶĞZĂĐĞƌ  ? ? ĂŶĚ&Žƌ'^W  ƚŽŐĞŶĞƌĂƚĞ  ? ? ?ďƉ ŽĨ ĐŽĚŝŶŐ ƐĞƋƵĞŶĐĞ ƉůƵƐ ƚŚĞ
ŶŽǀĞů ? ?UTR (FIGURE 4.5B).  
 
 
 
 
FIGURE 4.5  W ^ĐŚĞŵĂƚŝĐ ƌĞƉƌĞƐĞŶƚĂƚŝŽŶ ŽĨ  ? ? ĂŶĚ  ? ? ZE ŵŽĚŝĨŝĐĂƚŝŽŶƐ ? ? ? ĂŶĚ
priming locations for guinea ƉŝŐ ? ?ĂŶĚ ? ?ZƉƌŽƚŽĐŽůƐ ? ? ? 
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For maximum amplicon specificity, high fidelity Taq polymerase was utilised 
(Invitrogen) and a touchdown PCR approach taken. The cycling parameters were 
94oC for 2m; (94oC for 30s, 72oC for 2m) x5; (94oC for 30s, 70oC for 2m) x5; (94oC for 
30s, 65oC for 30s, 68oC for 2m) x 25 followed by a final elongation phase at 68oC for 
10m ? ŽƚŚ  ? ? ĂŶĚ  ? ? Z ƉƌŽƚŽĐŽůƐ ƌĞƐƵůƚĞĚ ŝŶ ƚŚĞ ĨŽƌŵĂƚŝŽŶ ŽĨ ŶƵŵĞƌŽƵƐ Z
amplicons, of varying size (FIGURE 4.6). 
 
 
 
 
FIGURE 4.6  W /ŶŝƚŝĂů ? ?ĂŶĚ ? ?ZƉƌŽƚŽĐŽůƵƐŝŶŐƉƌŝŵĞƌƐ'ĞŶĞZĂĐĞƌ ? ?ĂŶĚZĞǀ'^W
ĨŽƌ  ? ?ZĂŶĚ'ĞŶĞZĂĐĞƌ  ? ?ĂŶĚ&Žƌ'^WĨŽƌ  ? ?ZŽŶŐƵŝ ĞĂƉŝg derived cDNA. 
Lane 1: 1 Kb ladder, Lane 2: 100 bp ladder, Lanes 3  W  ? P ? ?ZŽŶƐŽůĞƵƐ ?>ĂŶĚ
quadriceps cDNA respectively, Lanes 6  W  ? P  ? ? Z ŽŶ ƐŽůĞƵƐ ?> ĂŶĚ ƋƵĂĚƌŝĐĞƉƐ
cDNA respectively. 
 
 
To increase the abundance of the intended RACE transcripts, the resulting PCR 
products from the first round of the RACE protocol (FIGURE 4.6) were column 
purified (Sigma GenElute) (METHOD 2.2.1) and used as template in a series of nested 
ƌĞĂĐƚŝŽŶƐ ƵƐŝŶŐ ƉƌŝŵĞƌƐ 'ĞŶĞZĂĐĞƌ  ? ? EĞƐƚĞĚ ĂŶĚ ZĞǀEĞƐƚĞĚ'^W ĨŽƌ  ? ? Z and 
ƉƌŝŵĞƌƐ'ĞŶĞZĂĐĞƌ ? ?EĞƐƚĞĚĂŶĚ&ŽƌEĞƐƚĞĚ'^WĨŽƌ ? ?Z ?FIGURE 4.5B). Although 
the reactions still resulted in the amplification of multiple products, the nested 
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protocol enhanced the abundance of the intended transcript over and above that of 
the competing non-specific products (FIGURE 4.7).  
 
 
 
FIGURE 4.7  W EĞƐƚĞĚ ? ?ĂŶĚ ? ?ZƉƌŽƚŽĐŽůƵƚŝůŝƐŝŶŐƉƌŝŵĞƌƐ'ĞŶĞZĂĐĞƌ  ? ?EĞƐƚĞĚ
ĂŶĚ ZĞǀEĞƐƚĞĚ'^W ĨŽƌ  ? ? Z ĂŶĚ 'ĞŶĞZĂĐĞƌ  ? ? EĞƐƚĞĚ ĂŶĚ &ŽƌEĞƐƚĞĚ'^W ĨŽƌ  ? ?
RACE and the amplicons from the first round of RACE as template. Lane 1: 1 Kb 
ladder, Lane 2: 100 bp ladder, Lanes 3  W  ? P  ? ? ZŽŶ ƐŽůĞƵƐ ?>ĂŶĚƋƵĂĚƌŝĐĞƉƐ
cDNA respectively, Lanes 6  W  ? P  ? ? Z ŽŶ ƐŽůĞƵƐ ? > ĂŶĚ ƋƵĂĚƌŝĐĞƉƐ ĐE
respectively. 
 
 
4.3.4.2  ? Cloning and EcoR1 dŝŐĞƐƚŽĨ ? ?ĂŶĚ ? ?Z products 
The resulting nested RACE products from the second round of RACE (FIGURE 4.7) 
were cloned into the TOPO TA vector system (Invitrogen) (METHOD 2.2.3). Following 
standard overnight culture on LB plates containing 100µg/ml ampicilin for the 
selection of insert containing resistant colonies, 10 colonies from each reaction were 
added to LB media containing 100µg/ml ampicilin and cultured for a further 18 hours 
(METHOD 2.2.3). To assess whether the plasmids from overnight culture contained 
RACE products, all 10 cultures from each RACE reaction were mini-prepped 
(METHOD 2.2.4), and subjected to the restriction endonuclease EcoR1 (METHOD 
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2.2.5), known to cut at two sites flanking the multiple cloning site (FIGURE 4.8) and 
thereby liberate any insert.  
 
 
 
 
FIGURE 4.8  W Representative EcoR1 ĚŝŐĞƐƚĞĚ DǇ,  ? ? ĂŶĚ  ? ? Z ƉƌŽĚƵĐƚƐ ĨƌŽŵ
guinea pig quadriceps cDNA. Lane 1: 1 Kb ladder, Lanes 2  W  ? ? P ĐŽZ ? ĚŝŐĞƐƚĞĚ  ? ?
RACE products. Positive insert containing colonies are present in lanes 3, 5, 8, 9 and 
10 (faint).  
 
 
4.3.4.3  ? Sequencing of positive RACE colonies 
5 positive colonies from each RACE reaction and muscle (30 clones in total) were 
selected for one-way sequencing using M13 primers to target a sequence within the 
vector. Following sequencing, the length of coding sequence amplified with each 
novel UTR was used to determine which MyH isoform the clone related to by using 
BLAT to compare each RACE product against the partially annotated guinea pig gDNA 
database.   
 
&ŽƌĞĂĐŚDǇ,ƚƌĂŶƐĐƌŝƉƚ ? ? ?ZƐĞƋƵĞŶĐĞƐencoded approximately 300bp of coding 
ƐĞƋƵĞŶĐĞ ĂĐĐŽŵƉĂŶǇŝŶŐ ƚŚĞ  ? ? hdZ ? ǁŚŝůƐƚ  ? ? Z ƐĞƋƵĞŶĐĞƐ ĞŶĐŽĚĞĚ
ĂƉƉƌŽǆŝŵĂƚĞůǇ ? ? ?ďƉŽĨĐŽĚŝŶŐƐĞƋƵĞŶĐĞĨŽůůŽǁĞĚďǇƚŚĞ ? ?hdZ ?&ŽƌĂůůƚŚƌĞĞDǇ,
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ĚĞƌŝǀĞĚZƉƌŽĚƵĐƚƐĂƐƐĞƐƐĞĚ ?ƚŚĞƌĞƐƵůƚŝŶŐŶŽǀĞů  ?hdZƐĞŶĐŽĚĞĚƚŚree distinct 
exons, the first two of which fell within a 100-200bp region, the third was located 
more distantly and encoded the signal to instigate translation (ATG in this instance). 
dŚĞ ŶŽǀĞů  ? ? hdZƐ ĞŶĐŽĚĞĚ Ă ƐŝŶŐůĞ ĞǆŽŶ ƐƚĂƌƚŝŶŐ ŝŵŵĞĚŝĂƚĞůǇ ĚŽǁŶƐƚƌĞĂŵ of the 
stop codon (TAA in MyH1 and MyH4, and TGA in MyH2) FIGURE 4.9. 
 
ůů ŶŽǀĞů  ? ? ĂŶĚ  ? ? ƐĞƋƵĞŶĐĞƐ ǁĞƌĞ ĚĞƉŽƐŝƚĞĚ ŝŶ 'ĞŶĂ Ŭ ĂŶĚ ĂƌĞ ŝŶĐůƵĚĞĚ ŝŶ
FIGURES 4.10A-B along with their accompanying accession numbers.
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FIGURE 4.9  ? Illustration of the relative  ? ?ĂŶĚ ? ?ŐĞŶŽŵŝĐƐƚƌƵĐƚƵƌĞŽĨŐƵŝŶĞĂƉŝŐDǇ, ? ? ? ? ? ? ?ĂŶĚ ? ? ?ĚĞƌŝǀĞĚĨƌŽŵ ? ?ĂŶĚ ? ?Z
products indicating the transcription start site and exon positions. Open boxes  W individual exons; Thick black arrow  W transcription start 
site; Thick grey arrow  W translation start site; Numbers indicate the position relative to the transcription start site in the respective 
gene. 
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DǇ, ? ? ?hdZĂŶĚ^ ?GenBank: GU288593) 
TCTTTCCTCATAAAGCTTCAAGTTCTGACCCACTTCAAGGTTTCATCCCTACAGGCAAGGTCCTTAGCC
GGGCTGCCATCAATAACCTGCAGCCATGAGTTCCGACTCTGAGATGGCCATTTTTGGGGAGGCTGCT
CCTTACCTCCGAAAGTCTGAAAAGGAGCGAATCGAAGCTCAGAACAAGCCTTTTGATGCCAAGTCCT
CTGTCTTTGTGGTGGACGCCAAAGAGTCCTTTGTGAAGGCGACCGTACAGAGCAGGGAAGGGGGGA
AGGTGACAGCCAAGACAGAAGGCGGAGCTACTGTAACAGTGAAGGATGACCAGGTGTTCCCCATGA
ACCCTCCCAAATACGACAAGATCGAGGACATGGCCATGATGACCCACCTGCACGAG 
 
DǇ, ? ? ?hdZĂŶĚ^ ?GenBank: GU288594) 
ACGGGCCTTTGAAGAGCGACACTGGCCGCGGCCACGCTGCCTCGGCGGCTGCTGCTGCTGCTGCTGC
TGCTGGTTCTGAACCGTCTGACGTCCAGGCTACATCTTCTTGCTTGCTAACAAGGACCTCTGAGTACA
ACAGCCATGAGTGGCGCCGACTCAGAAATGGCTGTCTTTGGGGAGGCTGCCCCTTACCTCCGAAAGT
CTGAGAAAGAGCGCATTGAAGCCCAGAATAGGCCCTTTGATGCCAAGACATCTGTCTTTGTGGCGGA
GCCCAAGGAGTCCTTTGTCAAAGGGACGATTCAGAGCAGAGAAGCAGGAAAAGTAACTGTGAAAAC
CGAAGCGGGAGCGACCTTGACAGTGAAGGATGACCAGGTGTTCCCCATGAACCCTCCCAAATTTGAC
AAGATCGAGGACATGGCCATGATGACCCACCTGCACGAG 
 
DǇ, ? ? ?hdZĂŶĚ^ ?GenBank: GU288595) 
GTCCTTCCTCAAAATTCTTACAGTAATTGCCTGCTTTGAGCCTGCCACCTGCTTCATCTGGTCACATAA
GAGGTACACCTAACCTGCAGCCATGAGTTCCGACTCTGAGATGGCCGTTTTTGGGGAGGCTGCTCCT
TACCTCCGAAAGTCTGAAAAGGAGCGAATCGAAGCTCAGAACAAGCCTTTTGATGCCAAGTCCTCTG
TCTTTGTGGTGGACGCCAAAGAGTCCTACGTGAAGGCGACCGTACAGAGCAGGGAAGGGGGGAAG
GTGACAGCCAAGACAGAAGGCGGAGCTACTGTCACAGTTAAGGAAGACCAAGTCTTTTCCATGAACC
CTCCCAAATATGACAAGATCGAGGACATGGCCATGATGACCCACCTGCACGAG 
 
FIGURE 4.10A  ? EŽǀĞů ? ?ƐĞƋƵĞŶĐĞƐƌĞůĂƚŝŶŐƚŽDǇ, ? ? ?ĂŶĚ ?ĂƐĚĞtermined by the 
accompanying 300bp of coding sequence. Diagram includes Novel UTR (underline), 
Coding sequence (CDS  W standard text), translation start site (grey shading) and 
RevNestedGSP primer location (open box). 
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DǇ, ?^ĂŶĚ ? ?hdZ ?GenBank: GU288596) 
AAGGGCGGCAAGAAGCAGATCCAGAAGCTGGAGGCCAGGGTACGTGAACTTGAAGGGGAAGTGG
AAAGCGAACAGAAGCGCAATGTTGAAGCCGTCAAGGGCCTGCGGAAACACGAGAGAAGAGTGAAA
GAACTCACCTACCAAACCGAGGAGGACCGCAAGAATGTTCTCCGGCTCCAGGACCTTGTGGACAAAC
TGCAAGCCAAGGTGAAGGCGTACAAGAGACAAGCAGAGGAAGCGGAGGAACAATCCAATGTCAAC
CTCTCCAAGTTCCGCAAGATCCAGCACGAGCTGGAGGAAGCTGAGGAACGGGCTGACATCGCTGAG
TCCCAGGTCAACAAACTCCGGGTGAAGAGCCGGGAGGTTCACACGAAAATCATCAGCGAAGAGTAA
TTCATCCAAATGCAGGAAAGTGACCAAAGACATACACAAAATGTGAAAATCTTTGTCACTGTTTTGTA
TTTATGACTTTTGGAGATAAAGAATTTATCTACCAAGAAAAAAAAAAAAAAAAAAAAAAAA 
 
DǇ, ?^ĂŶĚ ? ?hdZ ?GenBank: GU288597) 
AAGGGCGGCAAGAAGCAGATCCAGAAGCTGGAGGCCAGGGTGCGTGAGCTGGAAGGCGAGGTAG
AGAGTGAGCAAAAGCGTAACGCGGAGGCCGTCAAAGGTCTGCGCAAACACGAGAGGCGAGTGAAG
GAACTCACCTACCAGACGGAAGAAGGTCGGAAAAATATCCTCAGGCTCCAGGATCTGGTCGATAAAC
TTCAGGCAAAAGTAAAATCTTACAAGAGGCAAGCGGAGGAGGCTGAGGAACAATCCAACACGAATC
TATCCAAGTTCCGCAAGCTCCAGCACGAGCTGGAGGAAGCCGAGGAACGGGCTGACATCGCTGAGT
CCCAGGTCAACAAACTCCGGGTGAAGAGCCGTGAGGTTCACACAAAAATCATCAGCGAAGAGTGAT
CAAGCCCTGAGGCTGTGGAATGACCAGAGCAAGACACACAATGTGAAGTCTCTGGTCATTTCTCTTT
GTGTTTTGTCTGTCCTACCCTATTGCAAAGGAAATAAAGAGCAGAGGGTTCTTTGCAAATAAAAAAAA
AAAAAAAAAAAAAAAAAAA 
 
DǇ, ?^ĂŶĚ ? ?hdZ ?GenBank: GU288598) 
AAGGGCGGCAAGAAGCAGATCCAGAAGCTGGAGGCCAGGGTGAGGGAACTTGAAAACGAAGTTG
AAAATGAGCAGAAGCGCAATGTGGAGGCCGTCAAAGGTCTTCGTAAGCATGAGAGAAGAGTGAAG
GAACTCACTTACCAGACTGAGGAGGACCGCAAGAATGTTCTCAGGCTGCAGGACTTGGTGGACAAAT
TACAGAGCAAAGTGAAAGCTTACAAGAGACAGGCTGAAGAGGCCGAGGAACAATCCAATGTCAACC
TTGCCAAGTTCCGCAAGATCCAGCACGAGCTGGAGGAAGCCGAGGAGCGGGCCGACATCGCTGAGT
CCCAGGTCAACAAACTCCGGGTGAAGAGCCGGGAGGTTCACACGAAAGTCGTCAGCGAGGAGTAAC
TCCATCTACTGCTGCAACGTGACCAAAGAAATGCACAAAATGTGACGTTCTTTGTCACTGTCCTGTAT
ATCAAGGAAATAAAATCTGCAGAGTTTTGCAATCAAAAAAAAAAAAAAAAAAAAAAA 
 
FIGURE 4.10B  ? EŽǀĞů ? ?hdZƐĞƋƵĞŶĐĞƐƌĞůĂƚŝŶŐƚŽDǇ, ? ? ?ĂŶĚ ?ĂƐĚĞƚĞƌŵŝŶĞĚďǇ
the accompanying 400bp of coding sequence. Diagram includes Novel UTR 
(underline), Coding sequence (CDS  W standard text), stop codon (grey shading) and 
ForNestedGSP primer location (open box). 
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4.3.5  ? Designing MHC transcript isoform specific oligonucleotide primers for 
quantitative PCR 
In order to assess whether the novel untranslated region sequence was any less 
conserved across the three isoforms than the respective coding sequence, and 
ƚŚĞƌĞĨŽƌĞ ƚŚĞ ƉŽƚĞŶƚŝĂů ƚŽ ĚĞƐŝŐŶ ŝƐŽĨŽƌŵ ƐƉĞĐŝĨŝĐ ƉƌŝŵĞƌƐ ?  ? ? ĂŶĚ  ? ? hdZƐ ǁĞƌĞ
aligned using ClustalW2 (FIGURES 4.11A-B). As hypothesised, there was a distinct 
ƌĞĚƵĐƚŝŽŶ ŝŶ ƐĞƋƵĞŶĐĞ ŝĚĞŶƚŝƚǇ ŝŶ ďŽƚŚ  ? ĂŶĚ  ? ? hdZƐ ? ŵŽƐƚ ůŝŬĞůǇ ĚƵĞ ƚŽ ƌĞĚƵĐĞĚ
ƐĞůĞĐƚŝǀĞ ƉƌĞƐƐƵƌĞ ? ůƚŚŽƵŐŚ ďŽƚŚ ƚŚĞ  ? ĂŶĚ  ? ? hdZƐ ŽĨ ĞĂĐŚ D, ŝƐŽĨŽƌŵ ŵZE
were sufficiently distinct as to peƌŵŝƚƚŚĞĚĞƐŝŐŶŽĨ ŝƐŽĨŽƌŵƐƉĞĐŝĨŝĐƉƌŝŵĞƌƐ ? ƚŚĞ  ? ?
UTR was selected based on the larger number of bases available. 
 
ůůD,ŝƐŽĨŽƌŵƐƉĞĐŝĨŝĐƉƌŝŵĞƌƐǁĞƌĞĚĞƐŝŐŶĞĚĨƌŽŵƚŚĞŶŽǀĞů ? ?hdZƐĞƋƵĞŶĐĞĚĂƚĂ
using Primer3 software (Koressaar and Remm 2007) and are included in (FIGURE 
4.11B ? ?dŚĞƉƌŝŵĞƌƉĂŝƌƐǁĞƌĞŶĂŵĞĚDǇ, ? ? ?hdZ ?DǇ, ? ? ?hdZĂŶĚDǇ, ? ? ?hdZĂŶĚ
amplified MyH1, 2 and 4 respectively. To allow complete MHC isoform analysis of 
skeletal muscles, a primer pair to MyH7 (slow type MHC) were designed towards the 
 ? ? ƚĞƌŵŝŶŝ ŽĨ Ă ĨƵůů ůĞŶŐƚŚ ĐE ƐĞƋƵĞŶĐĞ available through Ensemble 
(ENSCPOG00000004208, Release 56).   
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0\+¶    ---------------------------------------------------TCTTTCCTC 9 
0\+¶--------------------------------------------------GTCCTTCCTC 10 
0\+¶ACGGGCCTTTGAAGAGCGACACTGGCCGCGGCCACGCTGCCTCGGCGGCTGCTGCTGCTG 60 
                                                                       * **  
 
0\+¶ATAAAGCTTCAAGTTCTGACCCACTTCAAGGTTTCATCCCTACAGGCAAGGTC-CTTAGC 68 
0\+¶AAAATTCTTACAGTAATTGCCTGCTTTGAGCCTGCCACCTGCTTCATCTGGTCACATAAG 70 
0\+¶CTGCTGCTGCTGGTTCTGAACCGTCTGACG--TCCAGGCTACATCTTCTTGCTTGCTAAC 118 
                      **    **  *   *    *   *  * *   *           *     **   
 
0\+¶CGGGCTGCCATCAATAACCTGCAGCCATGAGTTCCGACTCTGAGATGGCCATTTTTGGGG 128 
0\+¶AGGTACACC-----TAACCTGCAGCCATGAGTTCCGACTCTGAGATGGCCGTTTTTGGGG 125 
0\+¶AAGGACCTC-TGAGTA--CAACAGCCATGAGTGCCGACTCAGAAATGGCTGTCTTTGGGG 175 
                  *     *     **  *  *********** ******* ** *****  * ******* 
 
0\+¶$**&7*&7&&77$&&7&&*$$$*7&7*$$$$**$*&*$$7&*$$*&7&$*$$&$$*&&778 
0\+¶$**&7*&7&&77$&&7&&*$$$*7&7*$$$$**$*&*$$7&*$$*&7&$*$$&$$*&&77 
0\+¶$**&7*&&&&77$&&7&&*$$$*7&7*$*$$$*$*&*&$77*$$*&&&$*$$7$**&&&7 
                ******* ******************** ** ***** ** ***** ***** * *** * 
 
0\+¶  TTGATGCCAAGTCCTCTGTCTTTGTGGTGGACGCCAAAGAGTCCTTTGTGAAGGCGACCG 248 
0\+¶77*$7*&&$$*7&&7&7*7&777*7**7**$&*&&$$$*$*7&&7$&*7*$$**&*$&&* 
0\+¶77*$7*&&$$*$&$7&7*7&777*7**&**$*&&&$$**$*7&&777*7&$$$***$&*$ 
                *********** * ************* ***  **** *******  ** ** * ***   
 
0\+¶7$&$*$*&$***$$******$$**7*$&$*&&$$*$&$*$$**&**$*&7$&7*7$$&$* 
0\+¶7$&$*$*&$***$$******$$**7*$&$*&&$$*$&$*$$**&**$*&7$&7*7&$&$* 
0\+¶77&$*$*&$*$*$$*&$**$$$$*7$$CTGTGAAAACCGAAGCGGGAGCGACCTTGACAG 355 
                * ******** ****  ** ** ** ** *  ** ** ****  ***** **  * **** 
 
0\+¶7*$$**$7*$&&$**7*77&&&&$7*$$&&&7&&&$$$7$&*$&$$*$7&*$**$&$7** 
0\+¶77$$**$$*$&&$$*7&7777&&$7*$$&&&7&&&$$$7$7*$CAAGATCGAGGACATGG 365 
0\+¶7*$$**$7*$&&$**7*77&&&&$7*$$&&&7&&&$$$777*$&$$*$7&*$**$&$7** 
                * ***** ***** ** **  ******************  ******************* 
 
0\+¶&&$7*$7*$&&&$&&7*&$&*$* 
0\+¶&&$7*$7*$&&&$&&TGCACGAG 388 
0\+¶&&$7*$7*$&&&$&&7*&$&*$* 
                *********************** 
 
 
FIGURE 4.11A  W ^ĞƋƵĞŶĐĞĂůŝŐŶŵĞŶƚŽĨŶŽǀĞů ? ?hdZƐŽĨDǇ,ĐEƐ ?ƵŶĚĞƌůŝŶĞ ?ĂŶĚ
accompanying partial coding sequence. Transcription start codon is identified in grey. 
Asterisks indicate nucleotides which are conserved across all sequences. 
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MyH1 3          AAGGGCGGCAAGAAGCAGATCCAGAAGCTGGAGGCCAGGGTACGTGAACTTGAAGGGGAA 060 
0\+¶$$***&**&$$*$$*&$*$7&&$*$$*&7**$**&&$***7*&*7*$*&7**$$**&*$* 
0\+¶     AAGGGCGGCAAGAAGCAGATCCAGAAGCTGGAGGCCAGGGTGAGGGAACTTGAAAACGAA 060 
                *****************************************  * ** ** ***   **  
 
0\+¶*7**$$$*&*$$&$*$$*&*&$$7*77*$$*&&*7&$$***&&7*&**$$$&$&*$*$*$ 
0\+¶*7$*$*$*7*$GCAAAAGCGTAACGCGGAGGCCGTCAAAGGTCTGCGCAAACACGAGAGG 120 
0\+¶*77*$$$$7*$*&$*$$*&*&$$7*7**$**&&*7&$$$**7&77&*7$$*&$7*$*$*$ 
                ** ** *  ** ** ***** ** *  ** ******** ** ** ** ** ** *****  
 
0\+¶$*$*7*$$$*$$&7&$&&7$&&$$$&&GAGGAGGACCGCAAGAATGTTCTCCGGCTCCAG 180 
0\+¶&*$*7*$$**$$&7&$&&7$&&$*$&**$$*$$**7&**$$$$$7$7&&7&$**&7&&$* 
0\+¶$*$*7*$$**$$&7&$&77$&&$*$&7*$**$**$&&*&$$*$$7*77&7&$**&7*&$* 
                ******* ******** ***** ** ** ** *  ** ** *** * *** **** *** 
 
0\+¶*$&&77*7**$&$$$&7*&$$*&&$$**7*$$**&*7$&$$*$*$&$$*&$*$**$$*&* 
0\+¶*$7&7**7&*$7$$$&77&$**&$$$$*7$$$$7&77$&$$*$**&$$*&**$**$**&7 
0\+¶*$&77**7**$&$$$77$&$*$*&$$$*7*$$$*&77$&$$*$*$&$**&7*$$*$*GCC 240 
                **  * ** ** *** * **    ** ** **  * ******** ** ** ** ** **  
 
0\+¶UTR      GAGGAACAATCCAATGTCAACCTCTCCAAGTTCCGCAAGATCCAGCACGAGCTGGAGGAA 300 
0\+¶UTR      GAGGAACAATCCAACACGAATCTATCCAAGTTCCGCAAGCTCCAGCACGAGCTGGAGGAA 300 
0\+¶UTR      GAGGAACAATCCAATGTCAACCTTGCCAAGTTCCGCAAGATCCAGCACGAGCTGGAGGAA 300 
                **************    ** **  ************** ******************** 
 
0\+¶UTR      GCTGAGGAACGGGCTGACATCGCTGAGTCCCAGGTCAACAAACTCCGGGTGAAGAGCCGG 360 
0\+¶UTR      GCCGAGGAACGGGCTGACATCGCTGAGTCCCAGGTCAACAAACTCCGGGTGAAGAGCCGT 360  
0\+¶UTR      GCCGAGGAGCGGGCCGACATCGCTGAGTCCCAGGTCAACAAACTCCGGGTGAAGAGCCGG 360 
                ** ***** ***** ********************************************  
 
0\+¶UTR      GAGGTTCACACGAAAATCATCAGCGAAGAGTAATTCATCC-AAATGCAGGAAAGTGACCA 420 
0\+¶UTR      GAGGTTCACACAAAAATCATCAGCGAAGAGTGATCAAGCCCTGAGGCTGTGGAATGACCA 420 
0\+¶UTR      GAGGTTCACACGAAAGTCGTCAGCGAGGAGTAACTCCATC-TACTGCTGCAACGTGACCA 420 
                *********** *** ** ******* **** *      *     ** *     ****** 
 
0\+¶UTR      AAGACATACACAAAATGTGAAAATCTTTGTCACTGTTTTGTAT-TTATGACTTTTGGAGA 480 
0\+¶UTR      GAGCAAGACACACAATGTGAAGTCTCTGGTCATTTCTCTTTGTGTTTTGTCTGTCCTACC 480 
0\+¶UTR      AAGAAATGCACAAAATGTGACGTTCTTTGTCACTGTCCTGTATATCAAGGAAATAAAATC 480 
                 **  *  **** *******      * **** *    * * * *   *    *   *   
 
0\+¶UTR      TAAAGAATTTATCTACCAAAAAAAAAAAAAAAAAAAAAA(A) 522 
0\+¶UTR      CTATTGCAAAGGAAATAAAGAGCAGAGGGTTCTTTGCAA(A) 548 
0\+¶UTR      TGCAGAGTTTTGCAATCAAAAAAAAAAAAAAAAAAAAAA(A) 519 
 
FIGURE 4.11B  W ^ĞƋƵĞŶĐĞ ĂůŝŐŶŵĞŶƚ ŽĨ ŶŽǀĞů  ? ?hdZƐ  ?ĨƌŽŵ ƐƚŽƉ-codon) and 
accompanying partial coding sequence. Translation stop codon is identified in grey. 
Isoform specific primers are denoted in black (forward) and grey (reverse) underline. 
Asterisks indicate nucleotides which are conserved across all sequences.  
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4.3.6  ? Testing the specificity of guinea pig MHC transcript isoform specific primers  
Due to the high degree of homology between MHC isoforms MyH1, 2 and 4, the 
respective primer pairs were subjected to an experimental assessment of specificity. 
sĞĐƚŽƌƐ ĐŽŶƚĂŝŶŝŶŐ ƚŚĞ  ? ? hdZƐ ŽĨ DǇ, ? ?  ? ĂŶĚ  ? ǁĞƌĞ ůŝŶĞĂƌŝƐĞĚ ďǇ Bgl1 
endonuclease digestion (NEB) known to cut once within the vector sequence 
(METHOD 2.2.5). The resulting ůŝŶĞĂƌŝƐĞĚ ǀĞĐƚŽƌƐ ĐŽŶƚĂŝŶĞĚ ƚŚĞ ƌĞƐƉĞĐƚŝǀĞ  ? ? hdZ
sequences (FIGURE 4.10B) flanked by vector sequence (FIGURE 4.12).  
 
 
 
FIGURE 4.12  W Linearised vector maps (Bgl1) of clones MyH1 (A), MyH2 (B) and MyH4 
(C). Diagram shows MyH inserts (black box) with respective size (above box). The 
complete insert size, inclusive of the included region of PCR 4.0 vector sequence, is 
indicated under the bracket. An exemplar sequence is inset above part (A); please 
refer to figure 4.10B for details of each MyH insert.  
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Each vector (FIGURE 4.12) was adjusted to 2ng/µl and serially diluted 5-fold to 
produce a 7-point standard curve. Five-fold serial dilutions were then mixed 1:1 (v/v) 
with molecular biology grade water (control) or a combination of the two competing 
vectors aƚ Ă ĐŽŶĐĞŶƚƌĂƚŝŽŶ ŽĨ  ? ? ?ŶŐ ?A?ů ? &Žƌ ĞǆĂŵƉůĞ ƉƌŝŵĞƌ ƉĂŝƌ DǇ, ? ? ?hdZ ǁĞƌĞ
ƵƐĞĚƚŽĂŵƉůŝĨǇǀĞĐƚŽƌDǇ, ? ? ? ?ĐŽŶƚƌŽů ?ĂŶĚƚŚĞŶƵƐĞĚƚŽĂŵƉůŝĨǇĂĐŽŵďŝŶĂƚŝŽŶŽĨ
ǀĞĐƚŽƌƐDǇ, ? ? ? ?DǇ, ? ? ?ĂŶĚDǇ, ? ? ? ?ĐŽŵƉĞƚŝƚŽƌƐĂĚĚĞĚ ? ?YƵĂŶƚŝƚĂƚŝǀĞWZǁĂƐ
carried out using SYBR green quantification technology (Roche) (METHOD 2.1.7.2). 
FIGURE 4.13 shows the respective reactions for MyH1 (A), MyH2 (B) and MyH4 (C) 
with the concentration of product plotted against the crossing point (Cp). No cross 
reaction was observed between any of the primer pairs and the competing vectors as 
amplification of the target vector was unaffected in the presence of any completing 
vector, confirming the specificity of the primers for their intended target. 
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FIGURE 4.13 - Specificity of quantitative PCR reactions for each target MHC gene 
transcript (A) MyH1, (B) MyH2 (C) MyH4. Black line  W control reaction; Grey line  W 
reaction with competitor vectors added; Dashed line  W predicted observation should 
cross-reaction occur. 
 
 
4.3.7  ? MHC transcript expression in three distinct guinea pig skeletal muscles 
In order to validate further the utility of the oligonucleotide primers designed, three 
distinct guinea pig muscles were analysed in terms of their MHC mRNA expression. 
Based on studies in other laboratory rodents, the soleus is known to be a slow, 
postural muscle with a predominance of MyH7 and MyH2 mRNA variants. In 
contrast, extensor digitorum longus has a faster contractile phenotype and a 
predominance of MyH1 and MyH4 mRNA. Finally, quadriceps femoris is known to 
express all variants of MHC mRNA. Quantitative PCR analysis of guinea samples from 
the above muscles revealed expression patterns as expected. MyH7 and MyH2 were 
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most abundantly detected in the slow-twitch, postural Soleus. MyH1 and MyH4 were 
detected most abundantly in the fast twitch Extensor digitalis longus, whilst all four 
transcripts were detected at intermediate levels in the quadriceps muscle (FIGURE 
4.14).  
 
 
 
 
FIGURE 4.14 - Expression of transcripts MyH7 (A), MyH2 (B), MyH1 (C) and MyH4 (D) 
respectively in three distinct skeletal muscles as determined by quantitative PCR 
reactions in triplicate. SOL  W Soleus; QUAD  W Quadriceps; EDL - Extensor digitorum 
longus. Error bars indicate mean mRNA expression normalised to first strand cDNA 
concentration + S.E.M; n=6. 
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4.3.8  ? Multi-species MyH UTR and coding sequence comparisons 
Guinea pig-ƐƉĞĐŝĨŝĐ ? ?hdZƐĂŶĚĂƚƚĂĐŚĞĚĐŽĚŝŶŐƐĞƋƵĞŶĐĞƉĞƌƚĂŝŶŝŶŐƚŽDǇ, ? ? ? ?ĂŶĚ
4 (FIGURE 4.10A) were compared with respective rat, mouse and human cDNA 
sequences retrieved via Ensemble (Ensemble release 56) (TABLE 4.1) using ClustalW2 
(Larkin, Blackshields et al. 2007).  
 
Sequence conservation was expressed as a percentage identity using ClustalW2 and 
revealed a high level of conservation between guinea pig, rat, mouse and human 
sequence data within a single MyH gene. Interestingly, guinea pig MyH1 and MyH4 
displayed the strongest sequence identity with the respective human sequences (87 
and 86% respectively). Sequence conservation between guinea pig and human MyH2 
was lower (56%), however guinea pig MyH2 showed a high level of consensus 
sequence with both rat and mouse MyH2 (81 and 72% respectively) (FIGURES 4.15  ? 
4.17). 
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Cavia_MyH1       --TCTTTCCTCATAAAGCTTCAAGTTCTGACCCACT-TCAAGGTTTCATCCCTACAGGCA 
Homo_MyH1        TGTCTCTCCTCATAAAGCTTCAAGTTCTGATCCACT-TTAAGGTCGCATCTCTAC-GCCA 
Rattus_MyH1      --TCTTTCCTCATAAAGCTTCAAGTTCAGACCCACGGTCGAAGTTGCATCCCTAAAGGCA 
Mus_MyH1         -------------AAAGCTTCAAGTTTGGACCCACGGTCGAAGTTGCATCCCTAAAGGCA 
                              *************  ** ****  *  * **  **** ***  * ** 
 
Cavia_MyH1       AGGTCCTTAGCCGGGCTGCCATCAATAACCTGCAGCCATGAGTTCCGACTCTGAGATGGC 
Homo_MyH1        GGGTCCTTAACTGGGCTACCATCAATAACCTGCAGCCATGAGTTCCGACTCTGAGATGGC 
Rattus_MyH1      GACTCTCCCACTGGGCTGCCCCCAATAGCCCGCAGCCATGAGTTCCGACGCCGAGATGGC 
Mus_MyH1         GGCTCTCTCACTGGGCTGCAACCAATAGCCCGCAGCCATGAGTTCCGACGCCGAGATGGC 
                    **     * ***** *   ***** ** ****************** * ******** 
 
Cavia_MyH1       CATTTTTGGGGAGGCTGCTCCTTACCTCCGAAAGTCTGAAAAGGAGCGAATCGAAGCTCA 
Homo_MyH1        CATTTTTGGGGAGGCTGCTCCTTTCCTCCGAAAGTCTGAAAGGGAGCGAATTGAAGCCCA 
Rattus_MyH1      CGTTTTCGGGGAGGCTGCTCCTTACCTCCGGAAGTCTGAAAAGGAGCGAATCGAGGCTCA 
Mus_MyH1         CGTTTTCGGGGAGGCTGCTCCTTACCTCCGGAAGTCTGAAAAGGAGCGAATCGAGGCTCA 
                 * **** **************** ****** ********** ********* ** ** ** 
 
Cavia_MyH1       GAACAAGCCTTTTGATGCCAAGTCCTCTGTCTTTGTGGTGGACGCCAAAGAGTCCTTTGT 
Homo_MyH1        GAACAAGCCTTTTGATGCCAAGACATCAGTCTTTGTGGTGGACCCTAAGGAGTCCTTTGT 
Rattus_MyH1      GAACAAGCCTTTTGATGCCAAGTCATCCGTGTTTGTGGTGGATGCTAAGGAGTCTTTTGT 
Mus_MyH1         GAACAAGCCTTTTGACGCCAAGTCATCGGTGTTTGTGGTGGATGCTAAGGAGTCTTTTGT 
                 *************** ****** * ** ** ***********  * ** ***** ***** 
 
Cavia_MyH1       GAAGGCGACCGTACAGAGCAGGGAAGGGGGGAAGGTGACAGCCAAGACAGAAGGCGGAGC 
Homo_MyH1        GAAAGCAACAGTGCAGAGCAGGGAAGGGGGGAAGGTGACAGCTAAGACCGAAGCTGGAGC 
Rattus_MyH1      AAAAGCAACGGTGCAGAGCAGGGAAGGGGGGAAGGTGACAGCCAAGACCGAAGGTGGCGC 
Mus_MyH1         AAAAGCAACGGTGCAGAGCAGGGAAGGGGGGAAGGTGACAGCCAAGACCGAAGGCGGAAC 
                  ** ** ** ** ***************************** ***** ****  **  * 
 
Cavia_MyH1       TACTGTAACAGTGAAGGATGACCAGGTGTTCCCCATGAACCCTCCCAAATACGACAAGAT 
Homo_MyH1        TACTGTAACAGTGAAAGATGACCAAGTCTTCCCCATGAACCCTCCCAAATATGACAAGAT 
Rattus_MyH1      TACTGTAACAGTAAAAGATGATCAAGTCTTCCCCATGAACCCTCCCAAGTACGACAAGAT 
Mus_MyH1         TACTGTAACAGTAAAAGATGATCAGGTCTACCCCATGAACCCTCCCAAGTACGACAAGAT 
                 ************ ** ***** ** ** * ****************** ** ******** 
 
Cavia_MyH1       CGAGGACATGGCCATGATGACCCACCTGCACGAG 
Homo_MyH1        CGAGGACATGGCCATGATGACTCATCTACACGAG 
Rattus_MyH1      CGAGGACATGGCCATGATGACCCACCTCCACGAG 
Mus_MyH1         CGAGGACATGGCCATGATGACCCACCTGCATGAG 
                 ********************* ** ** ** *** 
 
FIGURE 4.15  W Multi-species alignment comparison of guinea pig (Cavia), human 
(Homo), rat (Rattus) and mouse (Mus) MyH1  ? ?UTR and partial coding sequence. 
Asterisks denote nucleotides conserved across all four species; black box denotes 
translation start site.  
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Cavia_MyH2       ACGGGCCTTTGAAGAGCGACACTGGCCGCGGCCACGCTGCCTCGG--CGGCTGCTGCTGC 
Rattus_MyH2      ------------------------------------------------------------ 
Mus_MyH2         ------------------TAGCTAGCCATATAAAAGAGTCCCGAA--CGAGGCTGACTCG 
Homo_MyH2        -----------------ATAGCTATCCATATAAAAGAGCCCTTGGAATGAGGCTGACTCG 
                                                                              
 
Cavia_MyH2       TGCTGCTGCTGCTGGTTCTGA--ACCGTCTGACGTCCAGGCTACATCTTCTTGCTTGCTA 
Rattus_MyH2      TCCTGCTTTAAAAAGCTCCAAGGACCCTCTTACTTCCCAGCTGCACCTTCTCATTTGCCA 
Mus_MyH2         TCCTGCTTTAAAAAGCTCCAAGGACCCTCTTATTTCCCAGCTGCACCTTCTCGTTTGCCA 
Homo_MyH2        TCCTGCTTTAAAAAGCTCCAAGAACTGTCTCACTCCCAGGCTACATCTTCTCACTTGCTA 
                 * *****       * **  *  **  *** *   **  *** ** *****   **** * 
 
Cavia_MyH2       ACAAGGACCTCTGAGTACAACAGCCATGAGTGGCGCCGACTCAGAAATGGCTGTCTTTGG 
Rattus_MyH2      ATAAGGGTCTGTGAGTTCAGCAGCCATGAG---TTCCGACTCTGAGATGGCCGTTTTCGG 
Mus_MyH2         GTAAGGGTCTGTGAGTTCAGCAGTCATGAG---CTCCGACGCCGAGATGGCCGTTTTCGG 
Homo_MyH2        ACAAGGACCTCTGAGTTCAGCAGCCATGAG---TTCAGACTCAGAATTGGCTGTTTTTGG 
                   ****  ** ***** ** *** ******     * *** * **  **** ** ** ** 
 
Cavia_MyH2       GGAGGCTGCCCCTTACCTCCGAAAGTCTGAGAAAGAGCGCATTGAAGCCCAGAATAGGCC 
Rattus_MyH2      GGAGGCTGCTCCTTACCTCCGGAAGTCTGAAAAGGAGCGAATCGAGGCCCAGAATAGGCC 
Mus_MyH2         GGAGGCTGCCCCTTACCTCCGGAAGTCCGAAAAGGAGCGAATCGAGGCCCAGAATAGGCC 
Homo_MyH2        GGAGGCTGCTCCTTTCCTCCGAAAGTCTGAAAGGGAGCGCATTGAGGCCCAGAATAGGCC 
                 ********* **** ****** ***** ** *  ***** ** ** ************** 
 
Cavia_MyH2       CTTTGATGCCAAGACATCTGTCTTTGTGGCGGAGCCCAAGGAGTCCTTTGTCAAAGGGAC 
Rattus_MyH2      TTTTGATGCCAAAACATCTGTCTTTGTGGCGGAGCCCAAGGAGTCCTTTGTCAAAGGAAC 
Mus_MyH2         TTTTGATGCCAAAACATCTGTCTTTGTGGCGGAGCCCAAGGAATCCTTTGTCAAAGGAAC 
Homo_MyH2        CTTTGATGCCAAAACATCTGTCTTTGTGGCGGAGCCCAAAGAATCCTTTGTCAAAGGGAC 
                  *********** ************************** ** ************** ** 
 
Cavia_MyH2       GATTCAGAGCAGAGAAGCAGGAAAAGTAACTGTGAAAACCGAAGCGGGAGCGACCTTGAC 
Rattus_MyH2      CATTCAGAGCAAAGACGCAGGGAAAGTGACTGTGAAAACTGAAGCAGGAGCGACCCTGAC 
Mus_MyH2         CATTCAGAGCAAAGATGCAGGGAAAGTGACTGTGAAAACAGAAGCAGGAGCGACCCTGAC 
Homo_MyH2        CATCCAGAGCAGAGAAGGAGGAAAAGTGACGGTGAAGACTGAGGGAGGAGCGA--TGAGT 
                  ** ******* *** * *** ***** ** ***** ** ** *  *******        
 
Cavia_MyH2       AGTGAAGGATGACCAGGTGTTCCCCATGAACCCTCCCAAATTTGACAAGATCGAGGACAT 
Rattus_MyH2      GGTGAAAGAAGACCAGATCTTCCCCATGAACCCTCCCAAGTACGACAAGATCGAGGACAT 
Mus_MyH2         CGTGAAAGAAGACCAGATCTTCCCCATGAACCCTCCCAAGTACGACAAGATCGAGGACAT 
Homo_MyH2        TCAGACTCAGAATTGGCTGTTTTTGGGGAGGCTGCTCCTTTCCTCCGAAAGTCTGAAAGG 
                    **   *  *   * * **      **  *  * *   *    * * *    * *    
 
Cavia_MyH2       GGCCATGATGACCCACCTGCACGAG 
Rattus_MyH2      GGCCATGATGACCCACCTCCACGAG 
Mus_MyH2         GGCCATGATGACCCACCTGCACGAG 
Homo_MyH2        GAGCGCATTGAGGC-CCAGAATAGG 
                 *  *    ***  * **   *   * 
 
FIGURE 4.16  W Multi-species alignment comparison of guinea pig (Cavia), human 
(Homo), rat (Rattus) and mouse (Mus) MyH2  ? ?UTR and partial coding sequence. 
Asterisks denote nucleotides conserved across all four species; black box denotes 
translation start site. 
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Cavia_MyH4       GTCCTTCCTCAAAATTCTTACAGTAATTGCCTGCTTTGAGCCTGCCACCTGCTTCATCTG 
Rattus_MyH4      ---------------CCGTAAAGTACTTGTCTGACTCA-GCCTGCCTCCTTCTTCATCTG 
Mus_MyH4         ---------------------AGTACTTGTCTGACTCAAGCCTGCCTCCTTCTTCATCTG 
Homo_MyH4        ATCCTTCCTCAAAATTCTTGAAGTAGTTGTCTGCTTTGAGCCTGCCACCTTCTTCATCTG 
                                      **** *** ***  *   ******* *** ********* 
 
Cavia_MyH4       GTCACATAAGAGGTACACCTA--------------------ACCTGCAGCCATGAGTTCC 
Rattus_MyH4      GTAACACAAGAGGTGCACCTGGCCCTAAGCTGCCCCCAATAGCTCGCAGCCATGAGTTCC 
Mus_MyH4         GTAACACAAGAGGTGCACCTGGCCCTGAGCTGCCACCAATAGCCCGCAGCCATGAGTTCC 
Homo_MyH4        ATAATACAAGAGGTATACCTAGTCCAGTACTGCCATCAATAACCTGCAGCCATGAGTTCT 
                  * * * *******  ****                      *  **************  
 
Cavia_MyH4       GACTCTGAGATGGCCGTTTTTGGGGAGGCTGCTCCTTACCTCCGAAAGTCTGAAAAGGAG 
Rattus_MyH4      GACGCCGAGATGGCCGTTTTTGGGGAGGCTGCTCCTTACCTCCGGAAGTCTGAAAAGGAG 
Mus_MyH4         GACGCTGAGATGGCCGTTTTCGGGGAGGCTGCTCCTTACCTCCGGAAGTCTGAAAAGGAG 
Homo_MyH4        GACTCTGAGATGGCCATTTTTGGGGAGGCTGCTCCTTTCCTCCGAAAGTCTGAAAAGGAG 
                 *** * ********* **** **************** ****** *************** 
 
Cavia_MyH4       CGAATCGAAGCTCAGAACAAGCCTTTTGATGCCAAGTCCTCTGTCTTTGTGGTGGACGCC 
Rattus_MyH4      CGAATCGAGGCTCAGAACAAGCCTTTTGATGCCAAGTCATCAGTGTTTGTGGTGGATGCT 
Mus_MyH4         CGAATCGAGGCCCAGAACAAGCCTTTTGATGCCAAGTCATCGGTGTTTGTGGTGGATGCT 
Homo_MyH4        CGAATTGAAGCTCAGAACAAGCCTTTTGATGCCAAGACATCAGTCTTTGTGGTGGACCCT 
                 ***** ** ** ************************ * ** ** ***********  *  
 
Cavia_MyH4       AAAGAGTCCTACGTGAAGGCGACCGTACAGAGCAGGGAAGGGGGGAAGGTGACAGCCAAG 
Rattus_MyH4      AAGGAGTCCTATGTGAAAGCAACCGTGCAGAGCAGGGAAGGGGGGAAGGTGACGGCCAAG 
Mus_MyH4         AAGGAGTCCTATGTGAAAGCAACAGTGCAGAGCAGGGAAGGGGGGAAGGTGACAGCCAAG 
Homo_MyH4        AAGGAGTCCTACGTGAAAGCAATAGTGCAGAGCAGGGAAGGGGGGAAGGTGACAGCCAAG 
                 ** ******** ***** ** *  ** ************************** ****** 
 
Cavia_MyH4       ACAGAAGGCGGAGCTACTGTCACAGTTAAGGAAGACCAAGTCTTTTCCATGAACCCTCCC 
Rattus_MyH4      ACCGAAGGTGGAGCTACTGTCACAGTTAAAGAAGATCAAGTCTTCTCCATGAACCCTCCC 
Mus_MyH4         ACCGAAGGCGGAGCTACGGTCACCGTCAAGGATGATCAAGTCTTCTCCATGAACCCTCCC 
Homo_MyH4        ACCGAAGCTGGAGCTACTGTAACTGTGAAAGAAGACCAAGTCTTCTCCATGAACCCTCCC 
                 ** ****  ******** ** ** ** ** ** ** ******** *************** 
 
Cavia_MyH4       AAATATGACAAGATCGAGGACATGGCCATGATGACCCACCTGCACGAG 
Rattus_MyH4      AAGTACGACAAGATCGAGGACATGGCCATGATGACCCACCTCCACGAG 
Mus_MyH4         AAGTACGACAAGATTGAGGACATGGCCATGATGACCCACCTGCACGAG 
Homo_MyH4        AAATATGACAAGATCGAGGACATGGCCATGATGACTCACCTGCATGAG 
                 ** ** ******** ******************** ***** ** *** 
 
FIGURE 4.17  W Multi-species alignment comparison of guinea pig (Cavia), human 
(Homo), rat (Rattus) and mouse (Mus) MyH4  ? ?UTR and partial coding sequence. 
Asterisks denote nucleotides conserved across all four species; black box denotes 
translation start site. 
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4.3.9  ? Analysis of promoter elements 
Using the cDNA sequences described in TABLE 4.1, genomic DNA sequences 
pertaining to MyH1, 2 and 4 for guinea pig, human, rat and mouse were retrieved 
from Ensemble (Ensemble release 56). For the analysis of likely proximal promoter 
elements, -600 to +200bp of the transcription start site (UTR exon 1) of each genomic 
DNA sequence was aligned using ClustalW2 (Larkin, Blackshields et al. 2007).  
 
Previously identified myosin heavy chain promoter elements (identified in the mouse 
MyH4 promoter) including a conserved CAP motif, TATA-box, proximal motif (PROX), 
NF-1, serum response factor (SRF), two AT-rich regions (AT-1/2), myocyte enhancer 
factor-2 (MEF-2) and Oct-1  (Takeda 1992; Allen, Weber et al. 2005) were identified 
and are highlighted on FIGURES 4.18, 4.19 and 4.20 for MyH isoforms 1,  2 and 4 
respectively. 
 
4.3.9.1  ? Sequence conservation across species within each MyH gene 
Both AT-2 and NF-1/SRF/NF-1 (CArG) elements were well-conserved across the four 
species within myosin heavy chain genes MyH1, MyH2 and MyH4 respectively. Whilst 
AT-2 regions were 100% conserved across species within each MyH isoform, CArG 
elements were more divergent (FIGURES 4.18  ? 4.20). 
 
Multiple alignments of the promoter sequences (-600 to +200bp TSS) were used to 
construct phylogenetic trees and therefore assess how closely related the promoter 
elements of rat, mouse, guinea pig and human were. For all MyH isoforms assessed, 
two distinct pathways were present, one of which included the mouse and rat, the 
other comprising human and guinea pig (FIGURE 4.21 A-C). 
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                                                                 _____AT-2___ 
                                                                   Oct-1_             
                                                                       MEF-2_                
 
Cavia_MyH1       ACACCTTACATTATTCCAAGGGCAGATCTCTTCTAGATTGCCAACGACTCAAATTATTTA  
Homo_MyH1        ACACCTTACATT---CCAAAGGCCAACAACTTTAAGATTGCCAACGACTCAAATTATTTA 
Rattus_MyH1      ACACCTTACATTATTCCAAGGACGGATCGTTTTCCTATCACCAACAACTCAAATTATTTA 
Mus_MyH1         ACACCTTACATTATTCCAAGGACGGATCGTTTTCCTATCACCAACAACTCAAATTATTTA 
                 ************   **** * *  *    **    **  ***** ************** 
 
           
  ___                                                                                           AT-1  .  
 
Cavia_MyH1       TAGGAGATTGATTCATATACTTAACCCAATGTGAGAGGGAATATTTCTAATTATATCCAA 
Homo_MyH1        TAGGAGATTGATTCATATACTTAACCCAATATGAGAGGAAATATTTCTAATTATATCCAA 
Rattus_MyH1      TAGGAGATTGATTCATATACTTAACCCAATGTGAGAGGGAATATTTCTAATTATATCCAA 
Mus_MyH1         TAGGAGATTGATTCATATACTTAACCCAATGTGAGAGGGAATATTTCTAATTATATCCAA 
                 ****************************** ******* ********************* 
 
 
                                           NF-1_         NF-1_ 
                 ____                                          SRF___ 
 
Cavia_MyH1       ACATCTTTAATATGAGGGGAATTAGGCTTGGAGATCTTCTTTGCCAAAAACATGTTTTGC 
Homo_MyH1        ACATCTTTAATATGAGGGGAATTAGGCTTGGAGACCTTCAATGCCAAAAACATGTTTTGC 
Rattus_MyH1      ACATCCTTAATATGAAGGGAATTAGGCTTGGAGACCTTCCTTGCCAAAAACACATTTTGC 
Mus_MyH1         ACATCCTTAATATGAGGGGAATTAGGCTTGGAGACCTTCCTTGCCAAAAACACATTTTGC 
                 ***** ********* ****************** ****  ***********  ****** 
 
 
                                          PROX____                     TATA__ 
  
Cavia_MyH1       CAAATATGTTTTAAGAAAGAGGAGGAGGTTACGTGTTTTCCATATTTGATCCTATAAAAG 
Homo_MyH1        CAAATATGTTTTAAGAAAGAGGAGGAGGTTACGTGTTTTCCATATTTGAGCCTATAAAAG 
Rattus_MyH1      CAAATATGTTTTAAGAAAGAGGAGGAGGTTACGTGTTTTCCATATTTGATCCTATAAAAG 
Mus_MyH1         CAAATATGTTTTAAGAAAGAGGAGGAGGTTACGTGTTTTCCATATTTGATCCTATAAAAG 
                 ************************************************* ********** 
 
 
                                         mCAP________         
                                         +1--> 
Cavia_MyH1       GACCC-TTGGAATGACAGTGACTTGTCTTTCCTCATAAAGCTTCAAGGTAAGAGTGTGTG 
Homo_MyH1        TACCC-TTGGAATGAGTATGACTTGTCTCTCCTCATAAAGCTTCAAGGTAAGTGTGTGTG 
Rattus_MyH1      TACCCCTTGGAATGAGAATGACTTGTCTTTCCTCATAAAGCTTCAAGGTAAGAGTGTGTG 
Mus_MyH1         TACCCCTTGGAATGAGAGTGACTTGTCTTTCCTCATAAAGCTTCAAGGTAAGAGTGTGTG 
                  **** *********   ********** *********************** ******* 
 
 
 
 
Cavia_MyH1       AGGAC--GCCCTGGTCTGGAGGACAC--AGAGATGCCAGGCTCCCTGCATGCATGCCACA 
Homo_MyH1        AGGACAGGGCTCTGTCTGGAGGACGGTAAGGGATGTCTGGCTGCCCGCGTGCATGCCACA 
Rattus_MyH1      AGGACAGGGCTCTGTGTGGACGGGA---AGGGATGCCTGGCTGCTAGTGTGCATGCCACA 
Mus_MyH1         AGGACAGGGCTCTGTGTGGACGGGA---AGGGATGCCTGGCTGCTGGTGTGCATGCCACA 
                 *****  * *   ** **** *      ** **** * **** *  *  *********** 
 
FIGURE 4.18  W Multi-species alignment comparison of guinea pig (Cavia), human 
(Homo), rat (Rattus) and mouse (Mus) MyH1 genomic DNA sequence located -265 to 
+95bp of the transcription start site. Asterisks denote nucleotides conserved across 
all four species; +1 denotes the transcription start site.   
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                                     __  AT-2________ 
                                       Oct-1__                                
                                              MEF-2__            
 
Cavia_MyH2       CTTCCTTGCAGATCACCTTCTCAAATTATCCATAGGAGATTTATCCACATACTCAATAAG 
Homo_MyH2        T---CTTTCAGATCATCTTCTCAAATTATCCATAGGAGATTTATCCACATACTCAATAAG 
Rattus_MyH2      CTTCCTTTCGGATCATCTTCTCAAATTATCCATAGGAGATTTATCCACATACTCAATAAG 
Mus_MyH2         CTTCCTTTCAGATCATCTTCTCAAATTATCCATAGGAGATTTACCCACATACTCAATAAG 
                     *** * ***** *************************** **************** 
 
 
                                AT-1_________ 
 
Cavia_MyH2       AAAAATATTTCTAATTATATCCAACCATTCTTCATATGAATGAGAATCATGCAGGAACAC 
Homo_MyH2        AAAAATATTTCTAATTATATCCAACCATTCTTAATATGAATGAGAATTATGCGGGGACGC 
Rattus_MyH2      AAAAATATTTCTAATTATATCCAACCATTCTTAATATGAATGAGAATTATGCAGAGACGC 
Mus_MyH2         AAAAATATTTCTAATTATATCCAACCATTCTTAATATGAATGAGAATTATGCAGAGACGC 
                 ******************************** ************** **** *  ** * 
 
 
                      NF-1_         NF-1_ 
                           SRF____                                     PROX__ 
 
Cavia_MyH2       TATCGTGCCAGGAGGTTTTTTGCCAAACAATTCCTTTTGACTTAAGAAAGAAGAGGCAGC 
Homo_MyH2        TAGATTGCCAAGAGGTATTTTGCCAAACAATTCCTTTTGACTTAAGAAAGAAGAGGCAGC 
Rattus_MyH2      TCGATTGCCAAGAGGGCTTTTGCCAGACAATTCCTTTTGACTTAAGAAAGAAGAGGCTGT 
Mus_MyH2         TCGATTGCCAAGAGGGTTTTTGCCAGACAATTCCTTTTGACTTAAGAAAGAAGAGGCAGT 
                 *    ***** ****  ******** ******************************* *  
 
  
                 ____                     TATA__                      mCAP___ 
                                                                       +1--> 
Cavia_MyH2       TGCATTGTTTCCATAACTATCCATATAAAAGAGCCCTCGGAATGAGGCTGACT-GTCCTG 
Homo_MyH2        TGCATTGTTTCCATAGCTATCCATATAAAAGAGCCCTTGGAATGAGGCTGACTCGTCCTG 
Rattus_MyH2      CGCATTGTTTCCATAGCTAGCCATATAAAAGAGTTCC--GAACGAGGCTGACTCGTCCTG 
Mus_MyH2         CGCATTGTTTCCATAGCTAGCCATATAAAAGAGTCCC--GAACGAGGCTGACTCGTCCTG 
                  ************** *** *************  *   *** ********** ****** 
 
 
                 ______ 
 
Cavia_MyH2       CTTTAAAAAGCTCCAAG-----------GTAAGTGGGGGCCG-ACGGGCCT--------- 
Homo_MyH2        CTTTAAAAAGCTCCAAG-----------GTAAGTGGGAGCAGGACGGGCCT--------- 
Rattus_MyH2      CTTTAAAAAGCTCCAAG------------------------------------------- 
Mus_MyH2         CTTTAAAAAGCTCCAAGTAGCTAGCCATATAAAAGAGTCCCGAACGAGGCTGACTCGTCC 
                 *****************                                            
 
 
 
Cavia_MyH2       ----TTGAAGAGCGACACTGGCCGCGGCCACGCTGCCTCGGCGGCTGCTGCTGCTGCTGC 
Homo_MyH2        ----TTCAAGAGGGACACTGGTCACA-CCGCCCAGTGTCAGCAGCAGCTGCTAGTTCTGG 
Rattus_MyH2      -------------------GTAGGTGGGAGCAGGACACTGGCCACGGCCCCGGGCTGCAG 
Mus_MyH2         TGCTTTAAAAAGCTCCAAGGTAGGTGGGAGCAGGACACTGGCCACTGCCC-GAGCTGCAG 
                                    *          *         **  * **             
 
 
FIGURE 4.19  W Multi-species alignment comparison of guinea pig (Cavia), human 
(Homo), rat (Rattus) and mouse (Mus) MyH2 genomic DNA sequence located -235 to 
+104bp of the transcription start site. Asterisks denote nucleotides conserved across 
all four species; +1 denotes the transcription start site.   
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                                                ____  AT-2______ 
                Oct-1_                  ______              
                                                      MEF-2__            
 
Cavia_MyH4       CCTATAAAGAACCCTAGATCATCCTCTGTCAAATTATTTATAGGTGGCAAGAAATATTTC 
Homo_MyH4        CCTATAAAGAACCCTAGATCATCCTCTGTTAAATTATTTATGGGTGTCAAGAAATATTTC 
Rattus_MyH4      CCTATAAAGAACCCTAGATCATCCCCTGTCAAATTATTTATAGATGACAAGAAATATTTC 
Mus_MyH4         CTTATAAAGAACCCTAGATCATCCCCTGTCAAATTATTTATAGATGACAAGAAATATTTC 
                 * ********************** **** *********** * ** ************* 
 
                       AT-1_______           NF-1_ 
                                                                       SRF___ 
 
Cavia_MyH4       TAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTGCCAGAAAAG 
Homo_MyH4        TAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTGCCAAAAACG 
Rattus_MyH4      TAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTGCCAAAAATG 
Mus_MyH4         TAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGTAAAGAGATTGCCAAAAATG 
                 **************************************** ************* *** * 
 
      NF-1_  
                 __               PROX____ 
 
Cavia_MyH4       ATTTTGCCAAGTAGGTTCCCAAGCTGGACAGCTGAGGTGGCTGCTGTGTTTGCAGAATGG 
Homo_MyH4        GTTTTGCCAAGTAGGTTCCCAGCTAGGACAGCTGAGGTGGCTGCTGTGTTTGCAGAATGG 
Rattus_MyH4      GTTTTGCCAAGTAGGTCCCCAGCTAGGACAGCTGAGGTGGCTGCTGTGTTTGCAGAACGG 
Mus_MyH4         GTTTTGCCAAGTAGGTCCGCAGCTAGGACAGCTGAGGTGGCTGCTGTGTTTGCAGAACAG 
                  *************** * **    ********************************  * 
 
 
                       TATA                         mCAP        . 
                                                   +1--> 
Cavia_MyH4       TCTCTATAAAAGTAGAGCCCAGATGCCTCTGTCCCGTCCTTCCTCAAAATTCTTACAGGT 
Homo_MyH4        TCTCTATAAAAGTGGAGCTGAGATGCCTCTTTCCCATCCTTCCTCAAAATTCTTGAAGGT 
Rattus_MyH4      CCTCTATAAAAGTGAAGCTTTGGTGCCTCTGTCCTGTCCTTCCTCAAA-TCCGTAAAGGT 
Mus_MyH4         CCTCTATAAAAGTGAAGCTGGGGTGCCTCTGTCCTGTCCTTCCTCAAA-CCCTTAAAGGT 
                  ************  ***   * ******* ***  ************   * *  **** 
 
 
 
 
Cavia_MyH4       ATGTAC-CGTGGAGGAACACTTGGTTAAGACTACAGTCCCAAAGACAGTGATTGTTCATT 
Homo_MyH4        ATGTATATGTGGAAGAACACTTACTT----TTACATTCCTGATGATGATGATTTTTCATT 
Rattus_MyH4      AAGTATGTGTGGCAGAACACTTGGCTAGTTGTGCACTCCTGATGTGAGGGAGTTTCCCTG 
Mus_MyH4         AGGTATGTGTAGCAGAGCACTTGGCTAGCTGTGCACTCCTGATGGGAGCGGGTGCTCATG 
                 * ***   ** *  ** *****   *     * ** ***  * *     *  *   * *  
 
 
 
 
Cavia_MyH4       TAGGGGAGATG---ATTATCTCCCCAACTTTAATT-TCCTTTTTAACATTCCTAAGGATG 
Homo_MyH4        TAAGGGATGTCT--ACTGCTTCCCAAATTTTAATTATTCTTTCCAACATTCTTAAGGACG 
Rattus_MyH4      TGAGGGAGATGGCTATTCCTTCCCAAGCATTAAGT---ACAGTCAACATCCCTGAGAAAG 
Mus_MyH4         TGAGGGAGATGACTGTTCCTTCCCAAACTCTAAGT---AATGTCGGCATCCCTGAGAGAG 
                 *  ****  *      *   **** *    *** *           *** * * **   * 
 
FIGURE 4.20  W Multi-species alignment comparison of guinea pig (Cavia), human 
(Homo), rat (Rattus) and mouse (Mus) MyH4 genomic DNA sequence located -215 to 
+145bp of the transcription start site. Asterisks denote nucleotides conserved across 
all four species; +1 denotes the transcription start site.   
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FIGURE 4.21  W Phylogenetic trees representing the relationship of MyH1 (A), MyH2 
(B) and MyH4 (C) promoter sequence between the guinea pig (Cavia), human 
(Homo), rat (Rattus) and mouse (Mus) produced using ClustalW.  
Sequence homology was calculated as a percentage of the total number of bases 
included within each alignment. (A) Cavia MyH1 shared 82% sequence homology 
with Homo. (B) Cavia MyH2 shared 65% sequence homology with Homo. (C) Cavia 
MyH4 shared 84% sequence homology with Homo. 
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4.3.9.2  ? Sequence conservation between myosin heavy chain genes MyH1, 2 and 4 
Previous work has reported that divergent changes exist in the promoter elements of 
MyH1 and MyH2 when compared to the functional mouse MyH4 promoter in which 
they were initially described (Allen, Weber et al. 2005). Moreover, it has been 
reported that the AT-2 (Oct-1/MEF-2) and CArG regions (NF-1/SRF/NF-1) may 
regulate MyH4 promoter activity and therefore the expression of distinct MyH4 
transcripts and MHC IIB protein (Allen, Weber et al. 2005).  
 
Previously identified AT-2 and CArG regions from guinea pig, human, rat and mouse 
(FIGURES 4.17-4.20), were aligned within each species to assess the conservation 
between promoter elements of the three fast myosin heavy chain genes. The mouse 
MyH4 promoter AT-2 and CArG elements, previously reported to be functional, were 
also included within each alignment (FIGURES 4.22-4.23) for comparison.  
 
Guinea pig MyH1, 2 and 4 promoters had functional Oct-1 binding sites however 
displayed divergent changes to the myocyte enhancer factor-2 (MEF-2) binding site. 
Moreover, whilst both NF-1 binding sites appeared functional in comparison to the 
verified mouse MyH4 CArG element, several point mutations were noted in the core 
of the serum response factor (SRF) binding site. 
 
Human MyH1 and MyH2 promoters had functional Oct-1 binding sites however 
MyH4 encoded a single base change (T/G) in comparison to the verified mouse MyH4 
binding site. Human MyH1, 2 and 4 MEF-2 binding sites displayed similar divergent 
changes to those noted in the guinea pig. Both NF-1 binding sites appeared 
functional in comparison to the verified mouse MyH4 CArG element; however 
several point mutations were noted in the core of the SRF binding site as noted in the 
three guinea pig promoters assessed.  
 
Both AT-2 and CArG binding sites in the rat MyH4 promoter displayed complete 
sequence identity with the verified mouse sequence. Rat MyH1 and MyH2 promoters 
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displayed similar divergence from the mouse MyH4 promoter sequence as noted in 
the guinea pig and human sequence. Mouse MyH1 and MyH2 again displayed a 
similar level of sequence divergence located within the MEF-2 and SRF binding site 
and presented with conserved NF-1 and Oct-1 motifs.  
 
 
              Oct-1_                                
                             MEF-2__            
Cavia_MyH1_AT2      TCAAATTATTTATAGG 16 
Cavia_MyH2_AT2      TCAAATTATCCATAGG 16 
Cavia_MyH4_AT2      TCAAATTATTTATAGG 16 
Functional          TCAAATTATTTATAGA 16 
                    *********  ****  
 
 
              Oct-1_                                
                             MEF-2__            
Homo_MyH1_AT2       TCAAATTATTTATAGG 16 
Homo_MyH2_AT2       TCAAATTATCCATAGG 16 
Homo_MyH4_AT2       TTAAATTATTTATGGG 16 
Functional          TCAAATTATTTATAGA 16 
                    * *******  ** *  
 
 
              Oct-1_                                
                             MEF-2__            
Rattus_MyH1_AT2     TCAAATTATTTATAGG 16 
Rattus_MyH2_AT2     TCAAATTATCCATAGG 16 
Rattus_MyH4_AT2     TCAAATTATTTATAGA 16 
Functional          TCAAATTATTTATAGA 16 
                    *********  ****  
 
 
              Oct-1_                                
                             MEF-2__            
Mus_MyH1_AT2        TCAAATTATTTATAGG 16 
Mus_MyH2_AT2        TCAAATTATCCATAGG 16 
Mus_MyH4_AT2        TCAAATTATTTATAGA 16 
Functional          TCAAATTATTTATAGA 16 
                    *********  **** 
 
FIGURE 4.22  W Comparison of AT-2 element sequence across the three fast isoforms 
of guinea pig, human, rat and mouse in comparison to the functional sequence 
derived from mouse MyH4 (Allen, Weber et al. 2005). Nucleotides that differ from 
the mouse MyH4 sequence appear in red. 
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                      NF-1_           NF-1_ 
                           SRF____ 
Cavia_MyH1_CArG      TTGCCAAAAACATGTTTTGCCA 22 
Cavia_MyH2_CArG      GTGCCAGGAG-GTTTTTTGCCA 21 
Cavia_MyH4_CArG      TTGCCAGAAAAG-ATTTTGCCA 21 
Functional           TTGCCAAAAATG-GTTTTGCCA 21 
                      *****  *     ******** 
 
                      NF-1_           NF-1_ 
                           SRF____ 
Homo_MyH1_CArG       ATGCCAAAAACATGTTTTGCCA 22 
Homo_MyH2_CArG       TTGCCAAGAG-GTATTTTGCCA 21 
Homo_MyH4_CArG       TTGCCAAAAACG-GTTTTGCCA 21 
Functional           TTGCCAAAAATG-GTTTTGCCA 21 
                      ****** *     ******** 
 
                      NF-1_           NF-1_ 
                           SRF____ 
Rattus_MyH1_CArG     TTGCCAAAAACACATTTTGCCA 22 
Rattus_MyH2_CArG     TTGCCAAGAGGG-CTTTTGCCA 21 
Rattus_MyH4_CArG     TTGCCAAAAATG-GTTTTGCCA 21 
Functional           TTGCCAAAAATG-GTTTTGCCA 21 
                     ******* *     ******** 
 
                      NF-1_           NF-1_ 
                           SRF____ 
Mus_MyH1_CArG        TTGCCAAAAACACATTTTGCCA 22 
Mus_MyH2_CArG        TTGCCAAGAGGG-TTTTTGCCA 21 
Mus_MyH4_CArG        TTGCCAAAAATG-GTTTTGCCA 21 
Functional           TTGCCAAAAATG-GTTTTGCCA 21 
                     ******* *     ******** 
 
FIGURE 4.23  W Comparison of CArG element sequence across the three fast isoforms 
of guinea pig, human, rat and mouse in comparison to the functional sequence 
derived from mouse MyH4 (Allen, Weber et al. 2005). Nucleotides that differ from 
the mouse MyH4 sequence appear in red. 
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4.4  ? Discussion 
 
In this study, the structure of the MHC multi-gene family in the common guinea pig 
(Cavia porcellus) was ĐŚĂƌĂĐƚĞƌŝƐĞĚ ? hƐŝŶŐ  ? ? ĂŶĚ  ? ? Z ŵĞƚŚŽĚŽůŽŐǇ ? ŶŽǀĞů hdZ
ĂŶĚ ĐŽĚŝŶŐ ƐĞƋƵĞŶĐĞ ĨŽƌ ĞĂĐŚ ŽĨ ƚŚĞ  “ĨĂƐƚ ? D, ŵZEƐ ǁĂƐ ĞůƵĐŝĚĂƚĞĚ ? ĂŶĚ ƚŚĞ
boundaries of each gene demarcated.  The MHC genes were found to be located in a 
head-to-tail fashion in the order MyH3/ MyH2, MyH1/, MyH4 and MyH8/ MyH13, in 
Ă ? ?ƚŽ ? ?ĚŝƌĞĐƚŝŽŶ ?ůƚŚŽƵŐŚƚŚĞĞǆĂĐƚĐŚƌŽŵŽƐŽŵĂůůŽĐĂƚŝ ŶƐĂƌĞƐƚŝůůƵŶŬŶŽǁŶĚƵĞ
ƚŽ ƌĞƐƚƌŝĐƚĞĚ ŐĞŶŽŵŝĐ ĂŶŶŽƚĂƚŝŽŶ ? ƚŚĞ DǇ, ?ɴ ŐĞŶĞ ǁĂƐĨŽƵŶĚ ƚŽ ďĞ ůŽĐĂƚĞĚ ŝŶ Ă
distinct area of contiguous sequencing data. Numerous studies have previously 
reported that the MHC gene family is found in a highly conserved head-to-tail fashion 
in several species (Weiss and Leinwand 1996; Rinaldi, Haddad et al. 2008). Moreover, 
previous publications also report that the MyH7ɴ gene (encoding MHC I) is 
consistently found on a separate chromosome from other members of the multi-
gene family (Weiss and Leinwand 1996). These previous findings are consistent with 
the results obtained in this study. 
 
SpeĐŝĨŝĐŽůŝŐŽŶƵĐůĞŽƚŝĚĞƉƌŝŵĞƌƐĨŽƌDǇ, ?ɴ ?DǇ, ? ?DǇ, ?ĂŶĚDǇ, ?ŵZEǀĂƌŝĂŶƚƐ
were designed and validated, and for the first time, the adult skeletal muscle 
associated MHC variants were successfully differentiated and quantified in the 
guinea pig by quantitative PCR analysis. The use of PCR to quantify MHC mRNA in 
relation the skeletal muscle fibre type has been highly cited within the relevant 
literature. Furthermore, MHC mRNA has been shown to correlate highly with both 
MHC protein levels (Marx, Kraemer et al. 2002), and other measures of skeletal 
muscle fibre type including mATPase staining, MHC histochemistry and measures of 
metabolic profile (Quiroz-Rothe and Rivero 2004). To date, the resolution of MHC 
protein from guinea pig skeletal muscle has not been achieved. 
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^ĞƋƵĞŶĐĞ ĂŶĂůǇƐŝƐ ǁĂƐ ƉĞƌĨŽƌŵĞĚ ƚŽ ĐŽŵƉĂƌĞ ƚŚĞ ŐƵŝŶĞĂ ƉŝŐ  ? ? hdZ ĂŶĚ ƉĂƌƚŝĂů
coding sequences derived in this study with those of human, rat and mouse. Multiple 
species comparison revealed that guinea pig MyH1 and MyH4, coding for myosin 
heavy chain isoforms IIX and IIB, were most comparable to the human sequence data 
whereas guinea pig MyH2 was most comparable to the rat. Numerous muscle 
pathologies are associated with the atrophy of type II muscle fibres (Lexell, Taylor et 
al. 1988; Baracos, Devivo et al. 1995; Lecker, Jagoe et al. 2004), encoded by myosin 
heavy chain genes MyH1 and MyH4 (Weiss and Leinwand 1996). Given that the 
coding sequence of these two genes appeared highly conserved between the guinea 
pig and the human, and that humans do not generally express MHC IIB muscle fibres 
(encoded by MyH4) (Harridge 2007), it was of interest with respect to the use of the 
guinea pig as an in vivo model of human pathology, as to whether the regulatory 
elements of both genes were similar and moreover, whether guinea pig skeletal 
muscle expresses MHC IIB protein. 
 
With a view to assessing the control of MyH4 mRNA in the guinea pig, promoter 
analysis was performed on the proximal 600bp to the transcription start site in 
comparison to promoter sequence derived from rat and mouse which are known to 
express MHC IIB and human which has the capacity to express MyH4 mRNA (Horton, 
Brandon et al. 2001) but does not routinely express MHC IIB protein (Harridge 2007). 
Previously reported myosin heavy chain promoter elements (identified in the mouse 
MyH4 promoter) including a conserved CAP motif, TATA-box, proximal motif (PROX), 
NF-1, serum response factor (SRF), two AT-rich regions (AT-1/2), myocyte enhancer 
factor-2 (MEF-2) and Oct-1  (Takeda 1992; Allen, Weber et al. 2005) were identified. 
SRF and myocyte enhancer factor-2 have been previously shown to contribute to the 
expression of muscle-specific genes either independently, or via their interaction 
with other ubiquitously expressed proteins including NF-1, Sp-1 and Oct-1 (Allen, 
Weber et al. 2005). 
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Examination of the AT-2 region across the three fast MHC isoforms revealed that 
whilst functional AT-2 regions were present in the MyH4 promoters of the rat and 
mouse, these sites were mutated in the MyH 1 and 2 promoters assessed across all 
four species. Analysis of the AT-2 region of the guinea pig and human MyH4 
promoters revealed mutations in the MEF-2 binding site in the AT-2 region that were 
consistent with those mutations in the rat and mouse MyH1 promoters, and that 
have been previously shown to affect Oct-1 and MEF-2 binding (Allen, Weber et al. 
2005). Allen and colleagues, 2005 have previously reported mutations in the AT-2 
region of mouse MyH1 and MyH2 promoters in comparison with the MyH4 
promoter. Electrophoretic mobility shift-assays (EMSA) have demonstrated that the 
mutations in the MyH2 promoter were sufficient to completely prevent the binding 
of Oct-1 and MEF-2, and mutations in the MyH1 promoter sufficient to significantly 
reduce the binding of these transcription factors (Allen, Weber et al. 2005) and 
subsequently decrease promoter activation. It is therefore suggested that Oct-1 and 
MEF-2 induced activation of the MyH4 promoter (MHC IIB) in the guinea pig and 
human may be restricted to a level similar to MyH1 promoter activation in the mouse 
or rat.  
 
Examination of the CArG region (comprising two NF-1 sites and a single SRF core) 
across the three fast MHC isoforms revealed that whilst functional SRF binding 
elements were present in the MyH4 promoters of the rat and mouse, these sites 
were mutated in the MyH1 and 2 promoters assessed across all four species. Analysis 
of the CArG region of guinea pig and human MyH4 promoters revealed mutations in 
the site reported to bind SRF, a potent transcriptional activator (Joseph 2003). The 
CArG region binds NF-1 and SRF (Joseph 2003), and has been previously reported as a 
further activator (in addition to the AT-2 regions) of the MyH4 promoter (MHC IIB) 
(Allen, Weber et al. 2005). Allen and colleagues have reported that mutations in the 
mouse MyH1 and MyH2 promoters were sufficient to dramatically decrease 
promoter activity and it is therefore inferred that mutation of the SRF binding site in 
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the human and guinea pig MyH4 may have similar negative effects on promoter 
activity.  
 
Analysis of the two promoter elements shown to regulate MyH4 promoter activity 
(Takeda 1992; Allen, Weber et al. 2005) suggests that the human and guinea pig 
MyH4 promoter is less able to bind SRF, MEF-2 and Oct-1  and therefore activation of 
the MyH4 promoter via this system is likely to be reduced in these species. Despite 
these findings, MyH4 mRNA was detected in the EDL and quadriceps muscles of the 
guinea pig in this study (FIGURE 4.14) and has previously been detected in human 
quadriceps samples (Horton, Brandon et al. 2001). It is therefore possible that 
alternative regulatory mechanisms exist for the activation of MyH4 promoters in 
these species, the identity of which are not apparent at this time.  
 
In considering the apparent discrepancy between the ability of the guinea pig and 
human MyH4 promoters to bind their well-characterised transcriptional activators 
and the abundant expression of MyH4 mRNA, it is necessary to consider that the 
regulation of MHC gene expression is likely to occur at several levels. Such control 
mechanisms are likely to include potential promoter activation or inhibition (Lakich, 
Diagana et al. 1998) (as described in this study), differing mRNA stability, 
translational control of the various mRNAs and protein stability (Takeda 1992).  
 
At the level of transcriptional control, it appears that only the TATA box, located at -
30bp from the TSS, is required for the transcription of MyH4 (Swoap 1998). Despite 
this, the transcription of MyH4 mRNA in constructs lacking the AT-2 and CArG regions 
was much lower than that observed in guinea pig skeletal muscle (FIGURE 4.14). 
Given that the expression of MyH4 mRNA in the guinea pig was higher than that 
previously noted in constructs lacking AT-2 and CArG regions, and that MyH1 
promoters have been shown to bind SRF, MEF-2 and Oct-1 but with reduced avidity 
(Allen, Weber et al. 2005), it is one possibility is that the activation of MyH4 
promoters in these species is under similar control mechanisms to the MyH1 (MHC 
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IIX) promoter in the rat and mouse. To date, little is known about which factors 
specifically activate the MyH1 promoter, and recent attempts to characterise specific 
binding factors via gene transfer protocols have been unsuccessful (Pandorf, Haddad 
et al. 2007). 
 
 
4.4.1  ? Closing Remarks 
The methods developed here enable the rapid and accurate quantification of 
changes in the MHC expression of guinea pig skeletal muscle. Moving forward, the 
tools developed here will be utilised to quantify acute changes in the MHC 
expression of the guinea pig quadriceps skeletal muscle in response to developing 
and progressing knee-OA. 
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CHAPTER 5 - CHARACTERISATION OF THE DEVELOPMENT OF 
SPONTANEOUS OSTEOARTHRITIS, AND ASSOCIATED QUADRICPES 
CHANGES, IN THE DUNKIN HARTLEY GUINEA PIG 
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5.1  ? Introduction and Rationale 
 
In CHAPTER 3, the role of quadriceps muscle dysfunction in the rat meniscectomy-
induced model of OA was reported. The MNX model permitted the assessment of 
muscle dysfunction coincident with OA as well as the opportunity to modulate 
muscle function with various hypertrophic agents at defined time points prior to 
disease induction. Data derived from CHAPTER 3 confirmed that the MNX procedure 
resulted in OA-like lesions that were morphologically similar to those of the human 
condition and that clenbuterol administration was indeed able to induce marked 
muscle hypertrophy prior to OA induction. Despite these positive findings, the initial 
data suggested that increased quadriceps mass had no effect on disease severity in 
the MNX induced model. It was considered that the rate at which OA develops in the 
MNX model may have precluded any beneficial effects of increased muscle mass that 
would have otherwise be evident in the human population. Therefore a spontaneous 
model of OA was considered. Following successful molecular tool development as 
reported in CHAPTER 4, it was possible to study molecular changes in the quadriceps 
muscle following the development of spontaneous OA in the Dunkin Hartley guinea 
pig, which has similar disease progression rates to that of the human condition.  
 
The spontaneous development of knee OA in the Dunkin Hartley guinea pig is 
considered to be an improvement on surgically induced disease models in terms of 
comparative pathology and translational research; however the converse is that 
lesion development takes place over a period of months as opposed to days in the 
previously utilised rat model. OA occurs spontaneously in the Dunkin Hartley strain 
guinea pig in both males and females (Jimenez and Glasson 1997). Due to their larger 
body mass, males tend to develop more rapid and consistent pathologies than 
females making them more amenable to scientific research. Evidenced by previous 
studies, lesion development was found to be initially restricted to the medial 
compartment of the knee, the earliest changes being evident in 50% of animals 
around 3 months of age or 700g (Tokuda 1997). At 6 months of age, or 900g in 
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bodyweight, over 90% of animals are found to present with minimal to moderate 
lesions of the medial tibial plateau. 9 month old animals presented with mild to 
moderate medial tibial lesions, with mild femoral involvement (Bendele 2001) 
however it was not until animals reached one year of age that the first clinical signs 
of gait abnormality and or knee extension difficulties are noted (Bendele 2001).  
 
The Dunkin Hartley model of OA has demonstrated clear parallels with the human 
condition during both initiation and disease progression (Jimenez and Glasson 1997). 
Numerous studies have reported that OA develops predominantly on the medial 
aspect of the tibial condyle, with involvement of the medial femoral condyle only in 
response to disease progression (Bendele and White 1987; Bendele and Hulman 
1988; Bendele, White et al. 1989; Bendele and Hulman 1991; Jimenez and Glasson 
1997; Bendele 2001; Bendele 2002). This finding replicates the human situation 
where approximately 75% of the load is passed through the medial aspect of the 
knee (Bendele, et al., 2001). The development of OA in the Dunkin Hartley strain has 
also been strongly associated with increased age and body mass (Tessier, Bowyer et 
al. 2003) as with the human condition (Arden and Nevitt 2006). Further similarities 
between the Dunkin Hartley model and human OA have been described at the 
molecular level. The development of human knee OA has been associated with the 
expression of collagenase 1 and collagenase 3, also known as matrix 
matelloproteinases 1 and 13 respectively, at the site of OA development (Mitchell, 
Magna et al. 1996; Reboul, Pelletier et al. 1996). Both collagenases are found to be 
highly expressed in the Dunkin Hartley model but are absent from rodent and murine 
systems (Huebner, Otterness et al. 1998).  
 
Extensive literature characterises the development of OA in the Dunkin Hartley 
guinea pig at the level of the cartilage and subchondral bone (Bendele and White 
1987; Bendele and Hulman 1988; Bendele, White et al. 1989; Bendele and Hulman 
1991; Bendele, Sennello et al. 1997) however no literature exists regarding the 
effects of OA development on skeletal muscle function. The aim of this study was 
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therefore to investigate the contribution of muscle dysfunction to disease 
progression, and furthermore, begin to elucidate the likely mechanisms instigating 
muscle dysfunction if present.  
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5.1.1  ? Hypotheses and aims  
Bilateral knee OA will present in the Dunkin Hartley guinea pig from around 3 months 
of age. Consistent with other literature, it is expected that the severity of OA will 
increase with advancing age and increasing body mass. Functional changes to the 
quadriceps muscle will occur coincident with the development of knee OA, and 
animals may present with changes to contractile (MHC) or metabolic muscle 
parameters.  
 
The following specific aims will be addressed; 
 
 Characterise the development of knee OA at 2, 3, 5 and 7 months of age 
 Characterise coincident changes, indicative of functional changes, to the 
quadriceps muscle group 
 Elucidate the likely mechanisms driving muscle changes (if present) 
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5.2 - Experimental Protocol 
 
5.2.1 - Animals and housing 
Male Dunkin Hartley guinea pigs (N=24) were sourced from Charles Rivers, UK at 6 
weeks of age. Animals were group housed in a single large pen (4m x 8m) with free 
access to standard guinea pig chow (Purina, UK) and water. Animals were weighed 
twice per week to ensure all animals were gaining weight over the course of the 
study.  At 2, 3, 5 and 7 months of age, 6 animals were selected based on their 
proximity to the median weight of the cohort. Time and finances permitting, the 
experimental time course would have been increased to 18 months, at which point 
previous studies have shown marked osteoarthritic changes in all animals (Bendele 
and Hulman 1988). All animal procedures were carried out at the Bioresource Unit, 
Sutton Bonington. Given that the guinea pigs were simply allowed to age to pre-
defined time points and subsequently euthanised by a schedule I procedure, this 
study did not fall within the remit of the Home Office Animals (Scientific Procedures) 
Act 1986 however animals were maintained under such guidelines nevertheless. 
 
 
5.2.2  ? Termination and histopathology 
Animals were euthanised by intra-peritoneal injection of Pentobarbital Sodium, and 
death confirmed by cervical dislocation in accordance with Home Office Schedule I. 
Knee joints were obtained for histopathological analysis by making a full thickness 
cut 2 cm above and below the patella. The joints were formalin fixed and decalcified 
in 10% formic acid prior to processing by routine vacuum assisted wax infiltration 
(METHOD 2.4). Toluidine blue stained step-coronal sections were prepared at 300µm 
intervals and evaluated using a validated, guinea pig-specific scoring system 
(Huebner 2006) as show in TABLE 5.1. The observer was blinded to both the animal 
number and age in all cases. Pathological features at each condyle were combined to 
calculate a femoral, tibial and combined OA score.  
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5.2.3  ? Biospecimens 
Whole bilateral quadriceps muscle samples, inclusive of the rectus femoris, were 
dissected, weighed and immediately snap frozen in isopentane cooled with liquid 
nitrogen. Care was taken to avoid inclusion of any adipose tissue or additional 
muscle, most importantly the tensor fasciae latae and sartorius which are located 
within the dissected area (Tonge, Jones et al.). Whole blood was drawn via cardiac 
puncture into clot-activator tubes (Sarstedt) and serum obtained by centrifugation. 
All serum was kept at -80oC prior to analysis.  
 
TABLE 5.1  W Semi-quantitative grading scheme for guinea pig knee joints  re-drawn 
from (Huebner 2006) 
Parameter (grade) Description 
Articular Cartilage Structure 
 
0 Normal, smooth, uninterrupted 
1 Mild surface irregularities, no clefts 
2 Irregular surface, 1-3 superficial clefts 
3 >3 clefts and/or loss of superficial zone 
4 1-3 clefts extending into the middle zone 
5 >3 clefts and/or loss of the middle zone 
6 1-3 clefts extending into the deep zone 
7 >3 clefts and/or loss of cartilage into the deep zone 
8 Clefts extending to the zone of calcified cartilage 
Toluidine Blue Staining 
 
0 Uniform staining throughout the articular cartilage 
1 Loss in the superficial zone, < ½ surface 
2 Loss in the superficial zone A? ½ surface 
3 Loss in the superficial and middle zones < ½ surface 
4 Loss in the superficial and middle zones A?½ surface 
5 Loss in all 3 zones < ½ surface 
6 Loss in all 3 zones A? ½ surface 
Osteophytosis 
 
0 No osteophytes present 
1 Small osteophytes 
2 Medium-sized osteophytes 
3 Large osteophytes 
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5.2.4  ? Collagen Turnover 
Disruption to the structural integrity of articular cartilage is the major histological 
finding in osteoarthritis and rheumatoid arthritis. Type II collagen is the major 
organic constituent of articular cartilage (Pieper 2002) and degradation products 
which include the terminal telopeptide of type II collagen (CTX II) are released into 
the circulatory system following cartilage degradation (Nielsen and Stoop 2008). 
Non-pathogenic cartilage turnover (also presenting with increased serum CTX II) 
occurs at the growth plate during normal skeletal development, however serum 
levels decrease with age and stabilise following skeletal maturity  (Hoegh-Andersen 
and Tanko 2004). For the study of spontaneous OA, it is therefore imperative to 
characterise the change in serum CTX II concentration with advancing age, and to 
select appropriately aged animals to minimise growth plate contribution to serum 
CTX II concentration.  
 
Serum CTX II concentration was determined by a validated enzyme linked 
immunosorbent assay with a monoclonal antibody specific for the neo-epitope 
formed when collagen type II is degraded to form CTX II (Serum Cartilaps, IDS, USA). 
The assay was run according to the manufĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐƵƐŝŶŐ ? ?µl of guinea 
pig serum against standards produced from rat CTX II of known concentration (0 - 
247.6pg/ml). At the end of the procedure, absorbance was read at 450nm within 5 
minutes. The absorbance at 650nm was also taken to correct for optical 
imperfections on the supplied 96-well plate. 
 
The concentration of CTX II was determined by subtracting the absorbance at 650nm 
from the 450nm value, and delineating from a standard curve of A450-650nm against 
known CTX II concentration (pg/ml).   All samples were analysed in duplicate and a 
coefficient of variation < 5% deemed acceptable. 
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5.2.5  ? Haematology 
Osteoarthritis has been previously correlated with elevated serum cholesterol 
(Sturmer, Sun et al. 1998) and triglyceride (Cheras, Whitaker et al. 1997) 
concentration, as described in CHAPTER 1.1.4.1. As such, analysis of serum 
cholesterol and triglyceride was carried out by Mrs Laura Tonge, University of 
Nottingham. Serum cholesterol was determined from 30µl serum using the Infinity 
cholesterol determination kit (Sigma) according to the supplied instructions. Serum 
triglyceride concentration was determined from 30µl serum using a specific 
triglyceride determination kit (TR0100, Sigma) according to the supplied instructions. 
Cholesterol and triglyceride standards (7.76mM and 2.26mM respectively, Thermo 
Scientific) were included with each sample set to assess the accuracy of all 
determinations. All samples were run in triplicate and a coefficient of variation (CV) < 
5% deemed acceptable. 
 
 
5.2.6  ? Luminex analysis 
The involvement of cytokines and inflammation in the pathogenesis and progression 
of rheumatoid arthritis is well established; however, the role of such intracellular 
messengers in osteoarthritis is less well defined. Moreover, it is well-established that 
some cytokines elicit changes in skeletal muscle mass (Lang, Frost et al. 2007) 
including Interleukin 6 (IL-6) and tumour necrosis factor alpha (TNFɲ). Therefore, 
serum cytokines were quantified with respect to their association with developing 
OA, and in terms of their potential muscle modulating effects. 
 
Given the problems associated with obtaining specific antibodies that cross-react 
with guinea pig proteins, a novel protein array system (Bio-Plex Protein Array System 
Bio-Rad, Hercules, CA) targeting conserved peptide sequences was tested with 
regards its cross-reaction with guinea pig serum (School of Biology, University of 
Nottingham). The  protein array contained 23 cytokines and chemokines including IL-
 ?ɲ ?/>- ?ɴ ?/>-2, IL-3, IL-4, IL-5, IL-6, KC (a murine IL-8 homologue), IL-9, IL-10, IL-12p40, 
IL-12p70, IL-13, IL-17, granulocyte macrophage colony-stimulating factor (GM-CSF), 
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granulocyte colony-stimulating factor (G-CSF), interferon gamma (IFN-ɶ ? ?
macrophage inflammation protein 1 alpha (MIP- ?ɲ ? ? D/W- ?ɴ ? ZEd^  ?ƌĞŐƵůĂƚĞĚ
upon activation, normal T-cell expressed and secreted), tumour necrosis factor alpha 
(TNF-ɲ ? ? DW-1 and Eotaxin. Serum samples from all guinea pigs were analysed as 
recommended by the manufacturer (complete instructions available from Bio-Rad) 
against a range of rat cytokine standards (0 - 3200 pg/ml) and a sample dilution of 
1:3, utilising a total of 30 µl of sera.  
 
All samples were analysed (Bio-Plex 200) in triplicate, with a coefficient of variation < 
5% deemed acceptable. 
 
5.2.7  ? Expression analysis by quantitative PCR 
Quantitative PCR analysis was carried out on quadriceps muscle samples as described 
in (METHOD 2.1.7) using the standard curve method of data acquisition. To advance 
on previous methods of data normalisation (GeNorm), the expression data from this 
study was normalised to cDNA concentration using OliGreen (Invitrogen), shown to 
specifically bind with single stranded DNA molecules (Rhinn, Marchand-Leroux et al. 
2008; Rhinn, Scherman et al. 2008). Following reverse transcription as described in 
(METHOD 2.1.5), 3µl of the resulting cDNA was mixed with an equal volume of 
OliGreen reagent. Following incubation at room temperature for 5 minutes, 
fluorescence was read at 522nm at 80oC using the LightCycler (Roche, LC480). 
Reactions were read at 80oC as this temperature has been shown to increase 
specificity by reducing the contribution of fluorescence given off by the binding of 
OliGreen to RNA (Rhinn, Marchand-Leroux et al. 2008), to the cDNA signal. 
Normalising data in this manner not only accounts for variation in sample loading, 
but also controls for total reverse transcription reaction efficiency.  
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5.2.8  ? Oligonucleotide primer design 
Targets were selected to assess changes in factors associated with skeletal protein 
degradation and muscle atrophy, the apoptotic response, muscle fibre composition 
and those factors involved in metabolite signalling.  
 
5.2.8.1  ? Quadriceps muscle fibre-type composition 
Skeletal muscle fibre characterisation was determined by the expression of myosin 
heavy chain mRNAs using methodology developed in (CHAPTER 4).  
 
5.2.8.2  ? Skeletal protein degradation and atrophy 
To determine changes in skeletal protein degradative potential, key components of 
the proteosome and calpain system were assessed. The mRNAs of downstream E3 
ligases muscle RING finger protein 1 (MuRF1) and muscle atrophy F-box (MAFBx) 
which in combination with ubiquitin conjugating enzymes, target proteins for 
degradation by the proteosome via ubiquitination (Ardley and Robinson 2005) were 
assessed. Skeletal muscle fibres express both ubiquitous calpain I and II and skeletal 
muscle specific calpain III (p94) isoforms (Murphy and Lamb 2008). Calpain activation 
is associated with the initiation of proteosome dependent skeletal muscle protein 
degradation (Smith and Dodd 2007) and as such the mRNAs of calpain isoforms I  W III 
were also determined.  
 
5.2.8.3  ? Apoptotic potential 
The apoptotic response potential of quadriceps skeletal muscle was assessed by 
quantifying the mRNAs of pro-apoptotic Bax and anti-apoptotic Bcl2 which are key 
components of the mitochondrial-mediated apoptotic pathway (Otter, Conus et al. 
1998) using specific oligonucleotide primers for PCR.  
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5.2.8.4  ? Metabolite signalling and muscle fibre-type changes 
Factors involved in metabolite signalling, potentially related to metabolic changes in 
ƐŬĞůĞƚĂů ŵƵƐĐůĞ ǁĞƌĞ ĂƐƐĞƐƐĞĚ ? KůŝŐŽŶƵĐůĞŽƚŝĚĞ ƉƌŝŵĞƌƐ ǁĞƌĞ ĚĞƐŝŐŶĞĚ ƚŽ W' ?ɲ ?
W' ?ɴ ? WWZɲ ĂŶĚ WWZɷ ? ƚŚĞ ĨƵŶĐƚŝŽŶƐ ŽĨ ǁŚŝĐŚ ĂƌĞdescribed in (CHAPTER 3). 
Oligonucleotide primers were also designed to Six-1 and Eya-1, two novel 
transcription factors reported to induce slow-twitch to fast-twitch muscle fibre 
changes with an accompanied increase in glycolytic metabolic potential (Grifone, 
Laclef et al. 2004).  
 
Due to the limited availability of annotated guinea pig cDNA sequence data, rat and 
mouse cDNA sequences were compared to the partially annotated Cavia porcellus 
database using the BLAT utility (Kent 2002) available from Ensemble Release 56 
(Ensemble) in order to locate the corresponding guinea pig cDNA. 
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TABLE 5.2  W Oligonucleotide primer sequences for quantitative PCR reactions 
 
Gene Name Accession Number Forward Primer (5' - 3') Reverse Primer (5' - 3') Amplicon (bp) 
MyH1 (MHC IIX) GU288596 TTCATCCAAATGCAGGAAAG TCTTTATCTCAAAAGTCATAAATACAA 129 
MyH2 (MHC IIA) GU288597 TGTGGAATGACCAGAGCAAG CCTTTGCAATAGGGTAGGACA 90 
MyH4 (MHC IIB) GU288598 TCCATCTACTGCTGCAACG ACTCTGCAGATTTTATTTCCTTG 85 
MyH7 (MHC I) ENSCPOG00000004208 AAGTATCGCAAGGCTCAA CCTTTCCTTAATTCCAAGC 93 
Bax ENSCPOG00000011196 GGGTTGTCGCCCTTTTCTAT CCCATGTTCTTCCAGATGGT 250 
Bcl2 ENSCPOT00000019808 GAGTGTCAACCGGGAGATGT AAACAGAGGCCGTACACTGG 151 
MuRF1 ENSCPOT00000027054 GGAGCAGGAAGAGAAGCTGA TGCTTTGGATGAGTTGCTTG 158 
MAFBx ENSCPOT00000010062 GGCTGCTGTGGAAGAATCTC CCAGGAGAGAATGTGGCAAT 188 
Calpain I ENSCPOT0000004006 GGTGAAAGGCCATGCATACT CTCCCCATCTTCCATCTTCA 196 
Calpain II ENSCPOT00000024361 TGCAAGATCATGGTGGACAT TCAATGTTGAGCTCGTCGTC 245 
Calpain III ENSCPOT00000024237 GACAGCTGGAAGGACTGGAG CATTCACCGACACTGTCCAC 193 
PPAR Alpha ENSCPOT0000001502 GATGCCGAGGTCTGAGAAAG GGCCTTGACCTTGTTCATGT 151 
PPAR Delta ENSCPOT00000011491 TGTGCACGAGGCTATCTTTG TCACTGTCGTCGAGTTCCAG 186 
PGC1 Alpha ENSCPOT0000001538 CCAAAGCTGAAGTCCTCCTG GGGCCGCTTAGTCTTTCTCT 189 
PGC1 Beta ENSCPOT0000001980 GTCCGGAGAACTCTGAGACG ACGGTGTGTCTCCTTCATCC 177 
Six-1 ENSCPOT00000015700 AACTCCTCCTCCAACAAGCA TTCTGAGCTGGACATGATCG 72 
Eya-1 ENSCPOT0000000719 TGCATATGGGCAAACACAGT AATTCCATACGGCTGTCCTG 88 
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5.2.9- Statistical Analysis 
All data are reported as means + standard error of the mean (S.E.M).  Comparisons 
were performed by analysis of variance (ANOVA) between multiple groups. Where 
statistical significance of the ANOVA permitted, the Bonferroni test was used to test 
for significance, with significance accepted as P < 0.05. All statistical analyses were 
performed using SPSS 17.0. Symbols used to indicate statistical significance were; * P 
< 0.05; ** P < 0.01; *** P < 0.001. # P = < 0.1 was regarded as a trend (Tominaga, 
Ndu et al. 2006; Jung, Reichstein et al. 2010). 
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5.3  ? Results 
 
5.3.1 - Animal weight parameters 
All animals were in good general health throughout the study and all 24 were 
included in the following analyses. During the course of the study, both body mass 
(g) and quadriceps mass (g) were significantly increased with advancing age at all 
time points (P = <0.001). Animal weights progressed from a mean body mass of 
510.60 + 3.27g at 2 months to 1160.78 + 48.72g at 7 months of age, whilst mean 
quadriceps mass increased from 4.68 + 0.28g at 2 months to 13.40 + 1.24g at 7 
months of age. The quadriceps to body mass ratio, calculated by body mass (g) over 
quadriceps mass (g), remained constant at all ages (P = 1.000) (FIGURE 5.1). 
 
 
 
FIGURE 5.1  ? The effects of advancing age on bodyweight (A), quadriceps mass (B) 
and quadriceps mass to bodyweight ratio (C). Data are mean + S.E.M; n = 6. 
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5.3.2  ? Tibiofemoral pathology 
Histological examination of tibiofemoral joints was performed at all ages as per 
(METHOD 5.2.2). At 2 months of age, animals were generally free from OA, with the 
exception of one animal which presented with mild proteoglycan loss in the 
superficial zone.  At 3 and 5 months of age, animals presented with proteoglycan loss 
extending as deep as the mid-zone and mild cartilage surface irregularities. At 7 
months of age, proteoglycan loss and cartilage surface irregularities were more 
pronounced than at previous ages, although no animals exhibited osteophytosis at 
any of the joint margins studied. Significant differences in the combined OA score 
were apparent between the ages of 2 and 3 months (P = 0.002) and 5 and 7 months 
(P = 0.093; trend). OA severity between the ages of 3 and 5 months remained 
unchanged (P = 0.394) (FIGURE 5.2).  
 
 
 
 
FIGURE 5.2  ? The association of advancing age and tibiofemoral pathology. Data are 
mean modified Mankin scores + S.E.M; n = 6. 
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TABLE 5.3  W Individual modified Mankin scores for guinea pig joints. 
 
Animal 
Age 
(mo) 
Toluidine Blue Staining Articular Cartilage Structure Osteophytosis 
Med FEM Med TIB Lat FEM Lat TIB Med FEM Med TIB Lat FEM Lat TIB Med FEM Med TIB Lat FEM Lat TIB 
K 2 0 0 0 0 0 0 0 0 0 0 0 0 
M 2 0 0 0 0 0 0 0 0 0 0 0 0 
T 2 0 0 0 0 0 0 0 0 0 0 0 0 
U 2 0 0 0 0 0 0 0 0 0 0 0 0 
X 2 0 0 0 0 0 0 0 0 0 0 0 0 
Z 2 0 1 0 0 0 0 0 0 0 0 0 0 
B 3 2 1 2 3 1 0 0 0 0 0 0 0 
G 3 3 3 3 4 0 2 0 0 0 0 0 0 
H 3 0 1 4 2 0 0 0 0 0 0 0 0 
J 3 0 2 2 1 0 0 0 0 0 0 0 0 
L 3 2 2 2 2 0 0 0 0 0 0 0 0 
P 3 2 2 2 2 0 1 0 0 0 0 0 0 
D 5 1 2 2 2 0 0 0 0 0 0 0 0 
F 5 0 1 0 1 0 0 0 1 0 0 0 0 
N 5 2 3 1 3 0 0 0 3 0 0 0 0 
V 5 2 2 1 3 0 0 1 3 0 0 0 0 
W 5 0 1 0 0 0 0 0 0 0 0 0 0 
Y 5 1 1 0 1 0 2 0 1 0 0 0 0 
A 7 0 1 1 2 0 0 0 0 0 0 0 0 
C 7 2 5 2 4 1 1 0 1 0 0 0 0 
E 7 2 3 2 3 0 1 0 1 0 0 0 0 
I 7 1 3 2 3 1 3 1 1 0 0 0 0 
R 7 1 3 1 2 0 3 0 1 0 0 0 0 
S 7 2 3 3 2 2 1 0 1 0 0 0 0 
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5.3.3  ? Collagen type II degradation 
Serum CTX II telopeptide was measured using a quantitative ELISA (Cartilaps) as 
described previously (METHOD 5.2.4). At 2 months of age, when cartilage turnover 
was most active, mean CTX II was 462.340 + 7.316 pg/ml. Following growth plate 
closure around the age of 3-4 months, serum CTX II levels dropped significantly (P = 
<0.001) until 7 months of age when levels were detected at just 33.632 + 3.169 
pg/ml. 
 
 
 
 
FIGURE 5.3  ? The effects of advancing age on serum CTX II concentration. Data are 
mean + S.E.M; n = 6. P value refers to one-way analysis of variance. 
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5.3.4 - Serum cholesterol and triglyceride 
Serum cholesterol and triglyceride concentrations were determined by specific ELISA. 
Serum cholesterol concentration was lowest at 2 months of age, and appeared 
elevated at 3 months (P = 0.099).  Serum triglyceride concentration was unaffected 
by age (FIGURE 5.4).  
 
 
 
 
 
FIGURE 5.4  ? The effects of advancing age on serum cholesterol (A) and triglyceride 
(B) concentration. Data are mean + S.E.M; n = 6. P value refers to one-way analysis of 
variance. 
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5.3.5 - Serum cytokines and chemokines 
Serum cytokines and chemokines were determined quantitatively by Luminex ? 
analysis. In general, serum cytokine and chemokine levels remained static with 
advancing age with the exception of RANTES which was significantly affected by age 
(P = 0.034). Post-hoc analysis revealed a significant difference between the ages of 2 
months and 3 months (P = 0.033) (FIGURE 5.5).  A full serum analysis by Luminex ? 
quantification is included in (TABLE 5.4). 
 
 
 
 
FIGURE 5.5  ? The effects of advancing age on serum RANTES concentration. Data are 
mean + S.E.M; n = 6. P value refers to one-way analysis of variance. 
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TABLE 5.4 - Mean serum cytokine / chemokine concentration (pg/ml) ± S.E.M; n = 6 
Parameter 2mo S.E.M 3mo S.E.M 5mo S.E.M 7mo S.E.M P = 
IL-4 (39) 2.410 0.043 2.403 0.057 2.390 0.043 2.426 0.061 0.969 
IL-12(p70) (78) 77.360 17.177 67.119 11.414 76.704 10.052 76.713 16.242 0.946 
IL-1a (53) 5.585 0.446 6.354 0.572 5.968 0.501 6.097 0.578 0.776 
IL-1b (19) 51.139 3.655 54.865 4.227 49.284 2.429 52.148 3.366 0.722 
IL-2 (36) 6.239 0.144 6.213 0.123 6.132 0.131 6.505 0.190 0.344 
IL-3 (18) 2.803 0.065 2.697 0.118 2.536 0.090 2.749 0.097 0.246 
IL-5 (52) 4.202 0.202 4.227 0.272 4.213 0.185 4.418 0.254 0.944 
IL-6 (38) 1.898 0.428 1.839 0.223 2.099 0.339 1.878 0.343 0.950 
IL-9 (33) 71.479 2.160 72.722 4.190 71.739 2.159 75.254 3.677 0.829 
IL-10 (56) 25.784 2.533 23.746 2.141 23.688 1.816 26.580 2.837 0.824 
IL-12(p40) (76) 16.420 1.837 15.374 1.576 17.698 1.079 16.870 1.316 0.735 
IL-13 (37) 378.062 32.213 378.478 26.888 353.667 23.634 356.592 27.135 0.871 
IL-17 (72) 5.208 0.084 5.278 0.170 5.176 0.111 5.518 0.120 0.237 
Eotaxin (74) 1176.138 57.942 1198.557 57.804 1238.376 84.429 1215.193 80.605 0.937 
G-CSF (54) 5.724 0.276 5.615 0.218 5.768 0.216 5.883 0.338 0.914 
GM-CSF (73) 21.629 4.463 24.969 3.808 25.498 3.231 27.336 4.527 0.792 
IFN-g (34) 16.218 2.056 15.661 1.592 14.318 0.790 16.263 1.499 0.844 
KC (57) 2.042 0.182 2.011 0.195 1.918 0.102 1.923 0.163 0.945 
MCP-1 (51) 94.265 6.402 86.629 4.545 90.825 3.398 92.004 3.513 0.682 
MIP-1a (77) 142.137 31.764 163.923 18.540 161.734 33.596 198.083 28.391 0.353 
MIP-1b (75) 16.673 1.267 15.791 1.672 14.906 1.049 15.688 0.764 0.794 
RANTES (55) 4.017 0.369 13.416 2.907 12.014 2.497 8.937 2.209 0.034 
TNF-a (21) 38.155 4.374 34.993 3.688 33.216 2.395 39.588 3.379 0.576 
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5.3.6 - Quadriceps femoris contractile and metabolic associated parameters 
Quadriceps muscles were characterised with respect to their contractile and 
metabolic characteristics. Contractile properties of the quadriceps muscle were 
assessed by the expression of MHC specific mRNAs at all ages. MHC I mRNA 
expression was subject to considerable inter-animal variation at the ages of 3 and 5 
months. MHC IIA mRNA was stable with increasing age (P = 0.623). Similar stability 
was noted with regards MHC IIB mRNA (P = 0.423), the expression of which remained 
constant irrespective of age. MHC IIX mRNA levels demonstrated a trend increase 
between the ages of 2 and 3 months (P = 0.087) followed by a reduction to baseline 
at 5 and 7 months of age.  
 
 
 
FIGURE 5.6  ? The effects of advancing age on the myosin heavy chain isoform specific 
mRNAs of MHC I (A), MHC IIA (B), MHC IIX (C) and MHC IIB (D). Data are mean 
expression units + S.E.M normalised to total first strand cDNA concentration; n = 6. P 
values refer to one-way analysis of variance. 
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Isocitrate dehydrogenase (ICDH) enzyme activity, associated with slow-twitch muscle 
fibres, was determined in quadriceps tissue homogenates as an index of metabolic 
capacity. Similarly, lactate dehydrogenase (LDH) activity, associated with faster-
twitch fibres was determined as an indicator of glycolytic metabolic capacity. Enzyme 
activities were normalised to total extractable protein concentration and expressed 
as mOD/min/µg total protein. ICDH activity appeared to be modulated by age (P = 
0.096) and demonstrated a trend increase between the ages of 2 and 7 months (P = 
0.071). The increase in ICDH activity was also noted between the ages of 5 and 7 
months (non-significant). Glycolytic metabolic capacity remained static irrespective 
of age (FIGURE 5.6). 
 
 
 
FIGURE 5.7  ? The effects of advancing age on ICDH and LDH activity in whole 
quadriceps homogenates. Data are mean mOD/min normalised to total extractable 
protein + S.E.M; n = 6. P values refer to one-way analysis of variance. 
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 5.3.7  ? Protein synthetic potential 
As an index of protein synthetic potential, phosphorylated and total 4EBP1 protein 
was quantified by western blot. 4EBP1 is an elongation factor 4E (elF4E) associated 
protein that controls mRNA translation by regulating the formation of the cap-
initiation complex. When 4EBP1 is hyperphosphorylated by mTOR (mammalian 
target of rapamycin), its inhibitory binding to elF4E is prevented thereby enhancing 
protein synthesis (Connolly, Braunstein et al. 2006). No changes to the 
phosphorylation status (ratio) of 4EBP1 were noted with respect to advancing age.  
 
 
 
 
FIGURE 5.8  ? The effects of advancing age with the ratio of phosphorylated to total 
4EBP1 protein. Data are mean densitometric units, normalised to total protein load + 
S.E.M; n = 6. Inset  W representative blot showing 4EBP1 immuno-reactivity of animals 
aged 2, 3, 5 and 7 months from 75µg protein. 
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The gene expression profiles of known modulators of muscle function were assessed 
by quantitative PCR. Due to difficulties in obtaining annotated cDNA sequences 
specific to guinea pig, all cDNAs were derived by comparison with rat and mouse 
sequence data as previously described (METHOD 5.2.8). A description of the specific 
pathways targeted can be found within (CHAPTER 1.3.6).  
 
 
5.3.8  ? Skeletal protein degradation 
To gain an indication of changes in skeletal protein degradation, factors involved in 
proteosomal degradation and proteolysis via the calpain system were assessed. 
MuRF and MAFBx are involved in the targeting of proteins for degradation via the 
proteosome. Whilst MAFBx mRNA remained unaltered irrespective of age (P = 
0.637), MuRF mRNA was dramatically reduced at 7 months of age compared with all 
other age points studies, however this effect failed to reach the level of a statistical 
trend (P = 0.102). 
 
 
 
FIGURE 5.9  ? The effects of age with the mRNA expression of the E3 ligases MuRF 
and MAFBx. Data are mean normalised expression units + S.E.M; n = 6 
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Assessment of calpain family members I, II and III revealed little modulation with 
respect to age. Calpain I, II and calpain III showed no response to age (P = 0.208, 
0.103 and 0.407 respectively). 
 
 
 
 
FIGURE 5.10  ? The effects of age with the mRNA expression of calpain I, II and III. 
Data are mean normalised expression units + S.E.M; n = 6. 
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5.3.9  ? Apoptotic potential 
The apoptotic response potential of the quadriceps skeletal muscle was assessed by 
quantifying the mRNAs of pro-apoptotic Bax and anti-apoptotic Bcl2 (Otter, Conus et 
al. 1998). Whilst Bcl2 mRNA was relatively stable with respect to age, Bax mRNA 
decreased dramatically after 3 months of age (P = 0.004) suggesting a reduced 
apoptotic potential.   
 
 
 
 
FIGURE 5.11  ? The effects of age on mRNA expression of Bax and Bcl2. Data are 
mean normalised expression units + S.E.M; n = 6. P values refer to one-way analysis 
of variance. 
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5.3.10  ? Metabolite signalling 
To detect potential changes in metabolite signalling, members from the PGC1 and 
PPZ ĨĂŵŝůŝĞƐ ǁĞƌĞ ĂƐƐĞƐƐĞĚ ǁŝƚŚ ƌĞƐƉĞĐƚ ƚŽ ĂŐĞ ? W' ?ɲ ?W' ?ɴ ĂŶĚ WWZɲ
displayed similar expression profiles but were statistically unaffected by age (P = 
 ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ƌĞƐƉĞĐƚŝǀĞůǇ ? ? WWZɷ ŵZE ŚŽǁĞǀĞƌ ? ǁĂƐ ŵŽƐƚ ĂďƵŶĚĂŶƚůǇ
expressed at 2 months of age and reduced thereafter (P = 0.042). 
 
 
 
 
FIGURE 5.12  ? The association of age with the mRNA expression of factors involved 
in metabolite signalling. Data are mean normalised expression units + S.E.M; n = 6 
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The mRNA of Six-1 and Eya-1, two novel transcription factors reported to induce 
slow-twitch to fast-twitch muscle fibre changes with an accompanied increase in 
glycolytic metabolic potential (Grifone, Laclef et al. 2004) were also quantified in 
quadriceps skeletal muscle samples. Whilst the expression profiles of both genes 
appeared similar, the expression of Six-1 was increased between the ages of 2 and 3 
months and similarly 5 or 7 months (0.065) whereas Eya-1 expression remained 
unaltered by age. 
 
 
 
FIGURE 5.13  W The association of age with the mRNA expression Six-1 and Eya-1. 
Data are mean normalised expression units + S.E.M; n = 6. P values refer to one-way 
analysis of variance.  
 
 
5.3.11  ? Correlation of muscle parameters with OA severity 
WĞĂƌƐŽŶ ?Ɛ ƉƌŽĚƵĐƚ ŵŽŵĞŶƚ ĐĂůculation (PPMC) was used to elucidate correlation 
between OA severity and the parameters of quadriceps function assessed at each 
age. Both body mass and age displayed a strong positive correlation with OA severity 
(r2 = 0.671, P = <0.001; r2 = 0.642, P = 0.001 respectively). In order to elucidate more 
subtle relationships, partial correlation was performed controlling for body mass in 
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all animals. The fast-twitch muscle fibre associated MHC IIX isoform was found to 
positively correlate with OA severity (r2 = 0.527, P = 0.012) suggesting that those 
animals with more abundant MHC IIX mRNA had more severe osteoarthritic lesions. 
Both E3 ligases MuRF and MAFBx, and the skeletal muscle associated cysteine 
protease Calpain III, were negatively correlated with OA severity suggesting that OA 
was not linked with proteolytic activity in this study (TABLE 5.5). 
 
TABLE 5.5  W Correlation between combined OA score and various quadriceps 
parameters (controlled for body mass) 
 
Parameter Association with OA score (r2) P = 
MHC IIX mRNA 0.527 0.012 
MuRF mRNA -0.545 0.007 
MAFBx mRNA -0.446 0.033 
Calpain III mRNA -0.532 0.009 
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5.3.12  ? Correlation of serum cytokines with OA severity 
Serum cytokine and chemokine concentrations (pg/ml) were assessed with respect 
to their relationship with OA severity at all ages. Interestingly, none of the factors 
assessed demonstrated any significant relationship with the severity of knee OA 
noted (TABLE 5.6). 
 
TABLE 5.6  W Correlation between serum cytokines and OA severity (controlled for 
body mass) 
Parameter Association with OA score (r2) P = 
IL-4 (39) 0.106 0.630 
IL-12(p70) (78) -0.055 0.802 
IL-1a (53) 0.153 0.487 
IL-1b (19) 0.224 0.303 
IL-2 (36) 0.245 0.259 
IL-3 (18) -0.036 0.869 
IL-5 (52) 0.060 0.786 
IL-6 (38) 0.045 0.839 
IL-9 (33) 0.177 0.418 
IL-10 (56) 0.113 0.607 
IL-12(p40) (76) -0.132 0.547 
IL-13 (37) 0.064 0.771 
IL-17 (72) 0.166 0.448 
Eotaxin (74) 0.095 0.667 
G-CSF (54) -0.057 0.797 
GM-CSF (73) 0.052 0.812 
IFN-g (34) -0.005 0.983 
KC (57) -0.041 0.853 
MCP-1 (51) -0.097 0.659 
MIP-1a (77) 0.249 0.252 
MIP-1b (75) 0.181 0.408 
RANTES (55) 0.110 0.618 
TNF-a (21) -0.067 0.761 
IL-4 (39) 0.106 0.630 
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5.4  ? Discussion 
 
This is the first study to report age-related changes to contractile and metabolic 
parameters of the quadriceps femoris skeletal muscle group in the Dunkin Hartley 
guinea pig, and furthermore endeavour to link these to the severity of knee 
osteoarthritis which commonly affects this strain. As the initial development of 
osteoarthritis occurs in the DH guinea pig during the longitudinal growth phase, it 
was anticipated that body mass would be significantly elevated all time points 
studied.  As such, an ontogeny-based approach was taken by initially comparing the 
effects of age on both osteoarthritis and muscle function, and then subsequently 
correlating these findings to disease severity.  
 
5.4.1  ? Development of OA-like lesions and cartilage turnover 
As anticipated, advancing age was associated with increased body mass and 
quadriceps mass. The quadriceps to body mass ratio, indicative of quadriceps 
hypertrophy / atrophy in relation to body mass remained unaltered as age increased, 
suggesting that overt quadriceps atrophy was not present in any of the animals 
assessed. CTX II telopeptide was measured in serum as an index of growth plate 
maturity using an assay that detects degradation products of C-terminal type II 
collagen. Levels fell significantly as age increased and the growth-plate closed at 
approximately 3-4 months of age. CTX II concentrations were concurrent with other 
published reports in the same strain which have also reported growth plate-closure 
at approximately 3-4 months of age (Watson, Hall et al. 1996; Huebner, Deberg et al. 
2007). 
 
Assessment of toluidine blue stained step coronal sections revealed evidence of 
osteoarthritic-like lesions from as early as 3 months of age. OA-like lesions tended to 
be more severe on the tibial condyles than on the respective femoral condyles, with 
tibias presenting with higher OA scores than femurs at all ages assessed. OA-like 
lesions did not predominantly affect any particular aspect of the knee, with medial 
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and lateral aspects of both condyles presenting with similar OA scores. Pathology 
was associated with reduced proteoglycan staining at the joint margin and changes 
to articular cartilage structure as detailed in TABLE 5.1, however no osteophytosis 
was noted at any site in any of the animals assessed. In general, OA scores 
progressed concurrent with age through until 7 months of age when the final 
analyses were performed. With reference to the existing literature available for the 
assessment of OA in the Dunkin Hartley strain, total histological scores were 
concurrent with those of other published studies, utilising the same strain and joint 
scoring system (Huebner 2006). In this study, tibial condyles exhibited more 
pronounced osteoarthritic changes than the respective femurs, an observation 
reported by several other studies (Bendele and Hulman 1991; Bendele 2001; Bendele 
2002; Tessier, Bowyer et al. 2003). Given that guinea pigs transfer around 75% of 
load through the medial aspects of their joints (Bendele 2001), it may perhaps be 
expected that the medial portion of the tibial condyle would be predominantly 
affected by OA-like lesions. Medial predominance to OA was not noted in this study, 
however previous studies have not routinely separated medial and lateral pathology 
scores, and therefore it is unclear whether the increased medial joint load translates 
to increased medial OA severity in practice. 
 
5.4.2  ? Changes in biomarkers of skeletal muscle function 
Examination of factors indicative of contractile and metabolic properties of the 
quadriceps skeletal muscle revealed age-related effects on specific muscle fibre-
types. Slow-twitch associated MHC I mRNA demonstrated marked inter-animal 
variation, and increased mean expression around the time of OA initiation. Although 
this observation failed to reach statistical significance in isolation (P = 0.162); ICDH 
activity, associated with slow-type muscle fibres and indicative of oxidative potential 
(Brandstetter, Picard et al. 1997), also displayed a similar expression pattern, adding 
evidence towards an effect of age on MHC I mRNA. MHC I is associated with type I, 
fatigue resistant muscle fibres (Bamford, Putman et al. 2005) most commonly found 
in postural, stabilising skeletal muscles (Adams, Haddad et al. 1994). It is one 
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possibility that the changes in MHC I expression noted may indicate altered joint 
stability around the time of OA initiation, although joint biomechanics were not 
assessed in this study. 
 
When considering faster-twitch muscle fibres, MHC IIX was elevated at 3 months of 
age compared to all other ages (P = 0.083). The mRNA of Six-1 , a novel factor 
associated with fast-twitch muscle fibres was also increased at 3 months (Grifone, 
Laclef et al. 2004), however the anticipated increase in glycolytic activity did not 
concur with no apparent effect of age on quadriceps LDH activity. Although LDH 
activity remained unchanged, studies reporting strong correlations between LDH 
activity and fibre type have generally been carried out on untreated subjects and 
therefore assessed basal muscle fibre type (Briand, Talmant et al. 1981).  Moreover, 
studies inducing changes in muscle fibre type have previously reported a disparity 
between fibre type and LDH activity (Mounier, Cavalié et al. 2007), suggesting that 
different mechanisms are responsible for the control of MHC fibre type and 
metabolic potential. In this study, other measures of glycolytic potential such as the 
measurement of phosphofructokinase, the rate limiting glycolytic enzyme (Trivedi 
and Danforth 1966), may have provided a further indication of glycolytic potential, 
however the possibility still exists that MHC changes were present without the 
expected change in metabolic potential. The relative transcript abundance of MHC 
IIA and MHC IIB mRNAs were unaffected by age. MHC IIX is associated with the 
expression of fast glycolytic muscle fibres. MHC IIX is the second fastest MHC isoform 
in many laboratory species including the mouse and rat (Weiss and Leinwand 1996), 
however it is the fastest MHC isoform in the human (Harridge 2007). The elevated 
expression of MHC IIX, indicative of fast glycolytic muscle fibre expression, occurred 
around the time of OA induction, as with the change in MHC I expression. This finding 
may add further weight to the possibility of altered joint biomechanics around the 
time of OA induction. 
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5.4.3  ? Assessment of quadriceps transcriptome 
Quadriceps gene expression of known modulators of muscle function was 
determined by quantitative PCR. Assessment of factors involved in proteosomal 
degradation and proteolysis via the calpain system revealed no changes at the level 
of mRNA expression in response to advancing age.  
 
Pro-apoptotic Bax mRNA was however, significantly decreased with advancing age in 
all animals studied. Previous studies on aged rats have demonstrated age-related 
increases in Bax expression with concomitant decreases in Bcl-2 expression (Chung 
and Ng 2006). In the same context, Song and colleagues have shown increased Bax 
and decreased Bcl-2 in old sedentary rats with age-related sarcopenia (Song, Kwak et 
al. 2006). Interestingly, the latter study demonstrated that the pro-apoptotic state 
could be altered by 12 weeks of exercise training (Song, Kwak et al. 2006). Although 
such studies are unable to explain the decrease in Bax expression noted in this study, 
taken together with the unaltered quadriceps to body mass ratio, they further 
confirm that age-related sarcopenia / atrophy was not present and therefore unlikely 
to be the cause of OA in this strain. 
 
5.4.4  ? Serum analytes 
In this study, serum cholesterol concentration was found to be highest at 3 months 
of age, when the first histological evidence of osteoarthritis was found. Levels fell 
thereafter and by 7 months of age, were comparable to 2 month old animals. 
Osteoarthritis has been previously associated with elevated serum cholesterol 
concentration (Sturmer, Sun et al. 1998) which has been reported to be an 
independent risk factor for OA (Sturmer, Sun et al. 1998). In this study, it would 
appear that cholesterol concentration was more closely involved with the initiation 
of OA rather than its progression. Conversely, serum triglyceride levels were 
statistically unaffected by age in this study, however numerically levels increased 
with age. Previous clinical studies in human patients have positively associated 
elevated triglyceride levels with the incidence of OA (Cheras, Whitaker et al. 1997) 
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however this study was carried out in patients with degenerative hip OA. Although 
elevated serum cholesterol and triglyceride levels were not correlated with OA 
severity in this study, it must be noted that all animals presented with mild 
osteoarthritic lesions which have previously been shown to continue to progress until 
18 months of age (Bendele 2001). It is therefore possible that a potential relationship 
between serum cholesterol / triglyceride and OA may become apparent as disease 
progresses.  
 
^ĞƌƵŵ ĐǇƚŽŬŝŶĞ ĂŶĂůǇƐŝƐ ǁĂƐ ƉĞƌĨŽƌŵĞĚ ďǇ >ƵŵŝŶĞǆ ? ĂŶalysis as described in 
CHAPTER 5.2.6.  Cytokine determination revealed that although the majority of 
cytokines and chemokines remained static with advancing age, regulated upon 
activation, normal T-cell expressed and secreted (RANTES) concentration was 
significantly elevated around the time of OA initiation (3 months), and decreased 
with age thereafter. RANTES has been implicated in articular cartilage degradation by 
the enhancement of matrix metalloproteinase - 3 (MMP-3) production and 
suppression of proteoglycan in osteoarthritic chondrocytes (Yuan, Masuko-Hongo et 
al. 2001). Moreover, elevated serum RANTES concentrations have been specifically 
associated with active osteoarthritic disease when compared with healthy controls 
and people with established, non-active disease (Toncheva, Remichkova et al. 2009) 
suggesting that RANTES expression may play a role in the initial development of 
osteoarthritic disease. 
 
 It is noteworthy that other articular joints have yet to be assessed with respect to 
osteoarthritis in the Dunkin Hartley strain guinea pig. It must therefore be retained 
that elevated RANTES could, for example, be attributed to disease in a distant 
articular joint. 
 
5.4.5  ? Correlation between OA severity and biomarkers of skeletal muscle function 
Correlation between the severity of knee OA in the 24 subjects analysed, and the 
various measures of weight and muscle function revealed that OA severity was 
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correlated principally with bodyweight, however a strong positive correlation 
between OA severity and MHC IIX mRNA abundance was also statistically significant. 
MHC IIX mRNA expression was markedly elevated around the time of OA initiation (3 
months), adding further weight towards an association between muscle fibre-type 
and OA severity. Numerous studies have correlated OA with body mass both in the 
human population (Arden and Nevitt 2006; Grotle, Hagen et al. 2008) and in the 
Dunkin Hartley strain as utilised here (Bendele and Hulman 1991; Bendele 2001; 
Hyttinen, Arokoski et al. 2001). Furthermore, dietary restriction resulting in 
decreased bodyweight has been shown to reduce OA lesion severity in the Dunkin 
Hartley strain (Bendele and Hulman 1991). Increased MHC IIX mRNA expression may 
be indicative of increased expression of fast glycolytic muscle fibres. Although fibre 
type was not directly assessed in this study, if fast glycolytic fibres were expressed at 
the expense of slow, stabilising muscle fibres, it is therefore possible that altered 
joint biomechanics may be implicated in the development and progression of 
osteoarthritis in this strain. 
 
OA was significantly negatively correlated with quadriceps skeletal muscle expression 
of MuRF, MAFBx and calpain III at the mRNA level. These findings suggest that the 
severity of osteoarthritis was not associated with skeletal muscle proteolysis 
routinely reported in muscle atrophy conditions (Lecker, Jagoe et al. 2004). 
Considered in association with the lack of quadriceps to body mass ratio 
perturbations noted previously, and the age-related decreased in pro-apoptotic Bax 
mRNA expression, these changes suggest that skeletal muscle atrophy is not 
associated with OA severity in the Dunkin Hartley guinea pig.   
 
Furthermore, correlation analysis between serum cytokine and chemokine levels and 
OA severity revealed no significant association with any of the factors assessed, 
suggesting that OA severity differed irrespective of inflammatory status. Only one 
study directly assessing cytokine and chemokine levels in the Dunkin Hartley strain 
has been conducted to date. The authors reported that the histological grade of 
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osteoarthritis was significantly associated with serum interleukin-6 (IL-6) and 
granulocyte colony-stimulating factor (G-CSF) concentration (Huebner, Seifer et al. 
2007). Although the data obtained in this study does not concur with the 
observations of Huebner and colleagues, 2007, several differences in the study 
design exist which may preclude the direct comparison of results. Firstly, the oldest 
animals assessed within this thesis were 7 months of age whereas Huebner and 
colleagues were able to obtain animals up to 18 months of age when osteoarthritic 
changes are more pronounced.  Secondly, Huebner and colleagues had access to 
control animals (Strain 13), which have become subsequently unavailable due to out-
breeding, which permitted them to control for strain differences prior to correlating 
cytokine concentrations with histological evidence of OA.  
 
When considering further studies utilising the Dunkin Hartley strain guinea pig, the 
natural progression would be to perform an intervention study assessing the effects 
of clenbuterol induced hypertrophy on disease progression. This experimental design 
(treated verses control) would also circumvent the problems associated with 
obtaining a suitable control strain, as the untreated Dunkin Hartley guinea pigs would 
suffice for this purpose. 
 
5.4.6  ? Summary 
In summation, this study confirmed that the spontaneous development of knee OA in 
the Dunkin Hartley strain was indeed associated with altered quadriceps muscle 
properties. Data suggest that the development of OA in the Dunkin Hartley guinea 
pig was associated with changes in MHC expression, indicative of altered quadriceps 
muscle fibre type. Conversely, assessment of quadriceps mass and the expression of 
proteolytic signalling factors suggested that overt skeletal muscle atrophy did not 
develop coincident with OA in this strain. Taken together, these findings suggest that 
altered quadriceps function was more likely a product of altered MHC expression, 
and by inference altered muscle function, than of altered skeletal muscle mass per 
se. 
191 
 
CHAPTER 6 - THE EFFECTS OF OSTEOARTHRITIS ASSOCIATED CYTOKINES 
ON MARKERS OF MUSCLE DYSFUNCTION IN VITRO  
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6.1  ? Introduction 
 
Although traditionally osteoarthritis has been considered a non-inflammatory 
disease, the role of inflammatory cytokines such as TE&ɲ ĂŶĚ /> ?ɴ ŝŶ ƚŚĞ
pathogenesis of OA has gained extensive interest due to their involvement during 
disease initiation and progression, and the potential benefits of anti-cytokine 
therapeutics (Goldring 1999). Although there is still some disagreement within the 
ĐƵƌƌĞŶƚ ůŝƚĞƌĂƚƵƌĞ ? ŝƚ ŝƐŐĞŶĞƌĂůůǇĂĐĐĞƉƚĞĚƚŚĂƚ /> ?ɴ ŝƐ ŝŶǀŽůǀĞĚ ŝŶƚŚĞĞĂƌůǇĂŶĚ ůĂƚĞ
ƐƚĂŐĞƐ ŽĨ K ǁŚŝůƐƚ dE&ɲ ŝƐ ŝŶǀŽůǀĞĚ ĂůŵŽƐƚ ĞǆĐůƵƐŝǀĞůǇ ŝŶ ƚŚĞ ŝŶŝƚŝĂƚŝŽŶ ŽĨ
osteoarthritic changes (Goldring 1999), and considered a principal pro-inflammatory 
ĐǇƚŽŬŝŶĞ ? ŽƚŚ dE&ɲ ĂŶĚ /> ?ɴ are thought to be produced locally, by the inflamed 
synovium and chondrocytes (Chen, Lin et al. 2008) and are thought to contribute to 
the development and progression of OA via their ability to inhibit proteoglycan 
synthesis in chondrocytes (Fernandes, Martel-Pelletier et al. 2002). Moreover, 
extensive cell culture studies using chondrocytes or cartilage fragments have 
ĚĞŵŽŶƐƚƌĂƚĞĚƚŚĂƚdE&ɲ ?ŝŶĐŽŵďŝŶĂƚŝŽŶǁŝƚŚ/> ?ɴǁĂƐĂďůĞŝŶŝŶĚƵĐĞĚĞŐƌĂĚĂƚŝŽŶŽĨ
the cartilage matrix (Westacott and Sharif 1996; Goldring 1999).  
 
Although neither cytokine was found to be significantly elevated in association with 
the early stages of developing OA in the guinea pig model of disease (CHAPTER 5), 
extensive evidence reports their involvement in the human condition (Westacott 
1990; Westacott and Sharif 1996; Fernandes, Martel-Pelletier et al. 2002)  and it is 
therefore noteworthy as to whether these factors are able to induce changes in 
skeletal muscle phenotype and therefore ascertain whether they could, potentially 
be responsible for the skeletal muscle changes associated with OA of the knee. 
  
In order to assess the direct effects of cytokine treatment on skeletal muscle 
phenotype in the absence of other confounding factors, an in vitro model utilising 
rat-derived L6.G8.C5 myotubes was proposed. The myogenic L6.G8.C5 cell line was 
originally developed by Yaffe, 1968 (Yaffe 1968) and exhibits many myogenic 
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characteristics including the formation of myoneural junctions, contractility and the 
expression of creatine kinase (Elsner, Quistorff et al. 1998). Despite many 
publications spanning almost 50 years, little information is available with regards the 
myosin heavy chain (MHC) expression profile of this cell line. Whilst some 
publications suggest that the L6 cell lines express embryonic, neonatal and adult 
MHC IIB mRNAs  (Arcangelis, Coletti et al. 2005), others suggest that the cells are 
committed to producing MHC IIX fibres only (Pin and Merrifield 1997). It was 
therefore necessary to characterise the basal MHC expression profile of the L6.G8.C5 
cell line prior to embarking on the cytokine treatment study.  
 
 
6.1.1  ? Hypotheses and aims  
Rat-derived myotubes (L6.G8.C5) will express a range of MHC isoforms, indicative of 
the presence of multiple fibre types, and thus model the in vivo situation. 
Osteoarthritis has been associated with both elevated serum dE&ɲ concentration 
and type II muscle fibre atrophy. It is therefore hypothesised that the administration 
ŽĨƌĞĐŽŵďŝŶĂŶƚƌĂƚdE&ɲƚŽƌĂƚ-derived myotubes will result in changes to their MHC 
composition, indicative of fibre type shifts. More specifically, it is hypothesised that 
dE&ɲ will induce a reduction in the abundance of fast-type II fibre specific mRNAs 
(MHC IIX, MHC IIB), providing these fibre-types are in fact expressed by the L6.G8.C5 
cell line. 
The following specific aims will be addressed; 
 
 Characterise the L6.G8.C5 cell line with respect to MHC expression 
 ŽůůĞĐƚƉƌĞůŝŵŝŶĂƌǇĚĂƚĂƌĞŐĂƌĚŝŶŐƚŚĞĞĨĨĞĐƚƐŽĨdE&ɲŽŶD,ĞǆƉƌĞƐƐŝŽŶ 
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6.2  ? Experimental Protocol 
 
6.3.1  ? Characterisation study 
L6.G8.C5 rat derived myoblasts were obtained from ECACC (92121114). Cells were 
seeded at a density of 60,000 cells / ml media onto 6-well plates (Nunc) and cultured 
in Glutamax- ? ? ŵĞĚŝĂ  ?'ŝďĐŽ ? /ŶǀŝƚƌŽŐĞŶ ? ƐƵƉƉůĞŵĞŶƚĞĚ ǁŝƚŚ  ? ?A?  ?ǀ ?ǀ ? ĨŽĞƚĂů ĐĂůĨ
serum (FCS), 100 units penicillin and 100µg streptomycin / ml media (Gibco). The 
anti-mycotic fungizone, commonly included within commercially available anti-biotic 
/ anti-mycotic preparations for cell culture, was not included within the media as 
previous studies have reported altered cell morphology and differentiation following 
its administration (Ilarraza-Lomeli, Cisneros-Vega et al. 2007). At approximately 80% 
confluence, total RNA was extracted from three random wells.  The remaining cells 
were differentiated into myotubes by culture in serum restricted Glutamax- ? ?ŵĞĚŝĂ
containing 2% horse serum (HS), 100 units penicillin and 100µg streptomycin / ml for 
4, 6 and 8 days respectively. At each time point, total RNA was extracted from three 
random wells. 
 
6.3.2  ? Cytokine treatment studies 
L6.G8.C5 cells were cultured as above until 4 days post differentiation. Cells were 
ƚƌĞĂƚĞĚ ǁŝƚŚ ǀĂƌǇŝŶŐ ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ŽĨ ƌĞĐŽŵďŝŶĂŶƚ ƌĂƚ dE&ɲ  ?ďĞƚǁĞĞŶ  ? ? ? ĂŶĚ
10,000pg / ml media) (Fisher) for 48 hours in triplicate. Following cytokine treatment, 
total RNA was extracted and stored at -80oC.  
 
6.3.3  ? RNA extraction, DNase digestion and reverse transcription 
Total RNA was extracted in accordance with (METHOD 2.1.1) with the exception that 
1ml TRIzol was added directly to the 6-well plate, and the cells scraped from the 
surface and passed through a 23-gauge needle 10-times rather than homogenising 
with a Polytron probe to reduce sample loss. Contaminating genomic DNA was 
removed in accordance with (METHOD 2.1.2), and complementary DNA (cDNA) 
generated as in (METHOD 2.1.5) using random primers (Promega).  
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6.3.4  ? Quantitative RT PCR 
The expression of myosin heavy chain (MHC) isoforms I, IIA, IIX and IIB were 
determined by quantitative PCR as described in (METHOD 2.1.7.2) using 
oligonucleotide primers published previously by Jaschinski et al, 1998 (Jaschinski, 
Schuler et al. 1998). The embryonic isoform of MHC (MHC-Emb) was also determined 
based upon L6.G8.C5 cells being essentially of neonatal origin. Finally, myogenin 
mRNA was determined as an index of myoblast differentiation, using primers 
directed against rat cDNA sequence accession number ENSRNOG00000030743 
(Ensemble Release 56). Oligonucleotide primer sequences are included within (TABLE 
6.1). Expression data was determined using the comparative CP / dCT method 
(CHAPTER 3.2.7) and all quantitative PCR reactions were normalised to the 
concentration of first strand cDNA (OliGreen, Invitrogen) (METHOD 5.2.7). 
 
6.3.5  ? Statistical analysis 
All data are reported as means + standard error of the mean (S.E.M).  Comparisons 
were performed using analysis of variance (ANOVA) between multiple groups. The 
ƵŶŶĞƚƚ ?ƐƉŽƐƚ-hoc test was used to test for significance relative to control. Symbols 
used to indicate statistical significance were; * P < 0.05; ** P < 0.01; *** P < 0.001. # 
P = < 0.1 was regarded as a trend (Tominaga, Ndu et al. 2006; Jung, Reichstein et al. 
2010). 
 
 
TABLE 6.1  W Oligonucleotide primer sequences for quantitative PCR reactions 
Gene Name Forward Primer (5' - 3') Reverse Primer (5' - 3') Amplicon (bp) 
MHC I ACAGAGGAAGACAGGAAGAACCTAC GGGCTTCACAGGCATCCTTAG 81 
MHC IIA TATCCTCAGGCTTCAAGATTTG TAAAATAGAATCACATGGGGACA 265 
MHC IIX CGCGAGGTTCACACCAAA TCCCAAAGTCGTAAGTACAAAATGG 178 
MHC IIB CTGAGGAACAATCCAACGTC TTGTGTGATTTCTTCTGTCACCT 129 
MHC - Emb AGCAGAGGAGGCTGAGGAACAATC GGCCTCCTCAAGATGCGTTTACTC 181 
Myogenin AGTGAATGCAACTCCCACAGC GTGGCGTCTGACACCAACTCA 254 
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6.3  ? Results  
 
6.3.1  ? Characterisation of L6.G8.C5 rat derived myoblasts 
 
6.3.1.1  ? Cell morphology 
Seeded myoblasts reached 80% confluence 2 days post seeding. Following serum 
restriction, cells began to elongate and form multinuclear complexes as shown in 
(FIGURE 6.1), with myotubes becoming increasingly large up until 8 days post 
differentiation. At 8 days post differentiation, cells were still firmly adhered to the 6 
well plates in which they were grown, suggesting that culture for longer than 8 days 
was possible. 
 
 
 
FIGURE 6.1  W Photomicrographs of L6.G8.C5 cells (P3) myoblasts, and 4, 6, and 8 days 
post differentiation (M4, M6, and M8 respectively) x 20 magnification. 
Photomicrograph P3 shows proliferating single nuclear fibroblastic cells. M4 to M8 
show cells fusing to form multinucleated myotubes of increasing maturation.  
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6.3.1.2  ? mRNA expression  
Myogenin mRNA was quantified as an index of myoblast differentiation. Myogenin is 
one of many myogenic regulatory factors (Witzemann and Sakmann 1991) involved 
in muscle differentiation (Buckingham 2001). Myogenin mRNA was barely detectable 
in proliferating myoblasts cultured in FCS-containing growth media at 80% 
confluence. Following differentiation, abundant myogenin mRNA was detected in all 
samples. Myogenin mRNA levels remained elevated until eight days post 
differentiation when the final samples were taken for analysis.  
 
 
 
 
FIGURE 6.2  W Myogenin mRNA expression in proliferating (P3), and differentiating 
(M4, M6, M8) muscle cells. Data are mean normalised expression units + S.E.M; n = 
3; significant differences expressed relative to P3. 
 
 
Isoform-specific MHC mRNA was quantified as an index of muscle fibre type variation 
to assess the suitability of the L6.G8.C5 cell line as an in vitro model of skeletal 
muscle in vivo. Embryonic MHC (MHC-Emb) mRNA was barely detectable in 
proliferating myoblasts cultured in FCS-containing growth media at 80% confluence. 
Following differentiation, abundant MHC-Emb was detected in all samples, the 
abundance of which increased until eight days post differentiation.  MHC I, IIX and IIB 
mRNAs were detected in both proliferating myoblasts and differentiated myotubes. 
In general, transcript abundance increased with the number of days post 
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differentiation. MHC IIA mRNA was not detected within the L6.G8.C5 cell line at any 
developmental stage (data not shown).  
 
 
 
 
 
FIGURE 6.3  W MHC embryonic (A), I (B), IIX (C), IIB (D) mRNA expression in 
proliferating (P3), and differentiating (M4, M6, M8) muscle cells. Data are mean 
normalised expression units + S.E.M; n = 3; significant differences expressed relative 
to P3. 
 
6.3.2  ? The effects of TNF Alpha on the expression of MHC 
Myotubes cultured until four days post differentiation were treated with rat 
recombinant TNFɲ at concentrations between 100 and 10,000pg / ml media for 48 
hours (METHOD 6.3.2). Following treatment, total RNA extraction and reverse 
transcription were carried out as previously described (METHOD 6.3.3). Myogenin 
mRNA was quantified as an index of myotube differentiation. Treatment with 
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ĐŽŶĐĞŶƚƌĂƚŝŽŶƐŽĨdE&ɲƌĂŶŐŝŶŐĨƌŽŵ ? ? ?  W 10000pg/ml had no effect on myogenin 
mRNA expression (P = 0.298) (FIGURE 6.4). 
 
 
 
FIGURE 6.4  W Myogenin mRNA expression of differentiated (M4) myotubes treated 
with rat recombŝŶĂŶƚdE&ɲĨŽƌ ? ?ŚŽƵƌƐ ? Data are mean normalised expression units 
+ S.E.M; n = 3; P value refers to one-way analysis of variance 
 
 
Isoform-specific MHC mRNA was quantified as an index of muscle fibre type 
ǀĂƌŝĂƚŝŽŶ ? dƌĞĂƚŵĞŶƚ ǁŝƚŚ ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ŽĨ dE&ɲ ƌanging from 100  W 10000pg/ml 
had no effect on the mRNA expression of embryonic MHC or slow-twitch associated 
MHC I (P = 0.352 and 0.608 ƌĞƐƉĞĐƚŝǀĞůǇ ? ?dƌĞĂƚŵĞŶƚǁŝƚŚƌĂƚƌĞĐŽŵďŝŶĂŶƚdE&ɲĚŝĚ
however significantly reduce MHC IIX mRNA although this effect was only evident 
when cells were treated with the two highest concentrations (1000 and 10000pg/ml 
respectively) (FIGURE 6.5).  
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FIGURE 6.5  W MHC embryonic (A), I (B), IIX (C), IIB (D) mRNA expression of 
differentiated (M4) myotubes treated with rat recŽŵďŝŶĂŶƚdE&ɲĨŽƌ ? ?ŚŽƵƌƐ ? Data 
are mean normalised expression units + S.E.M; n = 3; P values refer to one-way 
analysis of variance; Stars designate a significant difference from the control group. 
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6.4  ? Discussion  
 
The initial aim of this study was to characterise the L6.G8.C5 rat derived muscle cell 
line with respect to differentiation, and MHC mRNA expression profile. Following 
ƐƵŝƚĂďůĞĐŚĂƌĂĐƚĞƌŝƐĂƚŝŽŶ ?ƚŚĞĞĨĨĞĐƚƐŽĨƚŚĞŽƐƚĞŽĂƌƚŚƌŝƚŝƐĂƐƐŽĐŝĂƚĞĚĐǇƚŽŬŝŶĞdE&ɲ ?
on the MHC mRNA expression were assessed in vitro. 
 
L6.G8.C5 cells reached confluence in 6-well plates 48 hours post seeding, and reliably 
differentiated to form myotubes approximately 4 days after serum restriction. 
Although cells were harvested 8 days following differentiation, microscopically, they 
appeared viable and still firmly adhered to the 6-well plates in which they were 
cultured suggesting they would be amenable to more prolonged culture. Indeed, 
other studies utilising L6 myotubes have reported prolonged culture times as long as 
20 days (Graber and Woodworth 1986).  
 
Myogenin mRNA was determined as a marker of myoblast differentiation as reported 
previously (Park, Kim et al. 2002). Myogenin mRNA was barely detectable in 
proliferating myoblasts (n = 3). Following serum restriction, a marked increase in 
myogenin mRNA was noted with all samples showing strong expression. Expression 
persisted until 8 days post differentiation when the last samples were taken. These 
results were consistent with other studies utilising myogenin as a marker of 
differentiation on similar cell lines (Park, Kim et al. 2002). Myogenic differentiation 
involves the expression of a family of regulatory factors including Myf5, MyoD, MRF4 
and myogenin which belong to the basic helix-loop-helix transcription factor family 
(Edmondson and Olson 1993). Whereas skeletal muscle differentiation has been 
shown to proceed in the absence of Myf5 (Braun, Rudnicki et al. 1992) or MyoD 
(Rudnicki, Braun et al. 1992), the targeted disruption of myogenin has been reported 
to induce severe skeletal muscle deficiency and lethality (Hasty, Bradley et al. 1993; 
Nabeshima, Hanaoka et al. 1993).  
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As an index of the likely muscle fibre types expressed by the L6.G8.C5 cell line, MHC 
mRNA was determined. Proliferating myoblasts expressed slow-twitch MHC I, faster-
twitch MHC IIX and fast-twitch MHC IIB at the mRNA level. No embryonic MHC mRNA 
was detected in any of the samples of proliferating myoblasts. Following 
differentiation, the expression of MHC I, IIX and IIB increased with the number of 
days post differentiation. Embryonic MHC was also detected from 4 days post 
differentiation onwards and displayed a similar increase in expression as the cells 
became more differentiated. Interestingly, the expression of MHC IIA, linked with 
oxidative glycolytic muscle fibre types was not detected at any developmental stage 
suggesting the absence of this fibre type. When considering these results in light of 
previous publications, it is clear that much variation exists within the literature. 
Whilst Arcangelis and colleagues, 2005 found that the L6 cell line expressed 
embryonic, neonatal and adult MHC IIB mRNAs  (Arcangelis, Coletti et al. 2005), Pin 
and colleagues, 1997 (Pin and Merrifield 1997) found the L6 cell line to be committed 
to the production of MHC IIX fibres only. These discrepancies may be due in part to 
ƚŚĞ ǀĂƐƚ ĂƌƌĂǇ ŽĨ ĚŝĨĨĞƌĞŶƚ ĐĞůů ůŝŶĞƐ ƚĞƌŵĞĚ  “> ? ? ? ǁŚŝĐ  ĂƉƉĞĂƌ ŚĂǀĞ ƐƵďƚůĞ
differences in their MHC profile (Pin and Merrifield 1997; Arcangelis, Coletti et al. 
2005) or the methods used to assess MHC composition.  
 
MHC determination was performed at the mRNA level in this study and not by the 
electrophoretic separation of MHC protein. This was purely due to insufficient 
material being available from cells grown in 6-well plates to permit both mRNA and 
protein extraction. The characterisation of MHC expression at the protein level would 
further enhance the utility of this study as it is the expression of MHC isoform 
specific proteins that essentially contribute towards muscle contractility. 
 
With reference to osteoarthritis, L6.G8.C5 cells were treated with recombinant rat 
dE&ɲ ? Ă ĐĂƌĚŝŶĂů ƉƌŽ-inflammatory cytokine implicated in the pathogenesis of 
osteoarthritis, for 48 hours. dŚĞ ĚŽƐĂŐĞ ƌĂŶŐĞ ŽĨdE&ɲǁĂƐ ƐĞůĞĐƚĞĚƚŽĞŶĐŽŵƉĂƐƐ
pathological values in both osteoarthritis (mean 500pg/ml synovial fluid) and 
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rheumatoid arthritis (mean 390pg/ml synovial fluid) (Westacott 1990; Westacott and 
Sharif 1996), and include treatment at supra-pathological levels ?dE&ɲƚƌĞĂƚŵĞŶƚŚĂĚ
no discernable effects on differentiation as determined by myogenin mRNA, or the 
expression of embryonic MHC or D,/ ?dE&ɲƚƌĞĂƚŵĞŶƚĚŝĚŚŽǁĞǀĞƌŵŽĚƵůĂƚĞƚŚĞ
expression of MHC IIX by significantly reducing MHC IIX mRNA abundance. MHC IIX 
perturbations are noted in several pathologies with a component of skeletal muscle 
dysfunction. Although specific muscle fibre involvement in osteoarthritis has not 
been consistently described, the consensus is that fast-type muscle fibres atrophy 
preferentially to slow muscle fibres. Contrary to many laboratory species which 
express three fast fibre types (Weiss and Leinwand 1996), MHC IIX fibres are the 
fastest isoform expressed in the human (Harridge 2007). It is therefore possible that 
MHC IIX fibres are responsible for the reduction in quadriceps mass noted in 
osteoarthritic patients. Furthermore,  a distinct reduction in MHC IIX mRNA is noted 
in age related sarcopenia (Chow and Nair 2005; Boirie 2009) and a trend association 
in chronic obstructive pulmonary disease (Wijnhoven, Janssen et al. 2006). 
Interestingly all of the above conditions are aƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ŝŶĐƌĞĂƐĞĚ dE&ɲ
production (Phillips and Leeuwenburgh 2005; Matera, Calzetta et al.) and reduced 
MHC IIX fibre expression. MHC IIX mRNA was found to be elevated in the Dunkin 
Hartley model of knee-OA as reported in CHAPTER 5.3.6. Although the increase in 
MHC IIX mRNA is suggestive of increased MHC IIX containing muscle fibre 
abundance, it could also be a reparative response to reduced MHC IIX protein and 
certainly warrants further assessment at the protein level.   
 
TŚĞĞĨĨĞĐƚƐŽĨdE&ɲĂƌĞĞůŝĐŝƚĞĚďǇŝƚƐďŝŶĚŝŶŐƚŽƐƉĞĐŝĨŝĐƌĞĐĞƉƚŽƌƐ  ?dE&Z ? ?dE&Z ? ? ?
present on the cell surface of most cell types (Baud and Karin 2001) ?dE&ɲŚĂƐďĞĞŶ
reported to stimulate a large array of signalling events including the induction of 
ĂƉŽƉƚŽƐŝƐ ?ĂĐƚŝǀĂƚŝŽŶŽĨƚŚĞE&ʃɴƉĂƚŚǁĂǇ(Naggar, Kanda et al. 2004) and activation 
of the PI3K pathway (Kim, Lee et al. 1999) ? /ƚ ŝƐ ŽŶĞ ƉŽƐƐŝďŝůŝƚǇ ƚŚĂƚ dE&ɲ ŵĂǇ ďĞ
responsible for the induction of specific muscle fibre atrophy noted in numerous 
conditions associated with skeletal muscle dysfunction. Indeed, Naggar and 
204 
 
ĐŽůůĞĂŐƵĞƐ ŚĂǀĞ ƉƌĞǀŝŽƵƐůǇ ƌĞƉŽƌƚĞĚ ƚŚĂƚ dE&ɲ ĚĞĐƌĞĂƐĞĚ ƚŚĞ expression of 
myofibrillar proteins in L6 cells (Naggar, Kanda et al. 2004). With reference to the 
ƐƉĞĐŝĨŝĐ ĞĨĨĞĐƚƐ ŽĨ dE&ɲŽŶ D, //y ŶŽƚĞĚ ŝŶ ƚŚŝƐ ƐƚƵĚǇ ? WůŽŵŐĂĂƌĚ ĂŶĚĐŽůůĞĂŐƵĞƐ
ŚĂǀĞƌĞƉŽƌƚĞĚƚŚĂƚdE&ɲĞǆƉƌĞƐƐŝŽŶǁĂƐůŽĐĂůŝƐĞĚŝŶƚǇƉĞ//ĨĂƐƚŵƵƐĐůĞĨŝďƌĞƐ ?ǁith 
ŶŽ ĞǀŝĚĞŶĐĞ ŽĨ dE&ɲ ĞǆƉƌĞƐƐŝŽŶ ŝŶ ƐůŽǁ ƚǇƉĞ / ĨŝďƌĞƐ (Plomgaard, Penkowa et al. 
2005) ?&ƵƌƚŚĞƌŵŽƌĞ ?ŝƚŝƐƉŽƐƐŝďůĞƚŚĂƚdE&ɲƌĞĐĞƉƚŽƌĂďƵŶĚĂŶĐĞŵĂǇǀĂƌǇďǇŵƵƐĐůĞ
fibre type and therefore represent another plausible way by which fibre-specific 
ĞĨĨĞĐƚƐ ŵĂǇ ďĞ ŝŶĚƵĐĞĚ ?  ,ŽǁĞǀĞƌ ? dE&ɲ ƌĞĐĞƉƚŽƌ ĂďƵŶĚĂŶĐĞ ŝŶ ĚŝĨĨĞƌĞŶƚ ŵƵƐĐůĞ
fibres has not been studied to date. 
 
ůƚŚŽƵŐŚ ŽƚŚĞƌ ƉĂƚŚŽůŽŐŝĞƐ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ďŽƚŚ ŝŶĐƌĞĂƐĞĚ dE&ɲ ƉƌŽĚƵĐƚŝŽŶ ĂŶĚ
reduced MHC IIX may provide some confirmatory evidence for the in vitro results 
obtained here, it must be noted that MHC IIX mRNA was reduced only at the two 
ŚŝŐŚĞƐƚdE&ɲĐŽŶĐĞŶƚƌĂƚŝŽŶƐ  ? ? ? ? ?ĂŶĚ  ? ? ? ? ?ƉŐ ?ŵůƌĞƐƉĞĐƚŝǀĞůǇ ? ?ďŽƚŚ ŝŶĞǆĐĞƐƐŽĨ
the concentrations reported in the synovial fluid of osteoarthritic joints (500pg/ml). 
Furthermore, the lack of MHC IIA mRNA expression is an important consideration 
when evaluating the L6.G8.C5 cell line as an in vitro model of skeletal muscle 
development or pathology. When considering the reduction in MHC IIX mRNA noted 
ŝŶƌĞƐƉŽŶƐĞƚŽdE&ɲĂĚŵŝŶŝƐƚƌĂƚŝŽŶ ?ƚŚĞĂďƐĞŶĐĞŽĨD,// ?ĂƐĚĞƚĞƌŵŝŶĞĚĚƵƌŝŶŐ
the characterisation studies) may preclude any observations given that MHC IIA and 
MHC IIX are encoded by iteratively located genes (Weiss and Leinwand 1996), and 
some evidence suggests that they are co-regulated  (Pandorf, Haddad et al. 2006). It 
is therefore possible that the absence of MHC IIA expression will likely influence 
basal levels of MHC IIX prior to any experimental procedures, making the 
extrapolation of in vitro data to the in vivo situation more tentative. 
 
Finally, it is necessary to consider the relationship between in vitro findings and the 
in vivo setting in which they may be inferred. The L6 cell lines has been utilised in 
skeletal muscle research since its development in 1968. The L6 line displays many 
myogenic characteristics including the formation of myoneural junctions, 
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contractility and the expression of creatine kinase (Elsner, Quistorff et al. 1998). 
Moreover, the cell line has also been shown to respond to various treatments 
including dexamethasone induced atrophy (Sultan, Henkel et al. 2006) and IGF-1 
induced hypertrophy (Li, Hasselgren et al. 2004) as would be expected in skeletal 
muscle. A disadvantage of myotube culture is that cells are not routinely maintained 
under stretch, which has been previously shown to regulate skeletal muscle mass 
and fibre type (Wang, Kawano et al. 2006; Giger, Bodell et al. 2009), and may 
therefore limit the extrapolation of results from the in vitro to in vivo setting. More 
recent advances in cell culture techniques have described the development of cell 
culture plates, able to maintain myotubes under stretch and or electrical stimulation 
during experimentation, which may enhance the translational value of in vitro results 
in the in vivo setting (Ebihara, Hussain et al. 2002).   
 
In conclusion, the data presented here report that the L6.G8.C5 cell line is readily 
differentiated into myotubes using standard cell culture techniques, and that the 
resulting myotubes express all the adult isoforms of MHC with the exception of MHC 
// ? dE&ɲ ƚƌĞĂƚŵĞŶƚ ƌĞƐƵůƚĞĚ ŝŶ Ă ƌĞĚƵĐƚŝŽŶ ŝŶ D, //y ŵZE ŚŽǁĞǀĞƌ ƚŚĞ
ĐŽŶĐĞŶƚƌĂƚŝŽŶ ŽĨ dE&ɲ ƌĞƋƵŝƌĞĚ ƚŽ ĞůŝĐŝƚ ƚŚŝƐ ĐŚĂŶŐĞ ǁĂƐ ǁŝƚŚŝŶ ƚŚĞ ƐƵƉƌĂ-
pathological range. Given the lack of MHC IIA mRNA expression, the L6.G8.C5 cell line 
should be used with caution when attempting to model skeletal muscle development 
or pathology, in particular those conditions resulting in type II fibre muscle 
dysfunction. 
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CHAPTER 7  ? GENERAL DISCUSSION 
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7.1  ? Introduction and overall aims 
 
It is established that patients with knee osteoarthritis (OA) exhibit marked muscle 
weakness, one of the most frequent and earliest reported symptoms associated with 
knee OA. Weakness primarily affects the quadriceps muscle with little evidence of 
hamstring involvement. Traditionally, muscle weakness has been considered a 
secondary effect in knee OA, resulting from disuse of the affected joint due to the 
presence of pain and/or inflammation, and therefore has received little attention 
with regards to its involvement in the initiation or progression of OA. However, there 
is clinical evidence which suggests that quadriceps weakness may precede the onset 
of radiographic evidence of OA and subsequent pain, and therefore may be directly 
involved in its pathogenesis. Furthermore, targeted exercise regimes aimed at 
improving quadriceps function indicate therapeutic benefits with regards to both the 
initiation and progression of knee OA.  
 
Quadriceps muscle dysfunction in knee OA is currently poorly understood and 
represents a great and unmet clinical need. Unlike other atrophy associated 
conditions which have well-established effects on specific muscle fibre-types, it is 
unclear as to whether atrophy in OA is fibre-type specific. Whilst the majority of 
evidence suggests that type II fibres are preferentially affected (Nakamura and Suzuki 
1992), others report that up to one third of patients present with type I atrophy 
(Fink, Egl et al. 2007).  
 
In attempting to better understand the involvement of skeletal muscle in the 
initiation and progression of OA, the aims of this work were to characterise changes 
in the quadriceps skeletal muscle in two independent animal models of OA; the rat 
meniscectomy induced model, and the spontaneous development of OA in the 
Dunkin Hartley strain guinea pig. MHC isoform composition was used to detect 
subtle changes in skeletal muscle contractile phenotype whilst lactate 
dehydrogenase (LDH) and isocitrate dehydrogenase (ICDH) activity were determined 
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as an assessment of quadriceps metabolic potential. Throughout this work, evidence 
of skeletal muscle proteolysis, associated with atrophy, was determined by the 
assessment of several known atrophy associated factors (reviewed in CHAPTER 
1.3.6).  
 
Moreover, in attempting to assess the disease modulating potential of increased 
quadriceps skeletal muscle mass and increased type II fibre content prior to the 
development of OA, the ĞĨĨĞĐƚƐ ŽĨ ɴ ?-agonist administration on disease severity 
were assessed. &ŝŶĂůůǇƚŚĞĞĨĨĞĐƚƐŽĨdE&ɲŽŶƐŬĞůĞƚĂůŵƵƐĐůĞĐĞůůƐǁĞƌĞĚĞƚĞƌŵŝŶĞĚ
to investigate whether OA-associated cytokines were able induce the muscle fibre 
atrophy so commonly noted in the human condition.   
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7.2  ? Summary of Findings 
 
7.2.1 - The effects of osteoarthritis on markers of muscle function 
It was hypothesised that the development of OA would be associated with 
quadriceps muscle atrophy, predominantly affecting type II muscle fibres, presenting 
as a reduction in quadriceps mass and in MHC isoforms IIX and IIB. Whilst rat 
meniscal tear induced disease was associated with marginal quadriceps atrophy (as 
evidenced by reduced quadriceps mass relative to body mass), OA in the guinea pig 
was not associated with any gross changes to quadriceps mass. The induction of OA 
in the rat meniscal tear model was associated with the induction of MHC I, indicative 
of an increase in type I muscle fibres. Considerable inter-animal variation in MHC I 
mRNA was also noted in guinea pigs developing spontaneous knee arthritis 
(CHAPTER 5.3.6) around the time of disease initiation however this observation was 
not statistically significant given the small number of animals utilised. The two 
models differed with respect to their expression of MHC IIX, related to fast-twitch 
type II muscle fibres, which was increased in the guinea pig spontaneous model of 
OA, but remained unaltered in the rat. Indeed, MHC IIX expression was significantly 
correlated with disease severity in the guinea pig. Notably, neither of the two models 
assessed showed evidence of reduced type II muscle fibre-associated MHC isoforms.  
 
MHC I expression is associated with slow, postural anti-gravity muscles such as the 
soleus (Adams, Haddad et al. 1994). Although the induction of MHC I expression in 
the rat surgical model of OA could have perhaps been considered a response to joint 
destabilisation following transection of the collateral ligament (CHAPTER 3.2.3), the 
induction of inter-animal variation in the guinea pig suggests that this is more likely 
to be associated with the development of OA. The isolated effect of induced MHC IIX 
expression in the guinea pig is perhaps more difficult to reason. Whilst increased 
MHC IIX expression has not been previously associated with OA, it has been reported 
following the development of disuse atrophy in rodents (Caiozzo, Haddad et al. 1996; 
Adams, Haddad et al. 2000). This would not however explain why MHC IIX expression 
210 
 
was induced only around the time of disease initiation and not thereafter and 
warrants further investigation. There is a large body of evidence from human studies 
reporting reduced type II fibre number or cross-sectional area in response to 
developing OA when assessed by histochemical techniques. However, data derived 
from this study of MNX-induced and spontaneous OA suggest that altered skeletal 
muscle function may result preferentially from increased type I fibre-associated MHC 
isoforms rather than from reduced type II fibres or muscle mass per se. In considering 
the difference in the muscle fibre-type data presented here and in other 
histochemical studies, it is possible that increased type I fibre number or cross-
sectional area may artificially reduce the apparent abundance of other muscle fibre 
types when assessed by traditional histochemical techniques. It is therefore 
considered that the use of MHC protein electrophoretic techniques, as reported 
here, gives a more accurate overview, indicative of muscle fibre-type properties. 
 
7.2.2 - The effects of osteoarthritis on markers of atrophy 
As reviewed in CHAPTER 1, numerous atrophy conditions are associated with the 
induction of a similar set of genes which include the E3 ligases, the calpain system 
and apoptotic-associated factors Bax and Bcl2 (Lecker, Jagoe et al. 2004). The mRNAs 
of these systems were quantified by quantitative PCR in both in vivo models of 
disease. It was subsequently hypothesised that the same proteolytic systems 
implicated in the pathogenesis of numerous other atrophy associated conditions, 
would be noted in response to developing OA.  
 
The expression of E3 ligases MuRF and MAFBx was unaffected by the development of 
OA in both experimental models, suggesting that degradation via the proteasome 
system was not associated with the development of osteoarthritis. Although E3 
ligase activity has received little attention with reference to human OA, this result is 
of interest given that these factors are consistently elevated in numerous atrophy 
conditions (Dehoux, van Beneden et al. 2003; Lecker, Jagoe et al. 2004; Glass 2005) 
and that human knee-OA is associated with marked muscle atrophy (reviewed in 
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CHAPTER 1.3.8). Similar results were obtained for calpains I  W III, which were also 
unmodified in both disease models. Apoptotic potential of the quadriceps skeletal 
muscle was determined by quantification of mRNAs encoding pro-apoptotic Bax and 
anti-apoptotic Bcl2. The development of OA in the rat was not associated with 
expression changes in Bax mRNA; however Bax was reduced with advancing age in 
the guinea pig. Bcl2 mRNA remained unaltered by disease in both animal models of 
OA. The assessment of factors involved in muscle atrophy signalling, interpreted in 
context with quadriceps mass data and muscle fibre type assessment suggest that 
the muscle dysfunction noted in response to developing OA was most strongly 
associated with changes in muscle function rather than mass per se. 
 
7.2.3  ? The effects of clenbuterol pre-treatment on OA severity 
The effects of clenbuterol-induced quadriceps hypertrophy prior to the development 
of OA were investigated in the rat model of OA.  It was hypothesised that clenbuterol 
would induce skeletal muscle hypertrophy, and increase expression of fast-twitch 
muscle fibres detected as increased MHC IIX and IIB expression. Furthermore, it was 
hypothesised that increased quadriceps mass, with a faster contractile phenotype, 
would reduce disease severity following the induction of OA.  
 
Preliminary data demonstrated that clenbuterol administration induced marked 
quadriceps hypertrophy. Clenbuterol did not modulate the MHC composition of the 
quadriceps skeletal muscle following 14 days of administration although this was 
likely due to the high baseline complement of fast muscle fibres (CHAPTER 3, FIGURE 
3.2). The study design permitted the marked induction of skeletal muscle 
hypertrophy specifically prior to the induction of OA which enabled the assessment 
of whether a larger quadriceps was protective of OA severity following disease 
development. The quadriceps mass of the treated subjects was significantly larger at 
the time of OA induction, however the increased muscle mass was lost by the study 
end point. Clenbuterol administration was able to ablate the OA associated increase 
in MHC I protein noted in saline treated animals, however disease severity remained 
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unaltered. A full discussion of the effects of clenbuterol pre-treatment is included in 
CHAPTER 3.  
 
7.2.4  ? Characterisation of the guinea pig sarcomeric myosin heavy chain family 
The characterisation of the sarcomeric myosin heavy chain family in the guinea pig 
(CHAPTER 4) elucidated partial cDNA sequence data for MyH 1, 2 and 4 (MHC IIX, IIA, 
IIB). Furthermore, this study reported and validated a set of specific oligonucleotide 
primers for the differential determination of MHC isoforms I, IIA, IIX and IIB. Perhaps 
most striking is the observation that guinea pig MHC isoform-specific cDNAs and 
their promoter sequences appeared to be more closely related to the human than to 
other small mammals. This data is of considerable use to the numerous research 
groups who utilise the guinea pig in translational research, and also furthers our 
limited knowledge of this species.   
 
7.2.5  ? The effects of OA-associated cytokines on markers of muscle function 
The L6.G8.C5 cell line was found to readily differentiate into myotubes using 
standard cell culture techniques. The resulting myotubes were found express all of 
ƚŚĞĂĚƵůƚŝƐŽĨŽƌŵƐŽĨD,ǁŝƚŚƚŚĞĞǆĐĞƉƚŝŽŶŽĨD,// ?dE&ɲƚƌĞĂƚŵĞŶƚƌĞƐƵůƚĞĚŝŶ
a reduction ŝŶD,//yŵZEŚŽǁĞǀĞƌƚŚĞĐŽŶĐĞŶƚƌĂƚŝŽŶŽĨdE&ɲƌĞƋƵŝƌĞĚƚŽĞůŝĐŝƚ
this change was within the supra-pathological range. The finding that the L6.G8.C5 
cell line lacks the expression of MHC IIA is considered to have important implications 
in the in vitro modelling of disease. In particular, caution should be exercised when 
modelling diseases known to result in perturbations in type II muscle fibres in this cell 
line. 
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7.3  ? Limitations 
 
As with all scientific studies, it is necessary to consider possible limitations, in 
particular when utilising in vivo models of pathology. Many animal models of OA 
have been developed as tools to study the pathogenesis and progression of the 
disease. Some models serve to elucidate new mechanisms and pathways, whilst 
others are employed in the pharmacological testing of new anti-arthritic drugs and 
analgesics. Due to the rapid time-course over which OA develops in some of the 
induced models, and fundamental inter-species variations, it is appreciated that no 
single experimental model is without its disadvantages. The rat meniscectomy model 
is characterised by the rapid onset of well defined osteoarthritis-like lesions on both 
tibial and femoral condyles  W although a predisposition to increased tibial severity 
was noted in this study. Due to the regimented and consistent onset of disease, this 
model is particularly useful for targeting specific phases of its pathogenesis. For 
intervention studies, previous research recommends pre-treating animals with the 
experimental compound to a steady serum concentration prior to surgery (Bendele 
2001), as in this study. In terms of comparative pathogenesis, lesions in this model 
are morphologically similar to those of human OA (Bendele 2001), but occur at a 
significantly enhanced rate. It is considered that lesions progress as such due to the 
apparent lack of perception of the animal that it should discontinue use of the 
unstable joint, a key difference with respect to the human condition. Technically, this 
offers a restricted opportunity in which to elicit physiological changes prior to disease 
initiation as noted previously (Bendele 2001). It is therefore possible that potential 
improvements in OA that may be evident in the human population are precluded by 
the rapid onset and progression of disease in this rodent model.  
 
The spontaneous development of knee OA in the Dunkin Hartley guinea pig (as 
utilised in CHAPTER 5) is considered to be an improvement on surgically induced 
disease models in terms of its comparative pathology and translational research 
value (reviewed in CHAPTER 5.1). Despite this, the development of OA in the Dunkin 
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Hartley stain coincided with the longitudinal growth phase in this study. Due to the 
lack of a suitable control strain, separating the effects of osteoarthritis from those of 
normal growth was therefore more complex and restricted the assessment of muscle 
dysfunction and OA to the level of a correlation as reported in CHAPTER 5.3. The use 
of an intervention based protocol, and therefore the opportunity to compare treated 
and control subjects, would ensure more robust data was derived from subsequent 
studies.  
 
A further possible limitation of this collection of studies is the methodology utilised 
for the determination of skeletal muscle fibre characteristics. Due to the lack of 
reliable methodology by which to resolve the four MHC proteins in the guinea pig, an 
mRNA quantification technique was developed (CHAPTER 4) and utilised for the 
determination of MHC expression in the guinea pig quadriceps. Conversely, high-
resolution MHC protein electrophoresis was used to determine the MHC expression 
profile in the rat skeletal muscle samples. Although MHC profile in the two models 
was therefore quantified by different techniques, both MHC mRNA and protein 
measurements have been previously shown to correlate strongly (Marx, Kraemer et 
al. 2002) in addition to correlating well with other measures of fibre-type including 
mATPase staining, MHC immunohistochemistry and metabolic profile (Quiroz-Rothe 
and Rivero 2004). Despite this, it is likely that the quantification of specific MHC 
mRNAs enabled the detection of earlier changes indicative of muscle fibre-type 
transitions, given that a change in mRNA abundance is usually required to elicit a 
change in each respective MHC protein.   
 
 
7.4  ? Overview 
Considering only changes found to be concordant between both in vivo models of 
knee OA, the most striking observation was that the modulation of quadriceps 
parameters, indicative of contractile and metabolic function, coincided with the 
development of OA in both model species utilised. The quadriceps changes were 
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characterised by the induction of MHC I expression noted at the protein level in the 
rat and mRNA level in the guinea pig. Moreover, the expression of MHC IIX appeared 
to be correlated with disease severity in the guinea pig, although this correlation was 
derived from small animal numbers (n = 6).  Equally striking is that neither model 
presented with overt quadriceps muscle atrophy or increased atrophy signalling. It 
thus appears that altered quadriceps function in OA may result from altered 
contractile and metabolic properties rather than reduced mass which may have 
important implications for treatment and rehabilitation regimes.  
 
 
7.5  ? Main Implications and Future Work 
 
It is considered that the data presented within this thesis raise important issues with 
respect to our understanding of muscle dysfunction and OA, and therefore have 
potential implications in the design of pharmaceuticals and rehabilitation regimes for 
the treatment of OA. Although further human clinical studies are required to confirm 
the observations reported here, the apparent induction of MHC I as opposed to the 
anticipated reduction in fast-twitch fibre-associated MHC may highlight new targets 
with which to develop novel pharmaceuticals and therefore warrants further 
investigation as outlined below.  
 
Given the numerous beneficial findings obtained from this series of studies, it is felt 
that further scientific work is warranted. Firstly, it is suggested that any further study 
should include a physiological assessment of quadriceps function and thus draw 
comparison between the MHC isoform composition as determined by 
electrophoresis and functional aspects of the quadriceps muscle. Fish and colleagues 
have previously described an electrophysiological method for the determination of 
maximal twitch, maximal rate of rise of twitch tension, maximal time to peak tension 
and fatigue (Fish, McKee et al. 1989). It is felt that such measurements would 
complement existing MHC determination. In terms of MHC determination, it is 
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suggested that further studies should directly measure muscle fibre cross sectional 
area in addition to MHC electrophoresis, given that it is this parameter that 
essentially defines atrophy. A comparison of the two techniques could subsequently 
determine whether increased type I fibre abundance or cross-sectional area is in fact 
able to artificially reduce the apparent number of type II fibres when assessed by 
histochemical techniques. Numerous studies have described the existence of MHC 
isoform-specific antibodies which could be optimised for use with frozen sections of 
skeletal muscle. Such methodology would enable the determination of both MHC 
complement, and the cross-sectional area of each specific fibre-type. With regards 
metabolic enzyme determination, it is suggested that further markers of glycolysis 
are utilised in addition to LDH. Whilst LDH has been determined in numerous studies, 
it is not a rate-limiting enzyme in the glycolytic pathway, which may explain the lack 
of modulation noted in these studies. It is suggested that the inclusion of PFK and 
enolase activity measurements would give a more sensitive index of glycolytic 
potential.    
 
The promoter analysis reported in (CHAPTER 4), yielded some particularly interesting 
novel data which appear to show the differential regulation of guinea pig and human 
MyH4, encoding MHC IIB, in comparison to the mouse and rat. To follow-up on this 
initial work, it is suggested that electrophoretic mobility shift assays (EMSAs) are 
performed to determine whether the mutations noted in the promoter regions of 
the guinea pig and human MyH4 gene do in fact prevent the binding of their 
respective regulatory and enhancer factors. This further work will enhance our 
limited knowledge of fibre-type control and may have important implications in the 
targeted hypertrophy of specific fibre-types. 
 
Given the differences in quadriceps involvement in the two animal models of OA 
when compared with the human disease noted here, it is important to further 
confirm these changes in alternative models of pathology. A further assessment into 
the differential effects of altered fibre-type and quadriceps mass would require an 
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animal model in which disease results exclusively as a result of muscle atrophy. 
Longino and colleagues have described such a model in which quadriceps weakness 
results from the administration of botulinum toxin, a potent neurotoxin (Longino, 
Frank et al. 2005; Longino, Frank et al. 2005). The proposed system would enable 
dissection of the independent effects of altered fibre type, quadriceps mass or both 
on the development of OA. Further advantages of this system would include the 
opportunity to modulate the extent and anatomical location of muscle weakness 
both by varying the administration of botulinum toxin or the addition of hypertrophy 
ŝŶĚƵĐŝŶŐĂŐĞŶƚƐƐƵĐŚĂƐɴ ?-agonists.  Prior to any intervention studies, it would be 
necessary to perform a short pilot study to ensure that quadriceps weakness does in 
fact lead to the development of osteoarthritis in this species.  
 
The ideal design for any study of disease pathogenesis is to utilise tissue from the 
species in question. Whilst several large scale population-based osteoarthritis studies 
have been conducted over the years (Felson, Naimark et al. 1987; Wilson, Michet Jr 
et al. 1990; Oliveria, Felson et al. 1995; Cooper, Snow et al. 2000), none have 
included the collection of quadriceps muscle tissue as part of their protocols. 
Although several studies have reported the collection and analysis of muscle biopsy 
material (Nakamura and Suzuki 1992; Fink, Egl et al. 2007), these were from patients 
selected specifically due to their end stage disease (Fink, Egl et al. 2007) or 
conducted only on female participants (Nakamura and Suzuki 1992) and fibre-type 
determination was limited to muscle histochemical techniques. The ideal follow-up 
study would be population based, and characterise the incidence of quadriceps 
muscle changes at the individual fibre level within the human population in 
comparison to radiographic data. Although quadriceps biopsy material could be 
obtained from end-stage OA patients during knee-replacement surgery, it is 
envisaged that the collection of such biopsy material from early disease patients 
would be more problematic. Suggested endpoint measurements would include MHC 
immunohistochemistry, MHC electrophoresis, metabolic enzyme activities (ICDH, 
PFK, and enolase) and electrophysiological determination of quadriceps function.  
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7.6  ? Closing Remarks 
 
To date, there are no disease modifying drugs available for the treatment of knee-
OA, which still represents a great and unmet clinical need. Data reported in this 
thesis support the theory that OA is a whole-joint disease, affecting cartilage, bone 
and the surrounding musculature. Taking into account the numerous reports 
suggesting quadriceps involvement in the initiation and progression of knee-OA, and 
the data reported here, it is proposed that the standard care of knee-OA patients 
should include consideration of quadriceps skeletal muscle function and the 
prescription of appropriate strengthening exercises where indicated.  
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Appendix A  W Standard Buffers 
 
2 x SDS PAGE loading buffer  W 2mL glycerol, 1.25mL 1M Tris-HCl pH 6.8, 4mL  10% 
w/v sodium dodecyl sulphate (SDS), 1mL 1M DTT and 2.5mg of bromophenol blue 
made up to 10mL with distilled water  Wstored at -20oC. 
1 x SDS PAGE loading buffer  W Prepared by diluting 2 x SDS loading buffer (above) in 
distilled water - stored at -20oC. 
LB Agar  W Luria broth agar comprising 2% w/v tryptone, 1% w/v yeast extract, 2% w/v 
NaCl and 3% w/v Bacto-Agar (Oxoid) prepared in distilled water and autoclaved prior 
to use. 
LB Media - 2% w/v tryptone (Oxoid), 1% w/v yeast extract (Oxoid) and 2% w/v NaCl 
prepared in distilled water and autoclaved prior to use. 
Ponceau S Stain  W 0.5% (w/v) Ponceau S (BDH), 5% (w/v) trichloroacetic acid 
prepared in distilled water.  
Protein extraction buffer - 150mM NaCl, 50mM Hepes, 2.5mM EDTA, 1mM Na3VO3, 
10mM NaF, 10% v/v glycerol and 1% v/v triton X prepared in distilled water and 
stored at 4oC. 
SDS PAGE running buffer - 0.25M Tris-base, 1.92M glycine, and 1% (w/v)  W sourced 
as a 10 X stock solution from National diagnostics and diluted 10-fold in distilled 
water prior to use. 
SOC Media - 2% w/v tryptone, 0.5% w/v yeast, 10mM NaCl, 2.5mM KCl, 10mM 
MgCl2, 10mM MgSO4, 20mM glucose prepared in distilled water and autoclaved prior 
to use. 
TAE - Tris-acetate-ethylenediamine tetraacetic acid buffer comprising a final 
concentration of 40mM Tris-HCl, 1mM EDTA (pH 8.0) and 1.142mL glacial acetic acid 
per litre of distilled water. 
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TBS-T Buffer  W Tris buffered saline buffer comprising 20mM Tris-HCl pH7.5, 0.9% 
(w/v) NaCl and 0.1% (v/v) Tween 20 prepared in distilled water. 
 
